










The handle http://hdl.handle.net/1887/38737 holds various files of this Leiden University 
dissertation 
 
Author: Goeij, Bart E.C.G. de 
Title: Antibody-drug conjugates in cancer 
Issue Date: 2016-04-13 
502504-L-bw-deGoeij
antibody-drug conjugates in cancer
502504-L-bw-deGoeij
Cover art: Joost Bakker, scicomvisuals, Amsterdam, The Netherlands
Production: Joost Bakker, scicomvisuals, Amsterdam, The Netherlands
Design & Dtp: De vliegende kiep, Amsterdam, The Netherlands
Printed by: Ipskamp Printing, Amsterdam
ISBN/EAN: 978-94-028-0102-6
Proefschrift Universiteit Leiden, Faculteit Geneeskunde 
© 2016, Bart E.C.G. de Goeij, The Netherlands
Dit proefschrift werd mede mogelijk gemaakt met financiële steun van Genmab
502504-L-bw-deGoeij
proefschrift
Ter verkrijging van de graad 
van doctor aan de Universiteit Leiden, 
op gezag van Rector Magnificus 
prof.mr. C.J.J.M. Stolker
volgens besluit van het College voor Promoties 
te verdedigen op 
woensdag 13 april 2016 
klokke 15:00 uur
door
Bart Egbertus Cornelis Gijsbertus de Goeij
Geboren op 6 februari 1981,
te Utrecht
Antibody-drug conjugates in cancer
502504-L-bw-deGoeij
Promotor
Prof. dr. Paul W.H.I. Parren
Co-promotor
Dr. Esther C. Breij
Promotiecommissie
Prof. dr. C. van Kooten
Prof. dr. F.A. Ossendorp 
Prof. dr. W. Jiskoot 
Prof. dr. M. van Egmond, Vrije Universiteit medisch centrum, Amsterdam
Dr. P.H.C. van Berkel, ADC Therapeutics
502504-L-bw-deGoeij
Table of Contents
Chapter 1 General outline and aim of the thesis 7
Chapter 2 New developments for antibody-drug 
conjugate-based therapeutic approaches 17
Chapter 3 High turnover of Tissue Factor enables 
efficient intracellular delivery of antibody-drug 
conjugates 35
Chapter 4 An antibody-drug conjugate that targets tissue 
factor exhibits potent therapeutic activity against 
a broad range of solid tumors 69
Chapter 5 Human kappa light chain targeted Pseudomonas 
exotoxin A – identifying human antibodies and 
Fab fragments with favorable characteristics for 
antibody-drug conjugate development 107
Chapter 6 HER2 monoclonal antibodies that do not interfere 
with receptor heterodimerization-mediated 
signaling induce effective internalization and 
represent valuable components for rational 
antibody-drug conjugate design 133
Chapter 7 Efficient payload delivery by a bispecific 
antibody targeting HER2 and CD63 163
Chapter 8 General discussion 187
Summary 213
Samenvatting in het Nederlands 217
Dankwoord 221
List of publications 223
502504-L-bw-deGoeij
502504-L-bw-deGoeij
General outline and aim of the thesis 7
1 General outline and aim of the thesis
502504-L-bw-deGoeij
502504-L-bw-deGoeij
General outline and aim of the thesis 9
Antibodies (Abs) are part of the adaptive humoral immune response, which provides 
long-lasting protection against pathogens such as viruses and bacteria. During this 
immune response naïve B-cells recognize an antigen through their B-cell receptor. 
This results in clonal expansion of the B-cells and differentiation into plasma cells, 
which secrete large amounts of Abs. These Abs can bind to pathogens thereby flag-
ging the opsonized pathogen for destruction. Abs of the IgG isotype contain two 
binding arms, each containing a Fab (fragment antigen binding) region through which 
they recognize their cognate antigen (Figure 1). The Abs selectivity for the antigen is 
determined by the complementary determining region (CDRs) located at the top of 
the Fab-region. The population of B-cells in the human body may be able to respond 
to as many as 1 x 1011 different antigens. This huge diversity is determined by the 
different gene segments encoding variable, joining and diversity regions that recom-
bine randomly allowing for nearly 2.5 x 106 combinations. Nucleotide insertions and 
hypermutations further diversify the CDRs.
Abs are able to interact with the immune system through the constant Fc (fragment 
crystallizable) region. In humans, nine different antibody isotypes exist (IgA1 and 
2, IgD, IgE, IgG1, 2, 3 and 4 and IgM), each having a unique Fc region. The most 
abundant class in circulation is IgG1 (~50%). This antibody class is able to eliminate 
pathogens through a number of Fc-mediated effector mechanisms. Each of these 












FIGURE 1 Schematic representation of an IgG1 antibody structure.
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high density of Fc regions on the pathogen surface. These Fc regions may interact to 
form a high-avidity binding scaffold for C1q, which initiates complement dependent 
cytotoxicity (CDC) [1]. Alternatively, the IgG Fc region can be recognized by Fcγ- 
receptors that are expressed on immune effector cells such as NK-cells, granulocytes 
and macrophages. Binding of Fcγ-receptors expressed on NK-cells and granulocytes 
triggers the release of cytotoxic granules that kill the pathogen through a mechanism 
called antibody-dependent cellular cytotoxicity (ADCC) [2]. Binding of Fcγ-receptors 
on macrophages leads to the engulfing of the opsonized pathogen, also known as 
antibody-dependent cellular phagocytosis (ADCP) [3].
The ability to engage the immune system to induce killing of opsonized cells via 
Fc-mediated mechanisms led to the notion that monoclonal Abs might have great 
potential for the treatment of cancer. Numerous monoclonal Abs for the treatment 
of cancer have been developed in the past two decades, some of which have revolu-
tionized treatment of cancers such as non-Hodgkin lymphoma (Rituxan®) and breast 
cancer (Herceptin®). In addition to Fc-mediated effector functions, therapeutic anti-
bodies can exert anti-tumor activity through a number of different mechanisms. 
For example, inhibition of growth factor receptor signaling and induction of recep-
tor downmodulation (e.g. zalututmumab). Furthermore, therapeutic antibodies may 
 interact with the tumor microenvironment, for example by inhibiting regulatory 
 interactions between tumor cells and the adaptive immune system (e.g. ipilumumab, 
PD-1, PD-L1). Although the generation of tumor-targeting antibodies has generally 
been very successful, only a limited number of antibodies have been clinically ef-
fective [4]. As of today, 17 monoclonal antibodies have been approved for the treat-
ment of cancer by the Food and Drug Administration (FDA) and 15 by the European 
Medicines Agency (EMA) in addition to a comparable number of Abs for the treat-
ment of inflammatory, cardiovascular, infectious and other diseases. The challenge in 
cancer treatment is that tumors often develop resistance to antibody therapy. Down-
stream signaling pathways can be mutated (KRAS/BRAF) which limits the antibody’s 
capacity to inhibit growth factor receptor signaling [5]. Tumors can overexpress com-
plement inhibitory receptors such as CD46, CD55 and CD59, thereby blocking CDC 
[6]. Overexpression of certain HLA molecules (i.e. HLA-E and -G) that inhibit NK-cell 
mediated ADCC has been described for various tumors [7,8] and the tumor microen-
vironment can be infiltrated by T-regulatory cells and myeloid-derived suppressor 
cells that serve to suppress the anti-tumor immune response [9].
One approach to overcome such limitations in efficacy is the conjugation of cyto-
toxic compounds to monoclonal antibodies. These antibody-drug conjugates (ADCs) 
combine the tumor specificity, pharmacokinetics and biodistribution properties of 
antibodies with the potent cell-killing activity of small molecules. This concept was 
already postulated in the early 20th century by Paul Ehrlich who reasoned that if 
a compound could be made that selectively targeted a disease-causing organism, 
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then a toxin for that organism could be delivered along with the agent of selectivity 
[10]. Hence, a “magic bullet” would be created that only killed the targeted organ-
ism. An antibody would be extremely suitable for this purpose as antibodies can 
selectively bind to tumor antigens while maintaining a long half-life in circulation 
(~21 days for IgG1). The first generation of ADCs were conjugated with clinically 
approved chemotherapeutic agents such as vinblastine, mitomycin, methotrexate 
and doxorubicin [11]. These ADCs showed limited clinical success which was mostly 
attributed to the low potency of the conjugated drug. The second generation of ADCs 
made use of more potent payloads, namely calicheamicin, auristatin and maytansin 
analogs. Besides, pharmacokinetics of the conjugation linker was optimized and fully 
human mAbs were used to solve immunogenicity problems observed with murine 
mAbs. In 2000 the first ADC, gemtuzumab ozogamicin (Mylotarg®), was clinically 
approved for use in refractory acute myeloid leukemia (AML) [12]. Here, a CD33 
antibody was conjugated to calicheamicin, a drug that specifically binds to DNA and 
generates single and double strand DNA breaks. Gemtuzumab ozogamicin received 
accelerated approval for the treatment of patients with relapse AML. Unfortunately, 
ten years later, gemtuzumab ozogamicin was withdrawn from the US market due to 
lack of clinical benefit [13]. A confirmatory phase III trial showed no improvement 
in clinical benefit for patients who received standard chemotherapy plus gemtu-
zumab ozogamicin, but instead a greater number of deaths occurred in the group 
of patients who received gemtuzumab ozogamicin compared with those receiving 
chemotherapy alone [13]. Several factors have been identified that have limited the 
clinical efficacy of gemtuzumab ozogamicin, including poor stability of the acid-la-
bile conjugation linker, heterogeneous drug loading (approximately 50% of the CD33 
antibodies are unconjugated) and sensitivity to multidrug resistance pumps that are 
often overexpressed in AML.
More recently, two novel ADCs were approved by the FDA for the treatment of Hod-
gkin lymphoma and anaplastic large-cell lymphoma, brentuximab vedotin (Adcetris®) 
and HER2 positive breast cancer, trastuzumab emtansine (Kadcyla®) [14,15]. These 
ADCs showed improved liker stability and pharmacokinetics. Their clinical success 
has led to an impressive expansion of the clinical ADC pipeline (Chapter 2, Table 1). 
An overview of the recent developments in ADC based therapy is summarized in 
Chapter 2.
Although simple in concept, the success of a given ADC depends on careful selection 
of the tumor antigen, antibody, linker as well as the payload. The aim of this thesis 
was to better understand the antibody and antigen requirements that are essential 
for developing a therapeutically effective ADC. Chapter 2 reviews the different cy-
totoxic compounds that are currently being used as payloads, and the type of tumor 
antigens that can be utilized for their intracellular delivery, as well as the interplay 
of ADCs with the immune system. In Chapter 3 we explore tissue factor (TF) as a 
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novel target for an auristatin-based ADC. An effective ADC treatment requires that 
in circulation, the payload remains attached to the antibody. Following selective 
antigen binding, the ADC should be internalized and targeted to the lysosomes to be 
processed by lysosomal enzymes such as cathepsins. This leads to cleavage of the 
linker and/or degradation of the antibody moiety of the ADC, resulting in release of 
the payload. Once released, the payload can exert its cytotoxic effect through inhi-
bition of microtubule formation (Figure 2).
To investigate the suitability of TF as a target for an ADC approach, we compared the 
distribution, internalization and lysosomal targeting of TF with that of the clinically 
validated ADC target HER2 as well as for EGFR, for which an ADC is currently in 
phase II clinical development. ADCs were generated by conjugating TF-, HER2- and 
EGFR- Abs with the microtubule inhibiting agent duostatin-3. These ADCs allowed us 
to compare efficacy of TF-, HER2- and EGFR-specific ADCs in different in vitro and 
in vivo tumor models. Chapter 4 describes the selection of monoclonal antibody TF-
011 as the optimal candidate for the development of a TF-specific ADC. A large panel 
of TF Abs was generated from which clone 011 was selected based on excellent tar-
get binding characteristics, rapid internalization and efficient lysososomal targeting 
and the capacity to inhibit TF-Factor VIIa (FVIIa)-dependent intracellular signaling, 
























G2/M cell cycle arrest
and apoptosis
FIGURE 2 Mechanism of action of auristatin-based ADCs. The ADC should be stable in circulation 
(1) and bind (2) to its antigen when a tumor cell is encountered. The antigen/ADC complex has to be 
internalized and targeted to the lysosomes (3) where lysosomes enzymes can process the ADC and 
release the auristatin payload (4). The payload can then exert its cytotoxic effect by inhibition of tubulin 
formation (5), resulting in cell cycle arrest and apoptosis (6).
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candidate HuMax-TF-ADC (TF-011-MMAE) is analyzed in detail. Different patient-de-
rived xenograft (PDX) models with variable levels of TF expression were treated 
with TF-011-MMAE. In addition, tumor models that showed tumor recurrence after 
treatment with TF-011-MMAE and paclitaxel were retreated with TF-011-MMAE.
Chapter 5 describes the development of a high throughput assay that can be used to 
screen large antibody panels for their suitability to facilitate intracellular delivery 
of toxic payloads. A modified version of the Pseudomonas exotoxin-A was fused to 
a human kappa light chain binding antibody fragment. The resulting fusion protein 
(α-kappa-ETA’) was tested for binding to Abs with a human kappa light chain and its 
ability to inhibit proliferation of EGFR expressing cells when non-covalently linked 
to an EGFR Ab. In Chapter 6 we used the α-kappa-ETA’ assay to screen a large and 
diverse panel of HER2 antibodies for their ability to deliver α-kappa-ETA’ into tumor 
cells. Chapter 7 describes the development of a Fab-arm that can be used to facilitate 
internalization and lysosomal delivery of poorly internalizing tumor antigens in a 
bispecific antibody approach. Chapter 8 covers the general discussion of this the-
sis and addresses the key findings in comparison to the literature. General rules of 
thumb providing a road map for ADC development are presented and summarized.
To summarize, the clinical success of brentuximab vedotin and trastuzumab emtan-
sine has led to an extensive expansion of the clinical ADC pipeline. Although the 
concept of an ADC seems simple, designing a successful ADC is complex and requires 
careful selection of the tumor antigen, antibody, linker and payload. In this thesis, 
different tumor antigens and targeting antibodies were compared for their capaci-
ty to deliver cytotoxic payloads to tumor cells, uncovering general mechanisms. In 
the course of this work, TF was identified as an excellent ADC target because of its 
rapid internalization and lysosomal targeting characteristics. Furthermore we have 
explored a novel Ab platform that improves the intracellular delivery of cytotoxic 
payloads. These findings provide a better insight in the Ab and antigen requirements 
needed for optimal payload delivery and support the development of novel and im-
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2 New developments for antibody-drug conjugate-based therapeutic 
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ABSTRACT
The clinical success of Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastu-
zumab emtansine) has sparked clinical development of novel ADCs. These powerful 
anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic 
agents to tumour cells while sparing healthy tissues. Despite the use of tumor-spe-
cific antibodies, the emerging clinical data with ADCs indicates that adverse effects 
frequently occur before ADCs have reached their optimal therapeutic dose, resulting 
in a relatively narrow therapeutic window. This review summarizes the therapeutic 
window of ADCs currently in clinical development, along with some strategies that 
may help to widen the window.
INTRODUCTION
The prospects for development of antibody-drug conjugates (ADCs) as effective, 
well-tolerated anti-cancer therapeutics have changed dramatically since the approv-
al of Adcetris® (brentuximab vedotin) in 2011 and Kadcyla® (ado-trastuzumab em-
tansine) in 2013. Currently, over 50 different ADCs are in clinical development, the 
majority consisting of IgG1 antibodies conjugated with potent microtubule inhibitors, 
either derivatives of maytansine, or auristatins which are analogs of dolastatin 10 
(Table 1). These compounds display cytotoxicity at ~1000-fold lower concentration 
than standard chemotherapeutic agents [1], which makes them too toxic for systemic 
treatment [2,3]. By conjugating these potent cytotoxins to tumor-specific antibodies, 
their cytotoxic effect can be concentrated at tumor cells. At the same time, the phar-
macokinetic profile of the toxins will improve upon conjugation to antibodies, giving 
to the small molecular weight cytotoxin the long half-life of an immunoglobulin. 
Notwithstanding the clinical success of brentuximab vedotin and ado-trastuzumab 
emtansine, the development for therapeutic use of most ADCs is still hampered by 
a relatively narrow therapeutic window. Although tumor-specific antibodies allow 
enrichment of cytotoxic payloads in tumors, adverse effects frequently occur before 
ADCs have reached their optimal therapeutic dose, which may limit their clinical 
response. In this short review, we have summarized available data from clinical and 
preclinical studies to assess the therapeutic window of ADCs. In addition, this review 
will discuss three aspects of ADC design, that may be important factors in helping to 
increase the therapeutic window of ADCs (Figure 1): 1) the target selection require-
ments for ADC development; 2) the interaction of ADCs with the immune system; 3) 
the development of novel DNA damaging agents with low picomolar efficacy.
502504-L-bw-deGoeij
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THERAPEUTIC WINDOW OF ADCS IN CLINICAL DEVELOPMENT
The majority of ADCs in clinical development make use of tubulin-targeting anti-
mitotic agents. These agents (maytansinoids and auristatins [4]) bind to the vinca- 
binding domain of tubulin, thereby interfering with microtubule dynamics and caus-
ing cell cycle arrest in the G2/M phase [5]. Table 1 shows that antibodies coupled 
with the maytansinoids DM1 or DM4 typically reach a maximum tolerated dose 
(MTD) in humans in the range of 110-240 mg/m2 (about 3–6.5 mg/kg) [6-8]. For 
antibodies conjugated with the dolastatin 10 analogs, monomethyl auristatin E or 
F (MMAE; MMAF), MTDs were established at doses around 80-110 mg/m2 (about 
2–3 mg/kg) [9-11]. It is not known what dose would be required to achieve optimal 
therapeutic efficacy in the clinic. However, some lessons may be drawn from pre-
clinical studies in murine xenograft models. Given that both mice and humans have 
about 40–43 mL plasma per kg of body weight [12], and assuming that pharmacoki-
netic properties are approximately similar in mice and human, therapeutic activity 
should be observed at similar dose levels in mice and human. Thus, ADCs conjugated 
with maytansinoids or auristatins should show preclinical activity at doses at or 
below 3 – 6.5 mg/kg and 2–3 mg/kg, respectively. Preclinical studies in mice suggest 
that such doses levels are often suboptimal. For example, ado-trastuzumab emtan-
sine has an MTD of 3.6 mg/kg in humans [6]. In preclinical models of breast cancer, 
ado-trastuzumab emtansine induced tumor regression at dose levels at or above 
3 mg/kg, but more potent efficacy was observed at 15 mg/kg [13,14]. This suggests 
that at the clinically administered dose, ado-trastuzumab emtansine may not ex-
ert its maximal potential anti-tumor effect. Likewise, brentuximab vedotin has an 
MTD of 1.8 mg/ kg in humans [9], while in preclinical models of Hodgkin lymphoma, 
the lowest dose that induced partial tumor regression was generally about 1 mg/kg 
dose [15], suggesting that the therapeutic index of brentuximab vedotin is fairly 
narrow. Other examples can be drawn from compounds in development. For exam-
ple, CR011-vcMMAE (glembatumumab vedotin), an ADC that targets GPNMB, showed 
modest clinical activity in humans at the MTD of 1.9 mg/kg [16]. In preclinical models 
of melanoma CR011-vcMMAE induced complete tumor regression upon treatment 
with 2.5 mg/kg ADC, but the 1.25 mg/kg dose showed only modest activity [17]. 
Another vcMMAE conjugated antibody, MLN0264 (indusatumab vedotin) that tar-
gets guanylyl cyclase C (GCC) positive tumors, has an MTD of 1.8 mg/kg in humans 
[10]. Yet it has been described to show significantly better inhibition of GCC-positive 
xeno grafts at a dose of 7.5 mg/ kg compared to 3.75 mg/kg dose [18]. 
In summary, these ADCs are highly active in preclinical tumor models but their 
therapeutic window in the clinic is narrow and dosing regimens seem hampered 
by dose-limiting toxicities that could not always be predicted based on data from 
preclinical models. This lack of predictability is especially illustrated by the fact that 
non-cleavable auristatin and maytansine conjugates are virtually devoid of toxicity 
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in preclinical models at doses equivalent to the MTD for cleavable auristatin and 
maytansine conjugates. Yet in the clinic they induce toxicity at doses that are the 
same or even lower as compared to their cleavable-linked counterparts [8,13,19]. In 
addition several other factors make it difficult to extrapolate preclinical data to the 
clinic, such as differences in proliferation rates, tumor burden, multidrug-resistance 
pumps and target-mediated clearance. 
For most ADCs currently in clinical development, dose-limiting toxicities appear to be 
unrelated to the targeted antigen. For example, reversible ocular toxicity specific to 
the cornea has been reported as the dose-limiting toxicity (DLT) for disulfide-linked 
DM4-conjugated antibodies targeting antigens as diverse as CD19 [7], CanAg [20], 
folate receptor alpha [21] and mesothelin [22], none of which are thought to have 
significant expression in the eye. Similar toxicity has been reported for all ADCs 
conjugated with MMAF via an uncleavable linker [7,23]. In contrast, no ocular toxic-
ity has been described for a MUC16 ADC conjugated with vcMMAE, despite the fact 
that MUC16 expression has been described in human ocular surface epithelia [24]. 
In fact, most, if not all, ADCs made with vcMMAE have a similar toxicity profile, with 
acute neutropenia and neuropathy (upon repeated dosing) being the dose-limiting 
adverse events, irrespective of the target antigen, CD30 [9], PSMA [25], gpNMB [16], 
NaPi2b [26], MUC16 [27], GCC [10], CD22 [28] and CD79b [29]. The fact that normal 
tissue expression often does not drive ADC toxicity is further illustrated by clinical 
experience with ado-trastuzumab emtansine. HER2 expression has been described 
in various healthy organs such as heart, skin and epithelial cells of the gastrointes-
tinal tract [30]. Trastuzumab, the unconjugated antibody counterpart of ado-trastu-
zumab emtansine, has been reported to induce cardiotoxicity in combination with 
chemotherapy [31], which is thought to be related to HER2 expression in the heart. 
In contrast, the DLT of  ado-trastuzumab emtansine is reversible thrombocytopenia, 
thought to be an off-target toxicity, with no clinically significant toxicity reported in 
heart, skin or epithelial tissue [6].   
However, for some ADCs, certain toxicities observed in clinical trials appear to be 
on-target effects.  For example, in the case of glembatumumab vedotin, development 
of skin rash was one of the observed dose-limiting toxicities [16], which is likely 
due to membrane expression of gpNMB in epithelial cells of the skin [32]. Previous-
ly, development of an ADC directed against CD44v6 (bivatuzumab mertansine) was 
discontinued due to severe skin toxicity [33], which was also linked to high CD44v6 
expression in the skin. 
In general, antigens that are internalized well, with low expression on normal tissue 
and high expression on tumors are preferred for an ADC approach. However, the 
results of clinical trials indicate that it may be difficult to predict the toxicity profile 
based on target expression in healthy tissue. Therefore selection of antigens that are 
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not particularly tumor specific, but highly overexpressed in tumors may, in certain 
circumstances, increase the efficacy of tubulin based ADCs without changing the MTD.
ADCS AND THE IMMUNE SYSTEM
The mechanism behind the off-target toxicity of ADCs is poorly understood. Neutrope-
nia and thrombocytopenia could be explained by cytotoxicity of the free payload after 
processing of the linker-drug by the targeted cells or in the tumor microenvironment 
[34]. Alternatively, uptake and processing of ADCs by Fcγ-receptor bearing cells has 
been proposed as a potential mechanism of toxicity (Figure 2). For example, FcγRIIa 
binding has been proposed to be involved in the development of thrombocytopenia 
induced by ado-trastuzumab emtansine. Megakaryocytes showed uptake of trastu-
zumab and ado-trastuzumab emtansine which could be blocked with an FcγRIIa block-
ing antibody. The uptake of ado-trastuzumab emtansine as well as an isotype control 
ADC by megakaryocytes resulted in cytotoxicity, which was not observed with uncon-
jugated trastuzumab [35]. However, these experiments were not done in the presence 
of non-immune human IgG at levels comparable to those found in human blood, so it 
is also possible that non-specific mechanisms such as pinocytosis may contribute to 
uptake of ADC by antigen-negative hematological cells in vivo at the relatively high 
initial concentrations of ADC in blood plasma after administration (~ 0.1 mg/mL).
Whereas, on the one hand interactions with Fcγ-receptors have been implicated in 
toxicity of ADCs, on the other hand at least one ADC with enhanced Fc-receptor bind-
ing has entered clinical development. J6M0-mcMMAF (GSK2857916), an ADC target-
ing the B-cell maturation antigen (BCMA) that is selectively expressed on multiple 
myeloma (MM) cells, was able to eliminate MM tumors in subcutaneous and dissem-
inated MM models. The investigators used a defucosylated antibody with enhanced 
affinity for FcγRIIIa expressing immune cells. J6M0-mcMMAF induced antibody-de-
pendent cell-mediated cytotoxicity (ADCC) and macrophage-mediated phagocytosis 
in vitro and enhanced macrophage infiltration in bone marrow tissues from SCID 
mice bearing MM1Sluc tumors [36]. 
Just as the role of IgG-FcγR interactions to toxicity is unknown, it is unclear to what 
extent FcγR-mediated effector functions contribute to the clinical efficacy of ADCs. 
Generally, antibody-mediated effector functions were similar between the naked an-
tibody and the corresponding ADC. Considering the two approved ADCs, the capacity 
of trastuzumab to induce ADCC was not affected through conjugation with DM1 [37], 
while brentuximab has been described to induce antibody-dependent cellular phago-
cytosis in vivo, which is believed to contribute to the potent anti-tumor efficacy ob-
served for brentuximab vedotin [38]. Although in the latter case, the naked anti-CD30 
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antibody had no clinical activity [39], it may be that Fc-receptor-mediated anti-tumor 
activity compliments payload delivery by the ADC, for increased clinical benefit. 
More recently, ADCs based on auristatins have been suggested to stimulate a tu-
mor-specific adaptive immune response [40]. Using fully immunocompetent mice 
with syngeneic RMAThy1.1 tumors, it was demonstrated that MMAE-coupled ADCs 
can induce dendritic cell (DC) homing to tumor draining lymph nodes. Analysis of 
PBMCs from Hodgkin lymphoma patients obtained before and after treatment with 
brentuximab vedotin showed activation of adaptive immunity as indicated by a sig-
nificant decrease in the number of T-regulatory cells and increased activation of pe-
ripheral DCs and B-cells. These effects were not dependent on cytotoxicity towards 
the tumor cells, indicating a direct effect on DCs. Furthermore it was demonstrated 
that combined treatment of dolastatins with immune modulating antibodies target-
ing CTLA-4 and PD-1 resulted in slower outgrowth of MC38 tumors and altered ratio 
between regulatory and effector T-cells. These observations were also extended to 
maytansinoids and ado-trastuzumab emtansine [41]. The ability of chemotherapeu-
tic agents to stimulate immunological cell death has been widely appreciated [42]. 
However, the potential clinical benefit of this effect may be limited during classical 
chemotherapy treatment regimens, that are associated with major immunosuppres-
sive side effects [43]. The enhanced tumor-specificity of ADCs, however, may allow 
for reduced immunosuppressive side effects while increasing anti-tumor immunity. 
TOWARDS MORE POTENT PAYLOADS
The clinical success of maytansinoid- and auristatin-based ADCs has sparked in-
creased research into evaluation of even more potent cytotoxic compounds having 
different cell-killing mechanisms for utilization as ADC payloads. Most such research 
is with DNA-damaging agents such as pyrrolobenzodiazepine (PBD) dimers [44], 
 calicheamicins, duocarmycins [45] and indolinobenzodiazepine dimers [46]. PBD di-
mers have shown promising cytotoxicity and displayed anti-tumor activity at ~10 
fold lower concentration as compared to auristatins and maytansinoids. PBD dimers 
block cancer cell division by binding in the minor groove of DNA and crosslinking 
opposing strands of DNA without distorting the DNA helix, thus potentially avoiding 
DNA-repair mechanisms and emergent drug resistance [47]. Recently, several ADCs 
conjugated with PBD dimers have entered clinical development. SGN-CD33A, a hu-
manized anti-CD33 antibody conjugated to a PBD dimer via a protease-cleavable 
valine-alanine dipeptide linker is being tested in acute myeloid leukemia [44]. SGN-
CD33A showed impressive anti-tumor activity in xenograft models at doses as low 
as 0.1 mg/kg of ADC. This activity was dependent on the presence of cell surface 
antigen, although no correlation was observed between degree of efficacy and the 
levels of CD33 on the cell surface [44]. The same PBD-linker format was used to de-
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velop a CD70 ADC (SGN-CD70A), for the treatment of patients with renal cell carcino-
ma (RCC) and non-Hodgkin lymphoma (NHL). Here too, the ADC showed impressive 
anti-tumor activity in preclinical models dosed at 0.1 and 0.3 mg/kg of ADC [48]. The 
potential of PBD dimers to target cell populations that are drug-resistant has been 
demonstrated with rovalpituzumab tesirine, an anti-DLL3 antibody conjugated to a 
PBD dimer. In patient-derived xenograft models of small cell lung cancer (SCLC) the 
ADC was able to eradicate DLL3-positive drug-resistant tumor-initiating cells [49]. 
Moreover, a phase I study in patients with relapsed and refractory SCLC demonstrat-
ed that at the MTD of 0.2 mg/kg, rovalpituzumab tesirine was able to induce partial 
responses in 7 out of 16 patients and stable disease in a further 8 patients [50]. 
Recently, SYD985, a HER2 ADC conjugated with the cleavable linker-duocarmycin 
analog, vc-seco-DUBA, entered clinical development. The ADC was able to inhibit 
growth of low HER2 expressing patient derived xenografts (PDX) at a single dose 
of 1 mg/kg [51]. This effect may even be underestimated because vc-seco-DUBA 
conjugated ADCs have poor PK properties in mouse plasma, due to presence of 
mouse-specific carboxylesterase (CES1c) which can release the payload from the 
ADC [51]. In human plasma, vc-seco-DUBA conjugated ADCs are quite stable. How-
ever, once released from the ADC, the active compound DUBA is rapidly degraded 
with a half-life of approximately 1 hour. Although this seems unfavorable from an 
efficacy point of view, the rapid degradation of DUBA may also translate to lower 
systemic toxicity and allow for higher dosing in clinical testing [45]. 
These exciting preclinical data and emerging clinical results with ADCs containing po-
tent DNA-targeting payloads, both PBD dimers and duocarmycin based compounds, 
demonstrate that these ADCs are capable of inhibiting tumor growth at relatively low 
doses and require only modest expression of the targeted antigen. Studies addressing 
the safety and establishing the MTD will determine whether these extremely potent 
toxins can contribute to increasing the therapeutic index of ADCs towards such targets.
SUMMARY
The increased clinical experience with tubulin-based ADCs and emerging clinical 
data with ADCs containing DNA-targeting payloads, help us to better understand the 
target requirements needed for successful ADC design. The relative lack of immuno-
suppressive side effects of many ADCs, suggests that a potential component of the 
clinical benefit obtained with some ADCs may be the engagement of the immune 
system. There is still much to learn about the clinical application of ADC technolo-
gies, but the success of brentuximab vedotin and ado-trastuzumab emtansine have 
emboldened research into improved cancer treatments utilizing ADCs that has the 
prospect for improved outcomes for many cancer patients.
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ABSTRACT
Antibody drug conjugates (ADC) are emerging as powerful cancer treatments that 
combine antibody-mediated tumor targeting with the potent cytotoxic activity of 
toxins. We recently reported the development of a novel ADC that delivers the cy-
totoxic payload monomethyl auristatin E (MMAE) to tumor cells expressing tissue 
factor (TF). By carefully selecting a TF-specific antibody that interferes with TF:FVI-
Ia-dependent intracellular signaling, but not with the pro-coagulant activity of TF, an 
ADC was developed (TF-011-MMAE/HuMax-TF-ADC) that efficiently kills tumor cells, 
with an acceptable toxicology profile.
To gain more insight in the efficacy of TF-directed ADC treatment we compared 
the internalization characteristics and intracellular routing of TF with the epider-
mal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 
(HER2). Both in absence and presence of antibody, TF demonstrated more efficient 
internalization, lysosomal targeting and degradation than EGFR and HER2. By conju-
gating TF, EGFR and HER2 specific antibodies with duostatin-3, a toxin that induces 
potent cytotoxicity upon antibody-mediated internalization but lacks the ability to 
induce bystander killing, we were able to compare cytotoxicity of ADCs with dif-
ferent tumor specificities. TF-ADC demonstrated effective killing against tumor cell 
lines with variable levels of target expression. In xenograft models, TF-ADC was 
relatively potent in reducing tumor growth compared to EGFR- and HER2- ADCs. 
We hypothesize that the constant turnover of TF on tumor cells, makes this protein 
especially suitable for an ADC approach.
INTRODUCTION
Therapeutic antibodies are currently used in the clinic to treat a variety of diseases, 
including cancer. The tumor-killing capacity of therapeutic antibodies can be great-
ly enhanced by conjugation with cytostatic toxins, this way combining antibody- 
mediated tumor targeting with the potent cytotoxic activity of toxins. This was also 
demonstrated through the FDA approval of brentuximab vedotin, a CD30 specific 
 antibody coupled to the potent microtubule disrupting agent monomethyl aurista-
tin E (MMAE), for the treatment of patients with Hodgkin’s lymphoma or anaplastic 
T-cell lymphoma [1]. In addition, the approval of trastuzumab emtansine (T-DM1), an 
ADC composed of the HER2 antibody trastuzumab and the tubulin inhibitor maytan-
sine (DM1), for the treatment of patients with HER2-positive breast cancer [2,3] em-
phasizes that the potential of ADCs is not limited to hematological malignanices. The 
number of ADCs in clinical development has markedly increased in the last couple 
of years. This includes the development of HuMax-TF-ADC (TF-011-MMAE), a novel 
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ADC designed to deliver the cytotoxic payload MMAE to tumor cells expressing tis-
sue factor (TF) [4].
Tissue factor, also called thromboplastin, factor III or CD142, is aberrantly expressed 
in many types of cancers including NSCLC [5], colorectal cancer [6], genito-urethal 
[7,8] and gyneacological cancers [9-11], pancreatic cancer [12], head and neck cancer 
[13], glioma [14] and metastatic breast cancer [15]. Under physiological conditions, 
TF is expressed by fibroblasts, pericytes and smooth muscle cells in the sub-endo-
thelial vessel wall. In these cells, the majority of TF is localized in intracellular pools 
and remains sequestered from circulating factor VII (FVII) until vascular integrity 
is disrupted or until TF expression is induced [16-18]. Upon vascular damage, TF 
binds activated FVII (FVIIa) and forms the proteolytically active TF:FVIIa complex 
that can initiate the coagulation pathway. The TF:FVIIa complex can also activate 
cells by cleavage of the G-protein coupled receptor protease-activated receptor 2 
(PAR2) thereby inducing an intracellular signaling cascade that promotes prolifera-
tion, thrombosis and angiogenesis [19]. This makes TF an interesting yet challenging 
target for cancer immunotherapy.
TF-011-MMAE was designed to specifically target tumor cells that aberrantly ex-
press TF, without interfering with the role of TF in coagulation. TF-011-MMAE 
showed potent anti-tumor activity in xenograft models derived from a broad range 
of solid cancers, and an acceptable safety profile in non-clinical toxicology studies 
[4]. TF-011-MMAE and unconjugated TF-011 induced efficient antibody-dependent 
cell-mediated cytoxicity and inhibition of TF:FVIIa-dependent intracellular signaling, 
both of which may contribute to the anti-tumor activity of TF-011-MMAE. However, 
MMAE-mediated tumor cell killing was shown to be the dominant mechanism of 
action in vivo. This indicates that TF is a highly suitable target for the intracellular 
delivery of cytoxic agents through an ADC. To gain more insight in the target char-
acteristics, particularly the internalization characteristics of TF and TF-specific anti-
bodies, that contribute to the efficacy of TF-directed ADC treatment, we compared 
TF-specific ADCs with ADCs directed against HER2 and EGFR. HER2 is a well-known 
and clinically validated ADC target [3,20], and an EGFR antibody conjugated with 
DM1 through a non-cleavable linker system is currently being evaluated in a phase 
I clinical study. Antibodies targeting TF, HER2 and EGFR were conjugated with the 
cytotoxic compound duostatin-3, which blocks tubulin polymerization. This toxin 
lacks the ability to induce bystander killing and therefore only affects target-posi-
tive cells. Because tumor antigens are often heterogeneously expressed and there-
fore not always accessible to ADC treatment, an ADC capable of inducing bystander 
killing may be preferred from an efficacy point-of-view [4]. However, to study the 
target requirements needed for optimal intracellular delivery of cytotoxic agents, we 
selected a drug-linker combination that only affects antigen expressing cells.
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By comparing in vitro and in vivo cytotoxicity of ADCs targeting TF, HER2 and EGFR 
we found that TF-ADC was more effective compared to ADCs targeting the EGF-re-
ceptor family. TF-ADC induced relatively potent tumor cell killing, even in cell lines 
where TF expression was lower than expression of HER2 or EGFR. Confocal micros-
copy analysis demonstrated faster and enhanced transport of TF-antibodies into 
lysosomes of tumor cells compared to EGFR and HER2 antibodies. Strikingly, also 
without antibody treatment, large quantities of TF were found to internalize and 
colocalize with markers of endosomes and lysosomes, indicating that TF was consti-
tutively being replenished. Therefore, it seems that the high turnover of TF on tumor 




Human SK-OV-3 (ovarian cancer), AU565 (breast adenocarcinoma) and HCC1954 
(breast ductal carcinoma) cells were obtained from American Type Culture Collec-
tion (ATCC). Human A431 (epithelial squamous carcinoma) and Jurkat (T-cell leuke-
mia) cells were obtained from the Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ). SK-OV-3 cells were cultured in Minimal Essential Medium Eagles 
(ATCC) containing 10% heat inactivated calf serum (Hyclone). HCC1954, A431 and 
Jurkat cells were cultured in RPMI 1640 (Lonza) containing 10% heat inactivated calf 
serum. AU565 cells were cultured in RPMI 1640 supplemented with 10% heat inac-
tivated calf serum, 1% sodium bicarbonate (Lonza), 0.5% natrium pyruvate (Lonza) 
and 0.5% glucose (Sigma). To guarantee cell line authenticity, cell lines were aliquot-
ed and banked, and cultures were grown and used for a limited number of passages 
before starting a new culture from stock. Cell lines were routinely tested for myco-
plasma contamination. TF, HER2 and EGFR cell surface expression was quantified by 
QIFIKIT analysis (DAKO) according to the manufacturer’s guidelines, using a mouse 
anti-human TF antibody (CLB), mouse anti-human HER2 antibody (R&D) and mouse 
anti-human EGFR antibody (BD) as described in supplementary method S1.
Antibody generation and conjugation
Human IgG1ĸ monoclonal antibodies were generated in human antibody transgenic 
mice; HuMAb® mice (Medarex), using hybridoma technolgy [21]. Tissue Factor anti-
bodies were previously described [4]. In brief, TF-011 binds TF, interferes with FVIIa 
binding and inhibits ERK-phosphorylation. TF-111 binds TF and partially interferes 
with FVIIa binding and ERK-phosphorylation. The HER2 mAbs 153 and 005 were 
described by de Goeij et al. [22]. Both antibodies bound to epitopes distinct from 
those recognized by trastuzumab and pertuzumab. Upon binding to HER2, mAb 153 
inhibits ligand-induced HER2 proliferation. mAb 005 has no effect on HER2 induced 
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proliferation. The EGFR mAbs zalutumumab and nimotuzumab (Biacon) both inhibit 
ligand binding and EGFR driven proliferation. Zalutumumab does so with high affin-
ity [23], while nimotuzumab blocks EGF binding with low affinity [24].
Duostatin-3 conjugated antibodies were generated by covalent  conjugation of 
 valine-citrulline-duostatin-3 on antibody lysine groups as described in WO/2013/ 
173391. The synthesis of duostatin-3 is also described in the supplementary  method 
S2. Each resulting duostatin-3 conjugated ADC contained an average of 2 drug 
 molecules per antibody, as determined by hydrophobic interaction chromatography 
(HIC). Duostatin-3 conjugated antibodies were referred to as TF-ADC, HER2-ADC and 
 EGFR-ADC. TF-011 was also conjugated with maleimidocaproyl-valine- citrulline-p-
aminobenzoyl-monomethyl auristatin E (vcMMAE, licensed from Seattle Genetics) 
on cysteine groups in the antibody hinge region, to generate TF-011-MMAE (HuMax-
TF-ADC), as described [4]. This ADC was referred to as TF-011-MMAE throughout the 
manuscript. TF-011-MMAE contained an average of 4 drug molecules per antibody.
Confocal microscopy
Cells were grown on glass coverslips (Thermo Fisher Scientific) at 37°C for 16 hours. 
In case of antibody stimulation, cells were pre-incubated 1 hour with 50 μg/mL leu-
peptin (Sigma) to block lysosomal activity followed by 1 or 16 hours incubation with 
1 μg/mL EGFR-, HER2- or TF-antibody. Cells were fixed, permeabilizedand incubated 
45 min with mouse anti-human TF (CLB), HER2 (R&D) and EGFR (BD Pharmingen) 
antibodies, followed by goat anti-mouse IgG1-FITC (DAKO) to identify receptors, or 
goat anti-human IgG1-FITC (Jackson) to stain for human EGFR-, HER2- and TF- anti-
bodies. Endosomes were stained with rabbit anti-human transferrin (Life Technolo-
gy) and goat anti-rabbit IgG-Alexa-568 (Bio-connect), lysosomes were stained with 
mouse anti-human CD107a-APC (BD). Finally, coverslips were mounted (Calbiochem) 
on microscope slides and imaged with a Leica SPE-II confocal microscope (Leica 
Microsystems) equipped with LAS-AF software. 12-bit grayscale TIFF images were 
 analyzed for colocalisation using MetaMorph® software (Molecular Devices). Colocal-
isation was calculated as the FITC pixel intensity overlapping with APC (lysosomes) 
or AlexaFluor568 (endosomes) and expressed as percentage of total FITC intensity.
Surface protein downmodulation assay
SK-OV-3 and A431 cells were seeded in 96-wells non-binding plates (Greiner), 
100,000 cells/well, in serum-free culture medium, with or without 100 µM mon-
ensin (Dako) to block recycling of endosomes (30 minutes, 37°C) [25]. Next, human 
TF-, HER2- and EGFR- antibodies (10 µg/mL), EGF (Biosource, 50 ng/mL) or FVIIa 
(Novoseven, 100 ng/mL) were added for 3 hours (37°C). Remaining TF, HER2 or EGFR 
at the plasma membrane were stained with non-competing mouse TF (CLB), HER2 
(R&D) and EGFR antibodies (BD) (30 min, 4°C), followed by incubation with goat 
 anti-mouse IgG-FITC (Jackson, 30 min, 4°C). Mean Fluorescence Intensity (MFI) of 
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FITC was measured on a flow cytometer (BD). Quantification of cell surface proteins 
was done using QIFIKIT® (Dako) according to the manufacturer’s instructions [26].
Total protein downmodulation assay
Cells were seeded (100,000 cells/well) in 96-wells culture plates (Greiner). After 
4 hours cells were pre-incubated with 100 µM chloroquine (Sigma) or 100 µg/mL 
 leupeptin (Sigma, 30 min, 37°C), followed by incubation with 10 µg/mL human TF, 
HER2 or EGFR antibodies. After 48 hours, cells were washed, lysed and total protein 
levels were quantified using bicinchoninic acid (BCA) protein assay reagent (Pierce), 
according to manufacturer’s instruction. Next, ELISA plates (Greiner) were coated 
with 1 µg/mL mouse anti-human EGFR (Millipore), rabbit anti-human HER2 (Cell Sig-
nalling Technology) or mouse anti-human TF (CLB), blocked with 2% chicken serum 
(Hyclone) and incubated with 50 µL cell lysate. Subsequently, EGFR, HER2 and TF 
were detected with mouse anti-human EGFR-biotin (Leica Technologies, 0.5 µg/mL), 
goat anti-human HER2-biotin (R&D, 50 ng/mL) and goat anti-human TF-biotin (R&D, 
0.5 µg/mL). The reaction was visualized as described [27].
Intracellular antibody accumulation
Cells were incubated with 5 µg/mL FITC-conjugated antibodies at either 4°C or 37°C. 
At the indicated time points, cells were transferred on ice to stop internalization and 
washed with ice-cold phosphate buffered saline (B.Braun Melsungen). 50 µL ice-cold 
acid wash buffer (0.2M glycine [Sigma], 4M urea [Sigma], pH2.0) was added for 5 
minutes to remove extracellular bound antibodies and removed through centrifu-
gation. Remaining FITC-fluorescence, originating from internalized FITC-conjugated 
antibodies, was measured using flow cytometry.
CypHer5E internalization assay
Cells were seeded in 96-well plates (Greiner, 20,000 cells/well) and cultured over-
night at 37°C. Ice-cold culture medium with or without 100 μM chloroquine (Sig-
ma) was added for 1 hour at 4°C, to trap internalized antibody in endosomal com-
partments. Next, 1 μg/mL HER2, EGFR or TF antibody, conjugated with CypHer5E 
according to manufacturer’s instructions (GE Healthcare), was added. CypHer5E is 
a pH-sensitive dye which is non-fluorescent at basic pH (extracellular: culture me-
dium) and fluorescent at acidic pH (intracellular: endosomes, lysosomes). After 30 
minutes, the cells were washed and fresh culture medium (37°C) was added. The 
cells were incubated 24 hours at 37°C. At indicated time points MFI of internalized 
CypHer5E was measured per well using homogeneous Fluorometric Microvolume 
Assay Technology (FMAT, Applied Biosystems). As read out, fluorescence per cell was 




Mixed cell cultures were treated with ADC to simultaneously determine the amount 
of target cell kill and bystander kill. HER2, EGFR and TF expressing tumor cells were 
used as target cells and seeded (5,000 cells/well) in 96-well culture plates. Antigen 
negative Jurkat cells were used as bystander cells and added to the plate (20,000 
cells/well). To discriminate between both cell populations, Jurkat cells were labelled 
with CellTraceTM carboxyfluorescein diacetate succinimidyl ester (CFSE) according 
to manufacturer’s instructions (Invitrogen). Next, serially diluted ADCs (10-0.000001 
µg/mL) were added and the cells were incubated 4 days at 37⁰C. Cells were  harvested 
and viability was assessed through live/dead staining on a flow cytometer. Target 
cell kill was plotted as the percentage of viable CFSE-negative cells. Bystander kill 
was plotted as the percentage of viable CFSE-positive cells.
Alternatively, 500,000 CFSE labeled cells were cultured in T25 flasks (Greiner) in 
presence of 2 µg/mL ADC. After 3 days the viable cells were harvested and ana-
lyzed for antigen expression using mouse TF (CLB), HER2 (R&D) and EGFR antibodies 
(BD) and goat anti-mouse IgG1-APC (Jackson). Each sample was spiked with 10,000 
CFSE-negative Jurkat cells. During flow cytometry analysis, the CFSE-negative Jur-
kat cells were gated and 3,000 events were measured in this gate, while all events 
were stored and analyzed.
Tumor xenograft models
6-11 week old female SCID mice (C.B-17/IcrPrkdc-scid/CRL) were purchased from 
Charles River. Subcutaneous tumors were induced by inoculation of 5 x 106 cells 
in the right flank of the mice. Tumor volumes were calculated from digital caliper 
measurements as 0.52 x length x width2 (mm3). When tumors reached 200-400 mm3, 
mice were grouped into groups of 7 mice with equal tumor size distribution and 
mAbs were injected intraperitoneally at indicated time points (1 or 4 mg/kg). During 
the study, blood samples were collected into heparin-containing tubes to confirm the 
presence of human IgG in plasma. IgG levels were quantified using a Nephelometer 
(Siemens Healthcare). Mice that did not show human IgG in plasma were excluded 
from the analysis. Some mice developing ulcerations not related to tumor size, were 
euthanized for ethical reasons before the end of the study, which is indicated by the 
censored data points.
Statistical analysis
Data analysis was done using GraphPad Prism 5 software. Group data were  reported 
as mean ± SD. One-way ANOVA was applied for statistical analysis. Statistical  analysis 
of xenograft studies was done with one-way ANOVA at the last day that all groups 
were complete. Mantel-Cox analysis of Kaplan-Meier curves was performed to ana-
lyze statistical differences in progression-free survival time.
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RESULTS
Tissue Factor distribution in unstimulated tumor cells
In healthy tissue, TF is primarily expressed in intracellular pools and remains 
 sequestered from circulating FVII [17,18,28]. To determine TF distribution in can-
cer cells we applied confocal microscopy. For this, we selected two cell lines based 
on aberrant expression of HER2 and TF (SK-OV-3, ovarian cancer) or EGFR and TF 
(A431, epithelial carcinoma), as depicted in Table 1. The cells were grown on glass 
coverslips, left unstimulated and stained for TF, EGFR and HER2. Markers of recycling 
endosomes (i.e. transferrin) and lysosomes (i.e. LAMP1) were included to determine 
compartmentalization of the different proteins. Figure 1A-C demonstrates that, in 
resting SK-OV-3 cells, TF is primarily localized intracellularly and partially colocal-
izes with the lysosomal marker LAMP1. EGFR and HER2 staining on the other hand 
was mainly localized to the plasma membrane.
Cell line Origin TF (molecules/cell) EGFR (molecules/cell) HER2 (molecules/cell)
HCC1954 Breast cancer 400,000 100,000 600,000
A431 Epithelial cancer 200,000 500,000 30,000
SK-OV-3 Ovarian cancer 100,000 50,000 200,000
AU565 Breast cancer 20,000 100,000 500,000
TABLE 1 Number of molecules on plasma membrane. Average number of EGFR, HER2 and TF 
molecules expressed on the cell surface, calculated with quantitative flow cytometry as described in 
supplementary method S1.
Also in A431 cells (Figure 1D) and HCC1954 cells (Supplementary Figure S1), TF was 
more abundantly present in lysosomes as compared to EGFR and HER2, suggesting 
that TF has a high turnover in these tumor cells. This was confirmed by ELISA where 
total protein levels of TF, EGFR and HER2 were measured in absence and presence 
of inhibitors of lysosomal degradation (Figure 1E). Total protein levels of EGFR and 
HER2 were unaffected by addition of chloroquine, an inhibitor of endosomal acidi-
fication [29] or leupeptin, an inhibitor of lysosomal proteases. However, TF protein 
levels were increased over 2-fold when lysosomal degradation was blocked with 
chloroquine, indicating that TF is continuously transported from endosomal to lyso-
somal compartments to undergo degradation.
The enhanced colocalisation of TF with transferrin (Figure 1D) suggests that at least 
a part of the intracellular TF pool originated from the plasma membrane [30]. There-
fore we next investigated downmodulation of surface expressed receptors using 
quantitative flow cytometry. SK-OV-3 cells were incubated with the TF ligand FVIIa 
or the EGFR ligand EGF, after which residual receptor expression was quantified. 
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Monensin was added to block transport of intracellular receptors to the cell surface 
and thereby trap internalized proteins in the cell. Figure 1F shows that FVIIa alone 
had no effect on surface expression of TF, whereas monensin significantly reduced 
TF expression, indicating that TF is constitutively recruited from intracellular pools 
to the plasma membrane. Previous reports have described the internalization of 
TF in presence of FVIIa [16,31], our data demonstrate that TF is also internalized 
in  absence of FVIIa. EGF on the other hand induced significant downmodulation of 
surface expressed EGFR which was in line with previous reports [32], while HER2 
expression was unaffected by EGF and monensin.
In summary, unlike EGFR and HER2, TF was continuously internalized and degraded, 
even in resting tumor cells. This suggests that the efficacy of TF-specific ADCs may 
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FIGURE 1 Distribution of HER2, EGFR and 
TF in unstimulated tumor cells. (A-C, page 
44) Confocal microscopy images (8-bit) 
of unstimulated SK-OV-3 cells. The left 
panel shows staining of HER2 (A), EGFR 
(B) and TF (C) with murine antibodies and 
goat anti-mouse IgG-FITC (green). In the 
middle panel lysosomes were stained with 
mouse anti-human LAMP1-APC (red). The 
right panel shows the overlay (yellow). (D) 
Quantification of endosomal and lysosomal 
receptor colocalisation. Each bar represents 
4 different 12-bit images ± standard 
deviation. E=endosomes L=lysosomes. (E) 
Downmodulation of total protein expression. 
Cells were incubated for 2 days with 100 
μM chloroquine or 100 μg/mL leupeptin, 
after which protein levels were measured 
with ELISA and expressed as percentage 
compared to untreated cells. Data shown are 
mean ± standard deviatin. (F) Surface protein 
downmodulation on SK-OV-3 cells measured 
with quantitative flow cytometry. Cells were 
preincubated 30 minutes with (+) or without 
(-) monensin and incubated an additional 
3 hours with 50 ng/mL EGF or 100 ng/mL 
FVIIa. Surface expression of remaining TF, 
EGFR and HER2 was quantified and plotted 
as percentage relative to untreated cells. 
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Antibody binding to TF triggers internalization of mAb/TF-complexes
For certain receptors, antibody binding results in internalization of the Ab/recep-
tor-complex [32]. To investigate whether Ab/TF-complexes were internalized, we 
incubated SK-OV-3 and A431 cells for three hours at 37°C with antibodies directed 
against TF, EGFR and HER2. The cells were cooled to 4°C and remaining extracellular 
proteins were quantified using non-competing murine TF, EGFR and HER2 antibod-
ies. Figure 2A demonstrates that TF-011 and TF-111 induced significant downmod-
ulation of extracellular TF, which was not observed with Fab fragments of mAb TF-
011 or the TF physiological ligand FVIIa. The tested EGFR and HER2 antibodies had 
no effect on extracellular expression of EGFR and HER2 respectively. The experiment 
was also performed in presence of the recycling inhibitor monensin. For EGFR and 
TF, this further decreased extracellular expression (data not shown).
Next, it was investigated whether antibody-mediated downmodulation of total pro-
tein levels. SK-OV-3 and A431 cells were incubated for 2 days with EGFR, HER2 and 
TF antibodies, lysed and subjected to ELISA to measure the degree of protein. Figure 
2B shows that TF-011 induced downmodulation of total TF protein in both cell lines. 
Also a slight reduction of EGFR protein levels was observed upon incubation with 
EGFR antibody zalutumumab, but no effect on HER2 protein levels was observed 
with any of the HER2 antibodies.
To exclude that the reduced protein levels depicted in Figure 2A result from anti-
body-induced shedding of TF, intracellular accumulation of FITC-conjugated antibod-
ies was assessed to confirm that Ab/TF-complexes were indeed internalized. Cells 
were incubated with FITC-conjugated antibodies at 37°C for 0-9 hours. Prior to flow 
cytometry analysis, extracellular FITC-conjugated antibodies were removed through 
acid wash and residual FITC fluorescence, originating from internalized FITC-conju-
gated antibodies, was measured on a flow cytometer. As depicted in figure 2C and 
D, both TF antibodies showed accumulation of FITC fluorescence over time, demon-
strating that these antibodies were efficiently internalized.
TF/TF-011 complexes are rapidly targeted to the lysosomes
For an ADC-approach, it is typically required that internalized antibodies traffic to 
lysosomes where cellular proteases can initiate drug release [33]. Using confocal 
microscopy, lysosomal transport of TF, EGFR and HER2 antibodies was analyzed. 
SK-OV-3 and A431 cells were incubated with the indicated antibodies, and after 1 or 
16 hours cells were fixed, permeabilized and stained with FITC-conjugated goat-α-
human IgG1. After one hour, TF-011 already demonstrated clear internalization and 
lysosomal colocalisation (Figure 3A). EGFR antibody zalutumumab was also internal-
ized after one hour, but the internalized antibody had not yet reached the lysosomes 
(Figure 3C), while HER2 antibody 005 only stained at the plasma membrane (Figure 
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FIGURE 2 Antibody-mediated internalization and downmodulation of TF, EGFR and HER2. (A) 
Downmodulation of surface expressed proteins measured with flow cytometry. SK-OV-3 and A431 cells 
were incubated with 10 μg/mL antibody. After 3 hours, remaining surface expression of the different 
receptors was analyzed with quantitative flow cytometry and expressed as percentage relative to 
untreated cells. (B) Downmodulation of total protein levels. SK-OV-3 and A431 cells were incubated 
with 10 μg/mL antibody. After two days protein levels were measured with ELISA and expressed as 
percentage compared to untreated cells. Data shown are mean ± standard deviation. (C-D) Intracellular 
accumulation of FITC-conjugated antibodies measured with flow cytometry. (C) A431 and (D) SK-OV-3 
cells were incubated with 10 μg/mL Ab-FITC at 4°C and 37°C. At the indicated timepoints, extracellular 
bound Ab-FITC was removed through acid wash and MFI of intracellular FITC was analyzed with flow 


























































































































































































FIGURE 3 Lysosomal colocalisation of TF, EGFR and HER2 antibodies. (A-F) Confocal microscopy 
analysis of SK-OV-3 (A-B, E-F) and A431 (C-D) cells demonstrating fast and increased lysosomal 
transport of TF-011. Lysosomes were stained with mouse anti-human LAMP1-APC (red). Zalutumumab 
(anti-EGFR), 005 (anti-HER2) and TF-011 (anti-TF) were detected with goat anti-human IgG1-FITC 
(green). (G) Arbitrary units [AU] represent the total pixel intensity of antibody overlapping with the 
lysosomal marker LAMP1, divided by the total pixel intensity of LAMP1. Data shown are mean ± 
standard deviation of 4 images. (H-K) Lysosomal targeting of CypHer5E conjugated mAbs. SK-OV-3 
cells, preincubated with or without 100 μM chloroquine, were incubated with CypHer5E-conjugated 
antibodies: TF-011 (H), zalutumumab (I), 005 (J) and 153 (K).  At the indicated time points, CypHer5E 
fluorescence was measured using homogeneous Fluorometric Microvolume Assay Technology. The grey 















































































































































































































Rapid internalization of tissue factor antibody-drug conjugates 49
















































































































































































sosomal colocalisation, but TF mAbs were most abundantly present in lysosomes 
(Figure 3B, D, F and G). Additionally, receptor distribution was tested after antibody 
treatment (Supplementary Figure S2). Both TF-antibodies significantly increased the 
amount of TF in endosomes and lysosomes of SK-OV-3 and A431 cells. EGFR mAbs 
zalutumumab and nimotuzumab also enhanced endosomal and lysosomal colocal-
isation of EGFR in A431 cells. In contrast, cellular distribution of HER2 was hardly 
affected by HER2 antibodies 005 and 153.
The more rapid lysosomal colocalisation of TF-mAbs, led us to investigate TF me-
diated internalization and lysosomal targeting in more detail. By conjugating TF, 
HER2 and EGFR mAbs with CypHer5E, a dye that becomes fluorescent at acidic pH, 
we were able to follow internalization and lysosomal colocalisation over time. Both 
endosomes and lysosomes are acidic environments that induce fluorescence of 
 CypHer5E. To distinguish between fluorescence resulting from endosomal and lyso-
somal transport, SK-OV-3 cells were preincubated with chloroquine, which inhibits 
the acidification and fusion of endosomes with lysosomes [34]. Thus, inhibition of 
CypHer5E fluorescence by chloroquinine is indicative of lysosomal transport. This 
was most evident for TF-011 (Figure 3H). Whereas fluorescence of CypHer5E conju-
gated mAbs 005, 153 and zalutumumab was only inhibited after 24 hours incubation 
(Figure 3I-K), fluorescence of TF-011-CypHer5E was already inhibited within one 
hour. This shows that TF bound antibodies were rapidly transported to lysosomes, 
while lysosomal transport of EGFR and HER2 mAbs was relatively slow.
In vitro cytotoxicity induced by duostatin-3-conjugated TF, EGFR and HER2 
antibodies
To investigate whether the more rapid lysosomal targeting observed with TF mAbs, 
results in increased cytotoxicity of TF-directed ADCs, we conjugated antibodies TF-
011, 005 and zalutumumab with duostatin-3 using a valine-citrulline linker that is 
cleaved by intracellular proteases such as cathepsin B. Duostatin-3 is an antimitotic 
agent that inhibits cell division by blocking of tubulin polymerization. Unlike vcM-
MAE, duostatin-3 can not kill neighbouring tumor cells when the drug is released 
from the antibody. This was also demonstrated in Figures 4B, D and F, where duosta-
tin-3 conjugated antibodies did not induce bystander kill. Whereas TF-011-MMAE 
induced potent bystander kill which was in line with results published previously 
[4,33]. To study the target requirements needed for efficient intracellular drug deliv-
ery, a drug-linker that only affects antigen expressing cells was preferred. Figure 4A, 
C and E, show that duostatin-3 conjugated HER2 and EGFR antibodies only induced 
cytotoxicity when tumor cells highly overexpress their targets HER2 (AU565 and SK-
OV-3) and EGFR (A431 and AU565) respectively. Viability of tumor cells that display 
moderate overexpression of HER2 (A431) or EGFR (SK-OV-3) was hardly affected. 
In contrast, TF-mAbs conjugated with duostatin-3 induced cytotoxicity in all tested 
cell lines, including cells that express less than 20,000 TF molecules/cell. Analysis of 
target cell kill
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FIGURE 4 Cytotoxicity of TF-ADC, EGFR-ADC, HER2-ADC and TF-011-MMAE in vitro. SK-OV-3 (A-B), 
A431 (C-D) and AU565 (E-F) cells were seeded in 96-wells tissue culture plates together with CFSE-
labeled Jurkat cells. Serially diluted ADCs and isotype control antibody were added to the cells. After 
4-days incubation at 37°C viability was assessed on a flow cytometer. Target cell kill was plotted as the 
percentage of viable CFSE- SK-OV-3, A431, and AU565 cells (left panel). Bystander kill was plotted as 
the percentage of viable CFSE+ cells (right panel).
target cell kill




















































































































TF-expression in SK-OV-3 cells that survived TF-ADC-treatment demonstrated that 
TF expression was similar before and after treatment (Table 2 and supplementary 
figure S3). However, the proliferation-rate of the surviving cells was reduced, as in-
dicated by the high CFSE fluorescence of the surviving cells. This indicates that lack 
of efficacy against these cells was caused by their low proliferation-rate, rather than 
lack of target expression.
Anti-tumor activity of duostatin-3-conjugated TF, EGFR and HER2 antibodies in vivo
Finally, the effect of ADC treatment on tumor growth was assessed in vivo. The 
ADCs were compared in two different tumor xenograft models, starting with the 
breast cancer model HCC1954 (Figure 5A-B) which highly overexpressed HER2 and 
TF  (Table 1). Figure 5B demonstrates that treatment with a single dose of 1 mg/kg 
TF-ADC resulted in significant inhibition of HCC1954 tumor growth as compared to 
animals treated with isotype control ADC. At the same dose, HER2-ADC had no effect 
on tumor growth. At 4 mg/kg, both ADCs induced tumor regression, which was sus-
tained until at least 67 days post treatment.
Using the epidermal carcinoma model A431, ADCs targeting TF and EGFR were com-
pared (Figure 5C-D). A single dose of 1 mg/kg TF-ADC induced significant inhibition 
of tumor growth, which was increased at 4 mg/kg. EGFR-ADC only reduced tumor 
growth at 4 mg/kg, a dose at which TF-ADC treatment was significantly more ef-
fective. Overall, TF-ADC treatment induced significant inhibition of tumor growth. 
Despite the reduced expression of TF as compared to HER2 and EGFR, TF-ADC out-
performed HER2- and EGFR- ADCs. Hence these data demonstrate the potential of TF 
as tumor target for an ADC approach.
DISCUSSION
Antibodies conjugated with tubulin inhibitors have demonstrated impressive pre-
clinical and clinical anti-tumor activity [1,20,35,36]. However, the optimal target 
characteristics for ADC development are not entirely clear. Most ADCs are depen-
dent on internalization and lysosomal targeting to release their cytotoxic compound. 
Thus the internalization characteristics of a tumor target may greatly contribute to 
the efficacy of ADCs directed against that target. In addition, binding of antibodies 
or ADCs to specific tumor targets may change the internalization characteristics of 
the tumor target. In this study, the internalization characteristics of three different 
tumor targets, TF, EGFR and HER2, as well as antibodies and ADCs specific for those 
targets, were compared. Internalization, lysosomal sorting and intracellular degra-
dation of the three proteins were analysed in absence and presence of monoclonal 
antibodies. The combination of TF and antibody TF-011 was the only combination 
demonstrating efficacy in all assays. TF demonstrated significant and constitutive 
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FIGURE 5 Efficacy of TF-ADC, HER2-ADC and EGFR-ADC in tumor xenograft models. Mice were 
inoculated subcutaneously with 5 x 106 HCC1954 (A-B) or A431 (C-D) cells. When average tumor 
volume reached >200 mm3, mice were divided in groups of 7 mice with equal tumor size distribution 
and injected intraperitoneally at indicated time points with 4 mg/kg or 1 mg/kg mAb or ADC. Tumors 
were measured twice a week by using calipers, and the median (A) or mean ± SE (C) tumor volume 
(mm3) was plotted against time, as well as time to progression indicated by the percentage of tumors 
<750mm3 (B) or <500mm3 (D). In the HCC1954 model, some mice developed ulcerations unrelated 
to tumor size or Ab-treatment. These mice were withdrawn from the study as indicated by the 
censored data points (B). Median tumor volumes were not calculated when more than 3 mice had been 
withdrawn (A). *P<0.05, ** P<0.001
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internalization, lysosomal colocalisation and degradation in tumor cells, all of which 
were increased upon incubation with TF-011. Given the potential of TF as target 
for an ADC approach, TF-, EGFR- and HER2- mAbs were conjugated with the cleav-
able linker-drug vcDuostatin-3, generating ADCs that provide specific tumor target-
ing with a payload only affecting proliferating cells. We found that TF-ADC outper-
formed HER2-ADC and EGFR-ADC in two different tumor xenograft models.
Quantitative flow cytometry analysis of tumor cell lines revealed that, like EGFR 
and HER2, TF can be aberrantly expressed on tumor cells. Compared with normal 
melanocytes, more than 1000-fold increased TF expression has been reported on 
metastatic human melanoma cells [37]. In the tumor models selected here, extracel-
lular expression of TF was lower compared to EGFR and HER2. However, despite the 
lower antigen expression, the anti-tumor activity of TF-ADC was more potent com-
pared to HER2- and EGFR- ADCs. This can be explained by the efficient transport of 
TF-011 from the plasma membrane into lysosomes of tumor cells as demonstrated 
with confocal microscopy. Previous publications also indicate that TF has a higher 
turnover rate compared to EGFR and HER2. Hamik et al. demonstrated that the half-
life of TF on monocytes was 3.7 hours, which could be reduced to 1.3 hours when 
TF was bound by tissue factor protein inhibitor and FVII [38]. Unstimulated EGFR 
and HER2 on the other hand have a half-life of 6-24 hours depending on the cell 
line used [39]. Since TF is the main physiological initiator of the coagulation cascade, 
which represents a system that needs to be tightly regulated it makes sense that TF 







EGFR 40100 26613 65493
EGFR + EGFR-ADC 17858 21380 93951
HER2 39836 90735 65493
HER2 + HER2-ADC 7034 76490 122213
TF 42522 51237 65493
TF + TF-ADC 2403 45816 175662
TABLE 2 Flow cytometry analysis of SK-OV-3 cells after ADC-treatment. SK-OV-3 cells were labeled 
with CFSE, a dye that is stably fluorescent and that is transferred to daughter cells upon cell division 
with its fluorescence being halved. Thus reduced CFSE fluorescence indicates SK-OV-3 proliferation. 
CFSE labeled cells were treated 3 days with 2 µg/mL ADC after which cytotoxicity was analysed as well 
as expression of the antigen targeted by the respective ADC. Cytotoxicity was expressed as number of 
events measured on a flow cytometer. Antigen expression was detected with mouse anti-HER2, anti-
EGFR and anti-TF antibodies in combination with APC-conjugated rabbit anti-mouse and depicted as MFI 
of APC.
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Internalization of TF has been studied previously [16,40] and is believed to be an 
active process which can be enhanced through binding of FVIIa. We did not observe 
FVIIa mediated internalization of TF. Instead we found that TF was constitutively 
being turned over on tumor cells, a process which was not influenced by presence of 
FVIIa. Most studies focussing on internalization of TF:FVIIa complexes made use of 
radiolabelled FVIIa [16,31,41]. Our studies, using TF expression as read out, demon-
strate that FVIIa most likely piggy-backs with internalizing TF. Various cancer cells 
including ovarian cancer cells have been reported to produce FVII themselves [42], 
however we did not detect FVII production in culture supernatant (data not shown).
Although the more rapid internalization and lysosomal targeting of TF seem funda-
mental for effective ADC treatment, the potent anti-tumor effect of TF-ADC can not 
be fully ascribed to the target characteristics of TF alone. Antibody selection plays 
an important role as well. This was illustrated by the increased internalization and 
lysosomal targeting observed with TF-011. While TF-011 is expected to crosslink 
extracellular TF, Fab-011 and FVII lack the ability to crosslink TF, indicating that 
mAb-induced crosslinking may be critical to increase downmodulation of extracel-
lular TF. TF-111 on the other hand only seems to crosslink TF when highly overex-
pressed. Moreover differential antibody binding at low pH may influence intracel-
lular trafficking of ADCs and consequently increase their lysosomal transport. Flow 
cytometry analysis of antibody binding at pH6 and pH7.4 revealed no differences 
in binding at reduced pH (Supplementary Table S1). Also no substantial differences 
were observed between apparent affinities of antibodies targeting TF, EGFR and 
HER2 (Supplementary Table S1). The low affinity EGFR mAb nimotuzumab was an 
exception to this and showed low apparent affinity binding to EGFR expressing cells 
(EC50 value 15.6 nM). Furthermore, inhibition of receptor signalling and engage-
ment of immune effector cells may contribute to the anti-tumor activity of ADCs as 
well. However, treatment of established A431 xenografts with comparable dosing 
of unconjugated mAbs induced significantly less (EGFR-mAb [43]) or no (TF-mAbs 
[4]), inhibition of tumor growth. The unconjugated HER2 antibody 005 demonstrated 
modest inhibition of in vivo tumor growth, when tested at >10-fold higher dose in a 
high HER2 expressing tumor model (data not shown).
While EGFR and HER2 belong to a family of receptor tyrosine kinases, for which en-
docytic trafficking has been extensively investigated, TF is a member of the class II 
cytokine receptor superfamily. To date, little is known about intracellular trafficking 
of these proteins and their potential use in ADC based therapy. Our data indicate 
that such targets can be very attractive for an ADC-approach because of their rapid 
internalization, lysosomal targeting and degradation, which may be inherent to their 
physiological roles in regulating immune responses [44,45]. Taken together, these 
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data support the use of TF-ADC in cancer therapy and a clinical study is underway to 
assess the safety and efficacy of TF-011-MMAE, an auristatin-conjugate of antibody 
TF-011, for the treatment of patients with solid cancers.
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SUPPLEMENTARY METHODS
Quantitative determination of cell surface antigens.
Qifikit (DAKO) was used to detect and quantify cell surface expression of TF, HER2 
and EGFR, according to manufacturer’s protocol (1). In brief; cells were stained 
with 10 μg/mL mouse anti-human TF (CLB), mouse anti-human HER2 (R&D), mouse 
 anti-human EGFR (BD), following incubation with polyclonal goat anti-mouse IgG FITC 
(DAKO). In parallel a series of bead populations, containing a well-defined number 
of antibody molecules per bead, was stained with the polyclonal goat anti-mouse 
IgG FITC antibody. Mean fluorescence intensities (MFI) were measured using flow 
cytometry, and a calibration curve with the MFI of the individual bead populations 
was plotted against the number of mAb molecules on the beads. This curve was used 
to interpolate the number of TF, HER2 and EGFR molecules per cell.
Duostatin-3 synthesis
PREPARATION OF COMPOUND 3 To a solution of Boc-L-phenylalanine 1 (5.36 g, 20.2 mmol) in 
30 mL of methylene chloride (DCM), carbonyldiimidazole (CDI, 4.26 g, 26.3 mmol) was added and stirred 
for 1 hour. Then added a solution of 2 (3.67 g, 30.3 mmol) and 2,4-diaminobutyric acid (DBU, 4.5 mL, 
30 mmol) in 15 mL of DCM. The mixture was heated at 40°C for 16 hours. The mixture was diluted 
with 60 mL of DCM and 40 mL of water, then neutralized to pH 7 with conc. HCl. The DCM extract was 
collected, washed with 0.2M HCl (60 mL), then with brine (60 mL), dried over Na2SO4, and evaporated 
to give 7.47 g of Boc-protected sulfonamide. This material was suspended in 40 mL of methanol, then 
200 mL of 6N HCl/isopropanol was added and the mixture was stirred for 2 hours. The solvent was 
evaporated under vacuum, 100 mL of ether was then added. The precipitate was collected by filtration 








































































































PREPARATION OF COMPOUND 5 To a solution of compound 4 (1.09 g, 1.6 mmol) in 10 mL of 
N,N-Dimethylformamide (DMF) was added 2-(lH-7-azabenzotriazol-l-yl)-l,l ,3,3-tetramethyl uranium 
hexafluorophosphate (HATU, 0.61 g, 1.6 mmol), diisopropylethylamine (DIEA, 0.56 mL), and compound 
3 (0.49 g, 1.6 mmol) in that order. The mixture was stirred for 1 hour and diluted with 100 mL of water 
and 4 mL of acetic acid. The precipitate was collected by filtration, dried under vacuum and added 
to 10 mL of 4M HCl/dioxane. After 30 min, 200 mL of ether was added and insoluble precipitate was 
collected and purified by HPLC to give compound 5 as tetrahydrofuran salt (TFA, 1.3 g, 88%); MS m/z 
835.5 (M+H). Compound 5 is referred to as duostatin-3 throughout the manuscript.
PREPARATION OF COMPOUND 7 To a solution of compound 5 (500 mg, 0.527 mmol) in 5 mL of DMF 
was added compound 6 (483 mg, 0.631 mmol), N-Hydroxybenzotriazole (HOBt, 40 mg, 0.296 mmol), 
and DIEA (0.27 mL). The mixture was stirred for 16 hours after which 0.4 mL of piperidine was added. 
After 1 hour, the mixture was diluted with 100 mL of ether and the precipitate was collected and dried 
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PREPARATION OF COMPOUND 9 To a solution of compound 8 (219 mg, 0.62 mmol) in 5 mL of 
DMF was added HATU (236 mg, 0.62 mmol), DIEA (0.15 mL), and compound 7 (316 mg, 1.6 mmol), 
respectively. After 1 hour, 0.2 mL of piperidine was added and the mixture was stirred for 30 min, then 
purified by HPLC to give compound 9 as TFA salt (235 mg, 64 %); MS m/z 1353.8 (M+H).
PREPARATION OF COMPOUND 11 To a solution of compound 9 (235 mg, 0.16 mmol) in 2 mL of 
methanol and 1 mL of water was added a solution of dialdehyde 10 (1.6 mL of 0.3M in iPrOH) and 
NaCNBH3 (180 mg, 2.85 mmol). The mixture was stirred for 2 hours at RT, and then purified by HPLC 

































































































































































Antibody Antigen EC50 pH7.4 (nM) EC50 pH6.0 (nM)
011 TF 0.69 0.61
111 TF 0.49 0.47
005 HER2 1.63 1.10
153 HER2 0.57 0.55
Zalutumumab EGFR 0.93 1.45
Nimotuzumab EGFR 15.6 13.8
SUPPLEMENTARY TABLE S1 Apparent antibody affinities. Apparent antibody affinities at pH7.4 and 
6.0 measured using flow cytometry. SK-OV-3 cells, overexpressing TF, EGFR and HER2 were incubated 
with TF, EGFR and HER2 antibodies diluted in FACS-buffer at pH7.4 and FACS-buffer adjusted to pH6.0 
with NaCl. Antibody binding was detected using a phycoerythrin (PE)-conjugated goat anti-human IgG 
antibody diluted in FACS-buffer at pH7.4. PE fluorescence was measured on a flow cytometer and EC50 
values were calculated using GraphPad Prism 5 software.
SUPPLEMENTARY FIGURES
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SUPPLEMENTARY FIGURE S1 Distribution of HER2, EGFR and TF in unstimulated HCC1954 cells. 
(A-C, page 64) Confocal microscopy images (12-bit) of unstimulated HCC1954 cells. The left panel shows 
staining of HER2 (A), EGFR (B) and TF (C) with murine antibodies and goat anti-mouse IgG-FITC (green). 
In the middle panel lysosomes were stained with mouse anti-human LAMP1-APC (red). The right panel 
shows the overlay (yellow). (D) Quantification of endosomal and lysosomal receptor colocalisation. Each 
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SUPPLEMENTARY FIGURE S2 Endosomal and lysosomal colocalisation of TF, EGFR and HER2 in tumor 
cells after treatment with target-specific antibodies. (A-C, page 66) Confocal analysis of SK-OV-3 cells 
demonstrating enhanced TF colocalisation with the lysosomal marker LAMP1 after incubation with 
TF-antibodies. Lysosomes were stained with mouse anti-human LAMP1-APC (red, middle panel). EGFR, 
HER2 and TF were stained with mouse monoclonal antibodies and visualized using goat anti-mouse IgG-
FITC (green, left panel). Colocalisation of EGFR, HER2 and TF staining with the lysosomal marker LAMP1 
is depicted in the overlay (yellow, right panel). (D-E) Pixel intensity of TF, HER2 and EGFR overlapping 
with (D) the endosomalmarker transferrin and (E) the lysosomal marker LAMP1, plotted as a percentage 
of total TF, HER2 and EGFR intensities. Data shown are mean ± standard deviation of 4 images. The 



























































































































SUPPLEMENTARY FIGURE S3 Flow cytometry analysis of SK-OV-3 cells after ADC-treatment. 
Expression of TF, HER2 and EGFR on SK-OV-3 cells that survived ADC-treatment was analyzed using 
flow cytometry. Target expression was depicted on the X-axis as fluorescence intensity of APC. The 
number of surviving cells was depicted on the Y-axis as counts. The APC negative counts represent 
Jurkat cells that were spiked into each sample. Jurkat cells did not express EGFR, HER2 or TF and were 
used for quantification purposes.
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ABSTRACT
Tissue factor (TF) is aberrantly expressed in solid cancers and is thought to con-
tribute to disease progression through its pro-coagulant activity and its capacity to 
induce intracellular signaling in complex with factor VIIa (FVIIa). To explore the pos-
sibility of using TF as target for an antibody-drug conjugate (ADC), a panel of human 
TF-specific antibodies (TF HuMab) was generated. Three TF HuMab, that induced ef-
ficient inhibition of TF:FVIIa-dependent intracellular signaling, antibody-dependent 
cell-mediated cytotoxicity and rapid target internalization, but had minimal impact 
on TF pro-coagulant activity in vitro, were conjugated with the cytotoxic agents 
monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF). TF-specific 
ADCs showed potent cytotoxicity in vitro and in vivo, which was dependent on TF 
expression. TF-011-MMAE (HuMax-TF-ADC) was the most potent ADC and the domi-
nant mechanism of action in vivo was auristatin-mediated tumor cell killing. Impor-
tantly, TF-011-MMAE showed excellent anti-tumor activity in patient-derived xeno-
graft (PDX) models with variable levels of target TF expression, derived from seven 
different solid cancers. Complete tumor regression was observed in all PDX models, 
including models that showed TF expression in only 25-50% of the tumor cells. In 
conclusion, TF-011-MMAE is a promising novel anti-tumor agent with potent activity 
in xenograft models that represent the heterogeneity of human tumors, including 
heterogeneous target expression.
INTRODUCTION
Antibody-drug conjugates (ADCs), which combine the tumor-targeting capacity of 
monoclonal antibodies with the anti-tumor activity of cytotoxic agents, received re-
newed attention in recent years. Trastuzumab emtansine (T-DM1), an ADC composed 
of the HER2-specific antibody trastuzumab and the cytotoxic agent DM1, increased 
progression-free survival in patients that had received prior treatment with uncon-
jugated trastuzumab [1], demonstrating the added value of toxin conjugation to a 
monoclonal antibody. In addition, brentuximab vedotin, a CD30-specific antibody 
coupled to the microtubule disrupting agent monomethyl auristatin E (MMAE), was 
approved for the treatment of relapsed Hodgkin’s lymphoma and relapsed systemic 
anaplastic large cell lymphoma [2]. With at least thirty products in clinical develop-
ment, ADCs represent an exciting new class of anti-cancer drugs.
Tissue factor (TF), also called thromboplastin, factor III or CD142, is aberrantly ex-
pressed in many solid cancers including pancreatic, lung, cervical, prostate, bladder, 
ovarian, breast and colon cancer. Expression has been described on tumor cells and 
the tumor vasculature, and has been associated with poor disease prognosis and in-
creased metastatic properties (reviewed in [3]). This, in combination with the known 
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internalizing capacity of TF [4], led us to explore the possibility of using TF as a novel 
target for an ADC.
TF is the main physiological initiator of the extrinsic coagulation pathway. Proteo-
lytic cleavage of factor VII (FVII), the physiological ligand of TF, generates activated 
FVII (FVIIa), which associates with TF to form the TF:FVIIa complex. This complex 
proteolytically activates coagulation factor X (FX) to generate FXa, eventually lead-
ing to thrombin generation and clot formation [5]. TF is expressed in a wide range 
of organs, including brain, heart, intestine, kidney, lung, placenta, uterus and testes 
[6]. Under physiological conditions, TF expression is mostly restricted to the cells of 
the sub-endothelial vessel wall, such as smooth muscle cells, pericytes and fibro-
blasts, that are not in direct contact with the blood [6]. In healthy individuals, blood 
leukocytes do not express TF on the cell surface, although TF expression has been 
described on 1-2% of monocytes [7,8]. Activation of the coagulation cascade occurs 
when membrane-bound TF is exposed to circulating FVII(a), for example after dis-
ruption of the vessel wall by injury or after up-regulation of TF on monocytes under 
inflammatory conditions [9].
In addition to initiation of coagulation, formation of the TF:FVIIa complex on the cell 
membrane induces an intracellular signaling cascade by activation of protease-ac-
tivated receptor 2 (PAR-2), resulting in the production of pro-angiogenic factors, 
cytokines and adhesion molecules [10]. This signaling cascade is further amplified 
by coagulation factors generated downstream of the TF:FVIIa complex, such as FXa 
and thrombin, all of which recognize one or more receptors of the PAR family [10].
TF-expressing tumor cells are thought to exploit both TF pro-coagulant activity 
and TF:FVIIa-mediated intracellular signaling. Experimental tumor models showed 
that interference with TF using siRNA or monoclonal antibodies reduced tumor out-
growth, tumor-associated angiogenesis and metastatic potential in vivo [11-13]. Pre-
vious studies demonstrated that it is possible to generate TF-specific antibodies that 
have minimal impact on TF pro-coagulant capacity [13,14], potentially allowing spe-
cific targeting of TF-positive tumors without a major impact on hemostasis.
Here, we report the development of TF-011-MMAE, an ADC composed of a human 
TF-specific monoclonal antibody, a protease-cleavable linker and the potent cyto-
toxic agent MMAE. By carefully selecting TF-specific antibodies that interfere with 
TF:FVIIa-dependent intracellular signaling, but not with TF pro-coagulant activity, 
and that show efficient internalization and lysosomal targeting, we developed an 
ADC that efficiently kills tumor cells in vivo with only minimal effect on parameters 
of coagulation. TF-011-MMAE was extensively tested in pre-clinical efficacy studies, 
including studies in patient-derived xenograft (PDX) models that showed heteroge-
neous target expression.
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MATERIALS AND METHOD
Cells
Human tumor cell lines AsPC-1 (pancreas adenocarcinoma; 100,000-300,000 TF 
molecules/cell), BxPC-3 (pancreas adenocarcinoma; >350,000 TF molecules/cell), 
HCT-116 (colorectal carcinoma; <15,000 TF molecules/cell), HPAF-II (pancreas ad-
enocarcinoma; >350,000 TF molecules/cell), MDA-MB-231 (breast adenocarcinoma; 
>350,000 TF molecules/cell), SK-OV-3 (ovarian adenocarcinoma; 50,000-175,000 TF 
molecules/cell) and TOV-21G (ovarian adenocarcinoma; <7,000 TF molecules/cell) 
were obtained from the American Type Culture Collection. The epidermoid adeno-
carcinoma cell line A431 (>300,000 TF molecules/cell) was obtained from the Deut-
sche Sammlung von Mikroorganismen und Zellkulturen GmbH, and HaCaT human 
keratinocytes (150,000-200,000 TF molecules/cell) were a kind gift from Dr. Wiiger 
(Biotechnology Center of Oslo, Norway). To guarantee cell line authenticity, cell lines 
were aliquoted and banked, and cultures were grown and used for a limited number 
of passages before starting a new culture from stock. Cell lines were routinely tested 
for mycoplasma contamination. TF cell surface expression was quantified by QIFIKIT 
analysis (DAKO) according to the manufacturer’s guidelines, using a mouse anti-hu-
man TF antibody (R&D systems).
Recombinant expression of full-length TF or the TF extracellular domain
A codon-optimized construct was generated for the expression of full-length TF (Gen-
bank accession NP001984), cloned into the mammalian expression vector pEE13.4 
(Lonza Biologics) and transfected into Freestyle™ 293-F cells (HEK-293F, Invitrogen) 
or NSO cells as described [15]. To generate recombinant His-tagged soluble TF, PCR 
was used to amplify the part encoding the extracellular domain (aa 1-251) of TF from 
the construct, adding a C-terminal His tag containing 6 His residues (TF-ECDHis). The 
construct was cloned in pEE13.4 and expressed in HEK-293F cells. TF-ECDHis was 
purified from cell supernatant using immobilized metal affinity chromatography.
Generation of human TF-specific antibodies and ADCs
Human IgG1κ TF-specific antibodies (TF HuMab) were generated by immunization 
of HuMAb mice (Medarex) [16] with TF-ECDHis and/or TFexpressing NSO cells. Hy-
bridomas were generated from mice that showed TF-specific antibodies in serum, as 
assessed by binding to TF-transfected HEK293F or A431 cells, or to bead-coupled 
TF-ECDHis using Fluorimetric Microvolume Assay Technology (Applied Biosystems). 
TF-specific hybridomas were identified by screening supernatants for TF-specific 
antibodies as described above. To determine the antibody variable region sequences 
of TF-specific hybridomas, mRNA was extracted and the immunoglobulin variable 
heavy and light chain regions were amplified, cloned and sequenced. Recombinant 
antibodies were generated as described [17], and the recombinant IgG1κ was used 
for further characterization of the TF HuMab. Fab fragments were generated as de-
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scribed [17]. The IgG1κ antibodies IgG1-b12 [18] and HuMab-KLH [19] were included 
as isotype control antibodies.
Antibodies TF-011, -098 and -111, as well as IgG1-b12, were conjugated with MMAE 
through a protease-cleavable valine-citrulline (vc) dipeptide and a maleimido-
caproyl-containing (mc) linker, or with monomethyl auristatin F (MMAF) through an 
mc linker as described [20,21]. The average drug-antibody ratio was 4:1.
Flow cytometry
Binding of TF HuMab and TF-ADCs to membrane-bound TF was analyzed by flow 
cytometry as described [22], using phycoerythrin (PE)-conjugated goat anti-human 
IgG (Jackson ImmunoResearch Laboratories) to detect binding of TF HuMab or ADCs.
Biacore analysis
The affinity of TF HuMab for TF was measured by surface plasmon resonance in a 
Biacore 3000 (GE Healthcare). TF HuMab were immobilized on a CM-5 sensor chip 
(GE Healthcare), according to the manufacturer’s guidelines, and a concentration 
series of TF-ECDHis was injected over the HuMab (30 µL/min; 180 seconds). The 
HuMab surface was regenerated using 10 mM glycine-HCl pH 2.0. Kinetic analysis 
was performed using double reference subtraction and model 1:1 (langmuir) binding 
analysis.
FVIIa ELISA
TF-ECDHis (0.5 µg/mL) was immobilized and incubated with recombinant FVIIa (100 
nM, Novo Nordisk) in the presence of TF HuMab (1 hour (h), room temperature (RT)). 
Plates were washed and incubated with rabbit-anti-FVIIa (2.5 µg/mL; Abcam), fol-
lowed by incubation with swine-anti-rabbit IgG-HRP (1:2,500; DAKO). Binding was 
visualized as described [17].
Phosphorylation inhibition assay – Western Blot
BxPC-3 or HaCaT cells were cultured in serum-free medium for 1.5 h, prior to pre- 
incubation with TF HuMab (30 min, 37°C). Next, cells were stimulated with 10 nM FVIIa 
(10 min, 37°C) and lysed. Phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 were 
detected in cell lysates by Western Blot using standard procedures, using rabbit anti-
p-ERK1/2 and rabbit-anti-ERK1/2 (Cell Signaling technology) as primary antibodies, 
and donkey-anti-rabbit-IgG-HRP (Jackson Immunoresearch) as detection antibody.
IL-8 release assay
MDA-MB-231 cells were cultured in serum-free medium for 105 min, prior to incu-
bation with TF HuMab (15 min). FVIIa (10 nM) was added and after 5 h (37°C), IL-8 
production was measured in culture supernatant by ELISA (Sanquin), according to 
the manufacturer’s protocol.
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FXa generation assay
Recombinant lipidated full-length TF (Innovin; Dade Behring) was incubated with 
TF HuMab in HEPES buffer containing 3 mM CaCl2 (30 min, RT). FXa generation was 
initiated by adding 1 nM recombinant FVIIa and 200 nM FX (Enzyme Research Lab-
oratories). After 30 min (37°C), the reaction was stopped by adding 5 mM EDTA in 
HEPES buffer, and FXa was detected by measuring conversion of the FXa substrate 
Chromogenix-2765 (Instrumation Laboratory Company) according to the manufac-
turer’s guidelines.
Thromboelastography
Citrated human whole blood was obtained from healthy volunteers with the donor’s 
consent and approval from the Ethical committee of the Florida Hospital Center. 
Whole blood was incubated with 10 µg/mL lipopolysaccharide (LPS) or PBS without 
Ca2+ and Mg2+ (4 h, 37ºC), followed by incubation with TF HuMab (10 min, RT). Throm-
boelastography was performed as described [23]. In this system, the LPS-induced 
decrease in clotting lag time (R) represents a measure for TF activity. Antibody-me-
diated inhibition of TF activity was calculated as follows: % inhibition of TF activity = 
100 - ([RNo-LPS – Rtest item+LPS] / [RNo-LPS – Risotype-mAb+LPS] x 100).
Immunofluorescent confocal microscopy
SK-OV-3 and A431 cells were grown on glass coverslips (Thermo Fisher Scientific) at 
37°C for 16 h. Cells were incubated with 50 μg/mL leupeptin (Sigma) for 1 h to block 
lysosomal activity, followed by incubation with 1 μg/mL TF HuMab (1, 3 or 24 h, 
37°C). Cells were fixed with 4% formaldehyde (30 min, RT) and stained with fluores-
cein isothiocyanate (FITC)-labeled goat anti-human IgG (Jackson Immunoresearch) to 
identify TF HuMab, and mouse anti-human CD107a (LAMP-1)-allophycocyanin (APC) 
(BD Pharmingen) to identify lysosomes. Staining was analyzed with a Leica SPE-II 
confocal microscope and LAS-AF software.
Fab-TAMRA/QSY7 internalization and degradation assay
Goat-anti-human IgG Fab-fragments (Jackson Immunoresearch) were conjugated 
with the fluorophore and quencher pair TAMRA/QSY7 (Fab-TAMRA/QSY7) as de-
scribed [24]. TF HuMab (1 µg/mL) were pre-incubated with Fab-TAMRA/QSY7 (2 µg/
mL; 30 min, 4ºC) and the complex was added to SK-OV-3 or A431 cells while shaking 
(200 rpm, 37ºC). After 24 h, TAMRA-fluorescence was measured on a FACS Canto-II 
(BD Biosciences).
Cytotoxicity assay in vitro
Cells were seeded in 96-well plates (2,500-5,000 cells/well) and incubated for 6 h 
(37ºC), before adding ADCs. After 3-5 days (37ºC), the viability of the culture was 
 assessed using Alamar Blue (Biosource International), according to the manufactur-
er’s guidelines. Staurosporine (Sigma, 10 µg/mL) was used a positive control (100% 
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cell death) and untreated cells were used as a negative control. The percentage of 
viable cells was calculated as follows: % viable cells = [(fluorescence test sample 
– fluorescence staurosporine)/(fluorescence untreated cells-fluorescence staurospo-
rine)]*100.
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay
Lysis of tumor cells by ADCC was measured in a 51Cr release assay as described [25], 
using A431, BxPC-3 and MDA-MB-231 cells as target cells and human peripheral 
blood mononuclear cells (PBMC), isolated from healthy donors (Sanquin), as effector 
cells.
Immunohistochemical analysis of TF expression in PDX models
A tissue microarray (TMA) containing formalin-fixed, paraffin-embedded (FFPE) PDX 
tissue (Oncotest GmbH) was incubated with FITC-labeled TF-011 or mouse anti-hu-
man cytokeratin antibody (Cell Marque) (1 h, RT), after antigen retrieval (citrate/
EDTA buffer, pH8, in a pressure cooker for 5 min for TF-011-FITC and citrate buffer, 
pH6, for mouse anti-cytokeratin). Endogenous peroxidase (PO) activity was exhaust-
ed by incubation with H2O2 and non-specific antibody binding was blocked using 
chicken serum or normal human serum. Binding of TF-011-FITC was detected using 
rabbit anti-FITC (Zymed) and Powervision (anti-rabbit IgG1)-PO (Leica Biosystems). 
Mouse-anti-cytokeratin binding was detected using Ultravision-PO (Thermo Scien-
tific). PO was visualized with amino-ethyl-carbazole, resulting in a red color. Nuclei 
were visualized using hematoxylin. Immunostaining was scored manually, by esti-
mating the TF-positive tumor area in relation to the total tumor area as identified 
by human cytokeratin staining. The TF-positive tumor area was scored according 
to the following intervals: 0 (no TF-positive cells), 0-25%, 25-50%, 50-75% or >75% 
TF-positive cells.
Xenograft models
Cell line-derived xenograft models were established in female SCID mice by sub-
cutaneous (s.c.) injection of 2-10*106 (HPAF-II), 5*106 (A431, AsPC-1 and BxPC-3) 
or 0.5*106 (HCT-116) tumor cells as described [22]. TF HuMab were injected intra-
peritoneally 1 h after tumor injection (prophylactic treatment) or when tumors had 
reached a size of 100-400 mm3 (therapeutic treatment, starting between day 8-13). 
All experiments were approved by the Utrecht University Animal Ethics Committee. 
PDX models were initiated by s.c. implantation of human tumor fragments in the 
flanks of NMRI nu/nu mice at Oncotest GmbH (Freiburg, Germany). When tumors had 
reached a size of 80-200 mm3, mice were treated intravenously with 4 mg/kg ADC or 
20 mg/kg paclitaxel (Teva-Gry Pharma). Tumor volume was determined as described 
above. All experiments were conducted according to the guidelines of the German 
Animal Welfare Act (Tierschutzgesetz).
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Statistical analyses
Data were analyzed using GraphPad Prism 5 software. For mouse xenograft stud-
ies, differences in tumor size between treatment groups were analyzed by one-way 
ANOVA, using mean tumor sizes from the last day that all groups were complete (i.e. 
before mice in isotype control groups had to be sacrificed due to large tumor burden).
RESULTS
Target binding characteristics of TF HuMab
From a large panel of human TF-specific IgG1κ antibodies (TF HuMab), eight clones 
were selected for extensive functional characterization in vitro and in vivo. All TF 
HuMab showed dose-dependent binding to TF-positive MDA-MB-231 breast cancer 
cells (Figure 1A). EC50 values ranged from 0.07 µg/mL for TF-011 to 0.49 µg/mL for 
TF-109 (sub-nanomolar to nanomolar range) (Supplementary Table S1). Similar re-
sults were obtained using BxPC-3 pancreas adenocarcinoma and A431 epidermoid 
carcinoma cells (data not shown). Biacore analysis demonstrated that TF HuMab 
bound TF with affinities ranging from 1.8 nM for TF-025 to 307 nM for TF-098 (Sup-
plementary Table S1).
TF-specific antibodies interfere with TF:FVIIa-mediated intracellular signaling
TFspecific antibodies may interfere with the interaction between TF and FVIIa, pos-
sibly resulting in inhibition of TF:FVIIa-dependent intracellular signaling. To measure 
competition between TF HuMab and FVIIa for TF binding, FVIIa was incubated with 
TF-ECDHis in the presence of TF HuMab and binding of FVIIa was detected by ELISA. 
Except for TF-044 and TF-013, TF HuMab efficiently inhibited binding of FVIIa to TF, 
with only 9-21% of FVIIa binding remaining at the highest antibody concentration 
tested (30 µg/mL) (Figure 1B, Table 1).
Next, the capacity of TF HuMab to interfere with TF:FVIIadependent PAR-2 signaling 
was assessed by measuring antibody-mediated inhibition of ERK1/2 phosphoryla-
tion and IL-8 production, both of which have been implicated in tumor cell prolifer-
ation, migration and metastatic potential [26,27]. When pre-incubated with BxPC-3 
or HaCaT cells, all TF HuMab, except TF-013, inhibited TF:FVIIa-induced ERK phos-
phorylation, as shown by Western Blot analysis (Figure 1C and data not shown). 
Inhibition of TF:FVIIa-induced ERK phosphorylation was confirmed in A431 cells 
 using Alphascreen, which allowed more quantitative detection of p-ERK1/2  (Table 
1, Supplementary Figure S1). The TF HuMab that showed efficient inhibition of 
ERK1/2 phosphorylation, also inhibited TF:FVIIa-dependent production of IL-8 by 
MDA-MB-231 cells when antibodies were allowed to bind the cells before stimula-
tion with FVIIa (Figure 1D). In the reverse experiment, where the tumor cells were 
incubated with FVIIa prior to adding TF HuMab, inhibition of TF:FVIIa-induced IL-8 
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production was clearly less efficient, confirming competition between FVIIa and TF 
HuMab for TF binding (Supplementary Figure S2). In agreement with poor inhibition 
of FVIIa binding, TF-044 only moderately inhibited TF:FVIIa-dependent intracellular 
signaling, whereas TF-013 showed almost no inhibition.
These results suggest that TF HuMab recognize distinct functional epitopes in the TF 
extracellular domain. This was confirmed in a cross-competition study, which indi-
cated that TF-011, -025, -098, -111, -109 and -114 bind different, but overlapping, 
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FIGURE 1 Functional characteristics of TF HuMab in vitro. (A) Binding of TF HuMab to MDA-MB-231 
cells as assessed by flow cytometry. Results from a representative experiment are shown (n=3). (B) 
Competition between TF HuMab and FVIIa for TF binding. FVIIa was incubated with TF-ECDHis in the 
presence of TF HuMab, and binding of FVIIa was measured by ELISA. Results from a representative 
experiment are shown (n=3), error bars indicate SEM. (C) TF:FVIIa-induced ERK phosphorylation in the 
presence of TF HuMab. BxPC-3 cells were incubated with FVIIa after pre-incubation with TF HuMab, and 
p-ERK1/2 and total ERK1/2 were detected in cell lysates by Western Blot. Full-length blots are presented 
in Supplementary Figure S7. (D) TF:FVIIa-induced IL-8 production in MDA-MB-231 cells in the presence 
of TF HuMab. Cells were incubated with TF HuMab prior to stimulation with FVIIa. IL-8 production was 
measured in cell culture supernatants using ELISA. Results from a representative experiment are shown 
(n=3), error bars indicate SEM. (E, F) Effect of TF HuMab on whole blood coagulation as assessed by 
thromboelastography. Citrated whole blood was incubated with LPS to induce TF expression, followed 
by incubation with TF HuMab. Coagulation was initiated by re-calcification. (E) Inhibition of TF activity 
in the presence of TF HuMab. TF activity was defined as the difference in clotting lag time (R) between 
unstimulated and LPS-stimulated whole blood. TF HuMab-mediated inhibition of TF activity was 
expressed the percentage change in TF activity. Data represent the average of 3 donors, error bars 
represent SEM. (F) TEG trace overlays of coagulation in the presence of 20 µg/mL TF-011, TF-013, TF-098 
or an isotype control IgG. Results from a representative donor are shown (n=3).
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epitopes, whereas TF-013 and TF-044 recognize a non-overlapping epitope (Supple-
mentary Table S2).
TF HuMab show minor interference with FXa generation and coagulation in vitro
Proteolytic activation of FX by the TF:FVIIa complex, generating FXa, is an important 
step in the extrinsic coagulation pathway. Depending on the binding domain, TF-spe-
cific antibodies may interfere with binding of FX to the catalytic domain of TF:FVIIa, 
thereby impairing FXa generation and coagulation [14]. None of the TF HuMab in our 
panel substantially inhibited FXa generation as shown in a chromogenic FXa gener-
ation assay (Table 1). TF-013 induced the highest inhibition of FXa generation, but 
even for this antibody, the reduction in FXa activity was maximally 22%.
The impact of TF HuMab (TF-011, TF-013 and TF-098) on whole blood coagulation 
was assessed by thromboelastography (TEG). Citrated whole blood, obtained from 
healthy donors, was incubated with LPS to activity (66%). Results obtained at 10, 
20 and 50 µg/mL TF HuMab were comparable (Figure 1E). TF HuMab did not have 
impact on other parameters of clot formation such as the clot kinetics (K-value and 
α angle) or clot strength (maximal amplitude), as shown by the similar shape of the 
TEG trace in the presence or absence of TF HuMab (Figure 1F, Supplementary Table 
S3). This was as expected, as TF is thought to be important for the initiation but not 
the amplification or propagation of coagulation [9].





















TF-011 0.19 (0.07) 91 (3) 0.12 (0.03) 69 (4) 1.4 (0.4) 62 (6) 19 (9)
TF-013 2.9 (4.2) 27 (10) 1.37 (0.31) 26 (6) NA 0 (14) 22 (8)
TF-025 0.33 (0.01) 90 (2) 0.33 (0.06) 66 (0) 3.5 (2.7) 76 (5) 9 (2)
TF-044 0.21 (0.04) 54 (10) 60 (NA) 45 (5) 11.2 (4.8) 17 (19) 0 (3)
TF-098 0.16 (0.04) 85 (4) 0.28 (0.06) 64 (5) 1.4 (0.4) 59 (20) 14 (1)
TF-109 0.23 (0.10) 90 (2) 0.36 (0.08) 72 (4) 2.0 (0.8) 70 (14) 4 (1)
TF-111 0.33 (0.14) 79 (7) >10,000 52 (1) >10,000 40 (39) 0 (5)
TF-114 0.20 (0.05) 90 (4) 0.16 (0.05) 68 (0) 1.4 (0.7) 72 (6) 10 (4)
TABLE 1 Tissue factor HuMab: functional characteristics in vitro. aFVIIa ELISA, average of three 
experiments. bAlphascreen Surefire ERK assay, A431 cells, average of two experiments. cMDA-MB-231 
cells, average of three experiments. d-fInhibition measured at plateau of dose-response curve, at 30 µg/
mL (d), 10 µg/mL (e) or 120 µg/mL (f). gInhibition (percentage) measured at plateau of dose-response 
curve (at 0.9 µg/mL IgG); average of two experiments.
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TF HuMab are rapidly internalized after target binding
Since ADCs generally rely on internalization for release of the payload, we charac-
terized the internalization characteristics of TF HuMab in the TAMRA/QSY7 assay. 
This assay uses a fluorophore (TAMRA) and quencher (QSY7) pair. In close prox-
imity, e.g. upon conjugation to the same protein, TAMRA fluorescence is quenched 
by QSY7. TF HuMab were complexed with TAMRA/QSY7-conjugated anti-human IgG 
Fab fragments (Fab-TAMRA/QSY7), and the complex was incubated with A431 or 
SK-OV-3 cells. After 6 h, TAMRA fluorescence was detected in cells that had been 
incubated with TF-011, TF-098 or TF-111 (Figure 2A-B), indicating internalization of 
the HuMab-Fab-TAMRA/QSY7 complex and degradation in the reducing environment 
of the endosomes and lysosomes. Internalization was most efficient for TF-011 and 
TF-098. Interestingly, internalization of TF-011 was reduced when Fab fragments 
were used instead of the intact antibody (Figure 2B), suggesting that internalization 
of TF-011 is stimulated by bivalent target binding. Efficient internalization of TF-011 
was confirmed by confocal microscopy. 1 h after incubation with SK-OV-3 cells, TF-
011 was already detectable in intracellular vesicles, some of which co-localized with 
the lysosomal marker LAMP-1, indicating internalization and lysosomal targeting. 
Co-localization of TF-011 and LAMP-1 was enhanced after 3 h, and after 24 h, most 
TF-011 co-localized with LAMP-1, indicating efficient accumulation in the lysosomal 
compartment (Figure 2C). Similar results were obtained with A431 cells (data not 
shown).
Our results demonstrate that TF HuMab are rapidly internalized and degraded upon 
target binding, indicating that TF may be a very suitable ADC target.
Generation of TF-specific ADCs and cytotoxicity in vitro
TF-specific ADCs were generated by conjugation of TF-011, -098 and -111 with the 
dolastatin analogs MMAE or MMAF. Auristatins are potent cytotoxic agents that 
 induce cell death by disrupting microtubules [20,21]. MMAE was conjugated through 
the protease-cleavable vc linker, and can therefore be released from the antibody 
by lysosomal proteases, such as cathepsin B [21]. MMAF was conjugated through a 
non-cleavable linker, and relies on intracellular degradation of the ADC for release 
[20]. TF HuMab were conjugated with an average of four auristatins per antibody, 
a ratio that was shown to provide the optimal therapeutic index for brentuximab 
vedotin [29]. Direct comparison of TF HuMab and TF-specific ADCs (TF-ADCs) in vitro, 
confirmed that target binding and internalization characteristics were preserved in 
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FIGURE 2 TF HuMab are rapidly internalized and trafficked to the lysosomes. (A, B) TF HuMab or TF-
ADCs were complexed with anti-human Fab-fragments that had been conjugated with the fluorophore 
and quencher pair TAMRA/QSY7 (Fab-TAMRA/QSY7), and the complex was added to A431 (A) or SK-
OV-3 (B) cells. Upon internalization and degradation of the complex, dissociation of TAMRA and QSY 
results in de-quenching of TAMRA. The resulting fluorescent signal was measured by flow cytometry. 
Error bars indicate SEM of duplicates. (C) SK-OV-3 cells were incubated with TF-011 in the presence of 
an inhibitor of lysosomal degradation. After 1, 3 or 24 h, cells were fixed and TF-011 and the lysosomal 
protein LAMP-1 were detected using confocal microscopy. Left panel = TF-011 (green), middle panel = 
LAMP-1 (red), right panel = merge (yellow).
TF-ADCs showed excellent cytotoxicity in vitro. TF-ADCs efficiently and dose- 
dependently killed A431 and HPAF-II cells (Figure 3A,B), which express high lev-
els of TF on the plasma membrane (>300,000 molecules per cell). The EC50 for 
 TF-ADC-mediated tumor cell killing in A431 and HPAF-II cells ranged from 4-10 ng/
mL, for TF-011-MMAE and TF-098-MMAE, to 5-80 ng/mL, for TF-111-MMAF. In cell 
lines that showed low (HCT-116; <15,000 molecules per cell) or very low (TOV-21G; 
<7,000 molecules per cell) TF expression, TF-ADCs showed very limited or no cy-
totoxic activity (Figure 3C,D). Similarly, TF-ADCs did not show cytotoxic activity in 
TF-negative tumor cells (data not shown). This, in addition to the lack of cytotoxic 
activity of the non-binding control ADCs IgG1-b12-MMAE and IgG1-b12-MMAF, indi-
cates that the efficacy of TF-ADCs is dependent on target expression.
Unconjugated TF HuMab did not induce direct cytotoxicity in vitro (data not shown), 
indicating that the cytotoxicity of TF-ADCs was auristatin-dependent.
TF HuMab and TF-ADCs efficiently induce ADCC in vitro
Monoclonal antibodies of the IgG1 isotype may exert cytotoxicity through Fc- 
mediated effector functions such as ADCC, and these effector mechanisms may be 
preserved upon conjugation with cytotoxic agents [30]. Unconjugated TF-011,  TF-098 
and TF-111 potently induced killing of A431 cells by ADCC (Figure 3E), with median 
EC50 values of 15 ng/mL (range 0.5-19 ng/mL), 18 ng/mL (range 5.0-57 ng/mL) and 
76 ng/mL (range 15-102 ng/mL), respectively. Similar results were observed with 
BxPC-3 and MDA-MB-231 cells (data not shown). Importantly, the capacity to induce 
ADCC was preserved after conjugation with MMAE (Figure 3E).
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FIGURE 3 Cytotoxicity of TF-specific ADCs in vitro. (A-D) Cells were incubated in the presence of 
TF-ADCs and the viability of the cultures was assessed after 3-5 days using the Alamar Blue assay. 
IgG1-b12-MMAE and IgG1-b12-MMAF were included as isotype control ADCs. Curves represent dose-
dependent cytotoxicity of TF-ADCs in the different cell lines. Results are representative of at least two 
experiments, error bars represent SEM. The inserts show TF expression in the different cell lines as 
assessed by flow cytometry, using 1 µg/mL mouse-anti-TF antibody (black lines) or an isotype control 
IgG (filled grey histograms). (A-B) Cytotoxicity of TF-ADCs in (A) A431 and (B) HPAF-II cells, which show 
high TF expression on the cell surface (>300,000 TF molecules/cell). (C-D) Cytotoxicity of TF-ADCs in cell 
lines with low (C; HCT-116, <15,000 molecules/cell) or very low (D; TOV-21G, <7,000 molecules/cell) TF 
expression. (E) TF HuMab and TF-ADCs induce ADCC. 51Cr-labeled A431 cells were incubated with TF 
HuMab or TF-ADCs in the presence of freshly isolated PBMC, as a source of effector cells. 51Cr release 
was measured to assess cytotoxicity, and the percentage kill was calculated. Results are representative 
of experiments performed with PBMC from six (TF HuMab) or two (TF-ADC) different donors. Error bars 
indicate SEM.
Anti-tumor activity of TF-specific ADCs in cell line-derived xenograft models
All TF-ADCs potently inhibited tumor growth in established xenografts derived from 
HPAF-II and A431 cells, at a dose of 3 mg/kg (four injections in two weeks; Figure 
4A and Supplementary Figure S4A). MMAE-conjugates showed significantly better 
efficacy than their MMAF-conjugated counterparts (Figure 4B, Supplementary Figure 
S4B). Complete tumor regression, i.e. no measurable tumor remaining at 20-30 days 
after the last treatment, was observed for most mice in the TF-098-MMAE and TF-
111-MMAE treatment groups, and for all mice in the TF-011-MMAE group. Strikingly, 
3 out of 7 mice that had been treated with TF-011-MMAE, remained tumor-free until 
the end of the study (139 days after discontinuation of treatment). In mice that did 
show tumor recurrence after treatment with TF-011-MMAE (4 out of 7 mice in the 
HPAF-II model), measurable tumors were not detected until 56-70 days after discon-
tinuation of treatment. Recurring tumors could successfully be re-treated with TF-
011-MMAE, TF-098-MMAE or TF-111-MMAE (Figure 4C; Supplementary Figure S4C), 
indicating that TF expression was maintained in tumor cells that showed outgrowth 
after completion of the first treatment cycle.
The isotype control ADCs IgG1-b12-MMAE and IgG1-b12-MMAF did not inhibit 
 tumor growth, indicating that the efficacy of TF-ADCs was dependent on target bind-
ing. This was supported by the lack of activity of TF-ADCs in the low TF expressing 
HCT-116 xenograft model (Supplementary Figure S4D).
To study the potential contribution of ADCC and inhibition of TF:FVIIa-dependent 
intracellular signaling to the anti-tumor activity of TF-ADCs in vivo, xenograft studies 
were performed using unconjugated TF-011, TF-098 or TF-111. Prophylactic treat-
ment with TF-011, TF-098 or TF-111 significantly reduced outgrowth of BxPC-3, 
HPAF-II, AsPC-1 and A431 xenografts (Supplementary Figure S5A-D and data not 
shown). When treatment was initiated after the tumors had established (therapeutic 
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FIGURE 4 TF-ADCs show potent anti-tumor activity in vivo. HPAF-II xenografts were established 
by s.c. injection in SCID mice, and treatment with TF-ADCs was initiated at day 13 after tumor 
inoculation. (A-C) Treatment with 3 mg/kg TF-ADCs. (A) Tumor growth in the different treatment 
groups.  IgG1-b12-MMAE and IgG1-b12-MMAF were included as isotype control ADCs, IgG1-b12 was 
included as isotype control IgG. Curves represent average tumor size per treatment group (7 mice per 
group), error bars indicate SEM. The number of mice that showed complete tumor regression (i.e. no 
measurable tumor remaining) in each of the treatment groups is indicated between brackets. (B) Tumor 
volumes in the different treatment groups at day 27 after tumor inoculation. Differences in average 
tumor size between treatment groups were analyzed by one-way ANOVA, ** P<0.01, *** P<0.001. (C) 
HPAF-II xenografts that showed outgrowth after completion of the first treatment cycle were re-treated 
with 3 mg/kg TF-ADC (four doses, at the indicated time points). Mice were re-treated with the same 
TF-ADC as they had received in the first treatment cycle. Curves represent individual mice. (D-F) Anti-
tumor activity of TF-011-MMAE in the HPAF-II xenograft model at different dose levels and dosing 
frequencies. (D-E) Average tumor size after treatment with 0.5, 1, 2 or 4 mg/kg TF-011-MMAE (7 mice 
per group), at weekly dosing (D) or as a single dose (E). IgG1-b12 was included as an isotype control 
antibody. Error bars indicate SEM. (F) Tumor volume per treatment group at day 24, when mice had 
received either one or two doses of TF-011-MMAE. Differences in average tumor size between groups 




treatment), TF-098 and TF-111 induced a small, albeit significant, reduction of tumor 
growth in the BxPC-3 model (Supplementary Figure S5E,F). However, therapeutic 
treatment with unconjugated TF HuMab was unable to inhibit tumor growth in the 
A431, AsPC-1 and HPAF-II xenograft models (Supplementary Figure S5G,H and data 
not shown). This suggests that the anti-tumor activity of TF-ADCs in the established 
xenografts tested here is to a large extent mediated by the cytotoxic activity of 
MMAE or MMAF.
The anti-tumor efficacy of the most potent ADC, TF-011-MMAE, was assessed at 
different dose levels and dosing schedules. At weekly dosing (four doses), treatment 
with 1 mg/kg TF-011-MMAE was sufficient to induce tumor regression (Figure 4D). 
When administered as a single dose, 2 and 4 mg/kg TF-011-MMAE induced tumor re-
gression, whereas inhibition of tumor growth was observed after treatment with 0.5 
or 1 mg/kg (Figure 4E). Interestingly, comparison of tumor volumes on day 24, when 
mice had received either one or two doses of TF-011-MMAE, demonstrated that a 
single dose of 1 mg/kg TF-011-MMAE was more effective than two doses of 0.5 mg/
kg, although the cumulative dose was the same in both treatment groups. Similarly, 
treatment with a single dose of 2 mg/kg was more effective than two doses of 1 mg/
kg (Figure 4F). This suggests that, at the same cumulative dose (exposure), dosing 
schedules giving a higher peak plasma level (Cmax) are more effective. For treatment 
with a cumulative dose of 4 mg/kg, no difference in efficacy was observed between 
a single dose of 4 mg/kg and two doses of 2 mg/kg, because tumor regression was 
complete in both groups.
In summary, TF-ADCs showed potent anti-tumor activity in vivo, which was dependent 
on both TF targeting and conjugation with auristatins. TF-011-MMAE was selected for 
further preclinical studies and clinical development (designated as HuMax-TF-ADC).
TF-011-MMAE induces efficient tumor cell killing in PDX models with 
heterogeneous TF expression
Like most solid tumor targets, expression of TF in cancer is heterogeneous between 
patients, within patients and even within tumors [3]. We addressed the capacity of 
TF-011-MMAE to inhibit the growth of tumors with heterogeneous target expres-
sion using PDX models, which are thought to represent the heterogeneity that exists 
 between human tumors [31-33]. Immunohistochemical (IHC) analysis of xenografted 
primary human tumor biopsies confirmed heterogeneity of TF expression, and seven 
PDX models were selected based on variable levels of TF expression. TF expression 
was observed in >75% of tumor cells in the PDX models for lung and pancreas ade-
nocarcinoma (Figure 5A,B), and in 50-75% of tumor cells in the models for bladder 
carcinoma, prostate carcinoma and lung squamous cell carcinoma (Figure 5C-E). In 
PDX models for cervix squamous cell carcinoma and ovarian adenocarcinoma, only 
25-50% of tumor cells were TF-positive (Figure 5F,G).
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PDX tumors were implanted s.c. in nude mice, and when tumors had established, 
mice were treated with TF-011-MMAE (4 mg/kg, two doses). In models where the 
sensitivity to microtubule-targeting agents was not known, a paclitaxel treatment 
group (20 mg/kg, 3-4 doses) was included.
FIGURE 5 Heterogeneous expression of TF in PDX models. IHC analysis was performed to assess TF 
expression in PDX models. The percentage of TF-positive tumor cells was estimated by comparing 
human cytokeratin staining (which identifies human tumor cells) with TF staining (indicating TF-positive 
tumor cells). In PDX models for (A) lung adenocarcinoma and (B) pancreatic adenocarcinoma, >75% 
of the tumor cells showed TF expression. In PDX models for (C) bladder (urothelial) adenocarcinoma, 
(D) prostate adenocarcinoma and (E) lung squamous cell carcinoma, TF expression was observed in 
50-75% of the tumor cells. In PDX models for (F) squamous cell carcinoma of the cervix and (G) ovarian 
adenocarcinoma, 25-50% of the tumor cells showed TF expression. (H) Representative pictures showing 
immunostaining with the isotype control antibody IgG1-b12.
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FIGURE 6 Anti-tumor activity of TF-011-MMAE in PDX models with heterogeneous target expression. 
PDX models were established by s.c. implantation of tumor fragments in mice. When tumors had 
reached a size of 80-200 mm3, mice were randomized and treatment was initiated. Mice were treated 
with TF-011-MMAE or paclitaxel at the indicated doses and time points. IgG1-b12-MMAE was included 
as an isotype control ADC, IgG1-b12 was included as an isotype control IgG. (A) Tumor growth in PDX 
models showing >75% TF-positive tumor cells (lung adenocarcinoma and pancreatic adenocarcinoma), 
(B) Tumor growth in PDX models showing 50-75% TF-positive tumor cells (bladder adenocarcinoma, 
prostate adenocarcinoma and lung squamous cell carcinoma) and (C) Tumor growth in PDX tumors with 
25-50% TF-positive cells (cervical squamous cell carcinoma and ovarian adenocarcinoma). Data points 
represent average tumor size per group (8 mice per group). Error bars represent SEM.
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In the models for pancreas and lung adenocarcinoma, that showed >75% TF-posi-
tive tumor cells, TF-011-MMAE induced complete tumor regression in all mice (Fig-
ure 6A). Similarly, TF-011-MMAE induced efficient tumor regression in PDX models 
that expressed TF in 50-75% of tumor cells (bladder cancer, prostate cancer and 
lung squamous cell carcinoma; Figure 6B). Importantly, tumor regression was also 
observed in models that showed TF expression in only 25-50% of the tumor cells 
(ovarian and cervical cancer; Figure 6C).
Treatment with two doses of HuMax-TF-ADC was at least as efficient as treatment 
with three or four doses of paclitaxel (Figure 6). Moreover, TF-011-MMAE induced 
tumor regression in mice that showed tumor recurrence after paclitaxel treatment, 
even in mice with relatively large tumors (Supplementary Figure S6). This demon-
strates that prior treatment with paclitaxel did not affect the sensitivity of the tu-
mors to treatment with TF-011-MMAE, indicating that TF expression and sensitivity 
to MMAE-mediated tumor cell killing was retained in tumors that showed outgrowth 
after paclitaxel treatment.
DISCUSSION
TF-011-MMAE was selected from a panel of six TF-specific ADCs, consisting of three 
different TF HuMab conjugated with vcMMAE or mcMMAF. TF-011-MMAE showed 
excellent anti-tumor activity in vivo, with auristatin-mediated tumor cell killing as 
the dominant mechanism of action. Furthermore, TF-011-MMAE and unconjugated 
TF-011 induced inhibition of TF:FVIIa-mediated intracellular signaling and ADCC in 
vitro, although it is unclear to what extent these mechanisms may contribute to the 
inhibition of tumor growth in cancer patients. To our knowledge, TF-011-MMAE is 
the first ADC that uses a TF-specific antibody to deliver a cytotoxic agent to tumor 
cells. 
Importantly, TF-011-MMAE induced complete tumor regression in PDX models, even 
if only a sub-population of the tumor cells expressed TF. PDX models are thought to 
represent the genetic and histological heterogeneity in human tumors, and efficacy 
of treatment in such models was shown to have predictive value for the clinic [31-
33]. The high potency of TF-011-MMAE in tumors with non-homogeneous target 
expression, may be related to the capacity of MMAE to cause a bystander effect by 
diffusion across cell membranes after intracellular release [34]. Especially in solid 
tumors, where antibody penetration may be limited [35,36], this may be a major 
advantage. As opposed to uncharged MMAE, the negative charge of MMAF is thought 
to prevent diffusion across membranes [20]. This difference in membrane permea-




Although TF plays a crucial role in coagulation and hemostasis, TF-011 showed 
 minimal impact on coagulation in vitro. Previous studies suggested that TF- specific 
antibodies can roughly be divided into two categories: those that inhibit FVIIa 
binding and/or TF:FVIIa-induced intracellular signaling with minor impact on TF 
pro-coagulant activity, and those that interfere with FXa activation and coagulation 
without impacting on TF:FVIIa-induced intracellular signaling [14,37]. Our in vitro 
studies suggest that TF-011 belongs to the first category. This notion is supported by 
non-clinical toxicology studies in cynomolgus monkeys. TF-011 and TF-011-MMAE, 
which show comparable binding to cynomolgus monkey and human TF, did not sig-
nificantly impact on functional bleeding time or systemic parameters of coagula-
tion in cynomolgus monkeys at doses up to 100 mg/kg or 5-6 mg/kg, respectively 
(Genmab, data on file). It may seem counterintuitive that TF:FVIIa binding, the first 
step in the coagulation cascade, can be inhibited without impacting on hemostasis 
or clotting. This apparent paradox is most likely explained by the many amplifica-
tion steps in the coagulation cascade downstream of TF:FVIIa [38]. As a result, only 
little TF:FVIIa binding is required to maintain hemostasis. The work of Parry and 
colleagues, who demonstrated that transgenic mice expressing only 1% of normal TF 
activity were viable and had relatively normal hemostasis [39], supports this.
In summary, TF-011-MMAE is a promising new ADC that is being developed for the 
treatment of solid tumors. TF is thought to be an excellent ADC target, due to its 
broad expression profile across solid cancer types and rapid internalization and deg-
radation after antibody binding. TF-011-MMAE induced complete tumor regression 
in PDX models derived from a broad range of solid tumors, demonstrating the high 
potency of TF-011-MMAE for treatment of cancer.
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ELISA plates were coated with each of the TF HuMab (0.5 or 2 µg/mL in PBS) at 4°C, 
overnight. Plates were washed with PBS, blocked with 2% (v/v) chicken serum in PBS 
(1 h, RT) and washed again with PBS. Subsequently, 50 µL anti-TF HuMab (10 µg/
mL) was added, followed by 50 µL TF-ECDHis (0.5 or 1 µg/mL), and the mixture was 
incubated at RT (1 h) while shaking. Plates were washed three times with PBS+0.05% 
Tween-20, and incubated with a biotinylated polyclonal anti-His antibody (1:2,000 
dilution; R&D Systems, Abingdon, UK) at RT while shaking, for 1 h. Plates were 
washed and incubated with Streptavidin-poly-HRP (Sanquin, Amsterdam, The Neth-
erlands) at RT for 20 min, and washed again. The reaction was further developed 
with ABTS (Roche Diagnostics) at RT in the dark, stopped after 15 min by adding 2% 
(w/v) oxalic acid and absorbance at 405 nm was measured.
AlphaScreen assay to detect ERK phosphorylation.
A431 cells (30,000 cells/well) were seeded in 96-well tissue culture plates and 
 cultured in serum-free medium (RPMI containing 20% HSA and penicillin/strepto-
mycin), overnight. Medium was then replaced by DMEM without additives and cells 
were incubated for 1.5 h (37°C). Serial dilutions of TF HuMab or HuMab-KLH were 
added and cells were incubated for another 30 min (37°C). Cells were then stimulated 
with recombinant FVIIa at EC80 concentration (50 nM; 10 min). Cells were washed 
once with PBS, and lysed using 25 μL lysis buffer (Alphascreen® Surefire p-ERK1/2 
assay kit, Perkin Elmer). Cell lysates were transferred to 384-well Proxiplates (Per-
kin Elmer), and levels of p-ERK1/2 were detected using the Alphascreen Surefire 
p-ERK1/2 assay kit (Perkin Elmer), according to the manufacturer’s guidelines.
SUPPLEMENTARY TABLES
HuMab Cell surface bindinga, EC50 (SD), µg/mL Affinity (nM)b
TF-011 0.07 (0.02) 3.2
TF-013 0.25 (0.11) 2.8
TF-025 0.10 (0.10) 1.8
TF-044 0.14 (0.06) 9.7
TF-098 0.16 (0.10) 307
TF-109 0.49 (0.34) 4.8
TF-111 0.16 (0.11) 259
TF-114 0.11 (0.02) 11
SUPPLEMENTARY TABLE S1 TF HuMab: target binding characteristics and inhibition of FXa 
generation. a flow cytometry, MDA-MB-231 cells; average of 3 experiments. b Affinity for TF-ECDHis, 
measured by Biacore analysis.
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TF-013 TF-044 TF-011 TF-114 TF-098 TF-025 TF-109 TF-111
TF-013 19 5 101 105 320 89 110 175
TF-044 93 40 109 105 330 108 94 175
TF-011 96 143 20 19 9 104 109 175
TF-114 101 143 21 13 9 47 26 5
TF-098 95 143 90 94 24 94 86 35
TF-025 102 143 117 28 10 34 11 6
TF-109 96 143 101 44 9 51 17 6
TF-111 89 143 110 99 37 104 93 43
SUPPLEMENTARY TABLE S2 Cross-competition between TF HuMab. Numbers indicate the binding of 
TF-ECDHis to immobilized TF HuMab in the presence of competing TF HuMab, expressed as a percentage 
of the binding in the absence of competing antibody. Green boxes indicate competition between TF 
HuMab (<40% residual binding of TF-ECDHis), grey boxes indicate partial competition (40-80% binding 
of TF-ECDHis) and light boxes indicate absence of competition (>80% binding of TF-ECDHis).
R (min)a (SD) K value (min)b (SD) α angle (º)c (SD) MA (mm)d (SD)















52 (2) 58 (0) 39 
(12)
60 (1) 63 (1) 59 (1)
TF-011 9.5f 6.8 16.1 3.1 2.6 3.3 50 56 49 56 60 58
TF-013 17.7f 16.2 29.2 3.6 2.9 6.8 43 47 31 51 56 60
TF-098 6.6g 8.8 16.0 2.4 3.1 3.6 58 52 47 60 56 60
No LPS 
(run 1)
20.8f 18.6 39.1 6.2 4.0 5.0 30 41 37 47 50 15
No LPS 
(run 2)
23.5g NA NA 5.0 NA NA 34 NA NA 48 NA NA
SUPPLEMENTARY TABLE S3 Thromboelastography: coagulation of LPS-stimulated whole blood in the 
presence of 20 µg/mL TF-011, TF-013 and TF-098. Raw data of three donors are presented. aR = clotting 
lag time (time to initial fibrin formation). bK value = time (from initiation of fibrin formation) to reach a 
clot strength amplitude of 20 mm. cα angle = rate of fibrin build-up and cross-linking. dMA = maximum 
amplitude, representative of clot strength. eAverage of isotype control values at all concentrations 
tested (1, 10 and 20 µg/mL). f,gFor donor A, thromboelastography was performed in two separate runs. 





SUPPLEMENTARY FIGURE S1 TF HuMab inhibit TF:FVIIa-induced ERK1/2 phosphorylation. A431 
cells were incubated with 50 nM recombinant FVIIa in the presence of TF HuMab. Phosphorylated ERK 
(p-ERK1/2) was measured in cell lysates using Alphascreen®. Counts on the y-axis indicate light emitted 
(at 520-620 nm) by acceptor beads, upon excitation of donor beads (680 nm). Light emission only 
occurs when donor and acceptor beads, both of which are coated with p-ERK1/2 specific antibodies, 
are in close proximity due to cross-linking by soluble p-ERK1/2. Results are representative of two 
independent experiments.
SUPPLEMENTARY FIGURE S2 TF:FVIIa-induced IL-8 production in MDA-MB-231 cells is reduced in the 
presence of TF HuMab. MDA-MB-231 cells were pre-incubated with 10 nM FVIIa, followed by addition 
of TF HuMab. IL-8 production was measured in cell culture supernatants using ELISA. FVIIa-induced IL-8 
production in the absence of antibodies was 460 pg/mL and FVIIa-independent IL-8 production was 19 
pg/mL. Results are representative of three individual experiments. Error bars indicate SEM.
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SUPPLEMENTARY FIGURE S3 Binding of TF HuMab is unaltered after conjugation with vcMMAE 
or mcMMAF. TF-ECDHis was immobilized on 96-well plates, and incubated with unconjugated HuMab 
(black circles), vcMMAE-conjugates (red triangles) or mcMMAF-conjugates (blue squares). Binding of 
TF HuMab or TF-ADCs was detected by ELISA, using an HRP-labeled mouse anti-human IgG1 antibody. 
IgG1-b12-MMAE and IgG1-b12-MMAF were included as isotype control ADCs, IgG1-b12 was included as 
an isotype control IgG. Error bars indicate SEM.
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SUPPLEMENTARY FIGURE S4 Anti-tumor activity of TF-ADCs in the A431 and HCT-116 xenograft 
models. Xenografts were established by s.c. injection in SCID mice, and treatment with 3 mg/kg TF-ADCs 
was initiated 11 (A431) or 7 (HCT 116) days later. (A) Tumor growth in the different treatment groups 
in the A431 model. IgG1-b12-MMAE and IgG1-b12-MMAF were included as isotype control ADCs, 
IgG1-b12 was included as isotype control IgG. Curves represent mean tumor size per treatment group (7 
mice per group), error bars indicate SEM. The number of mice that showed complete tumor regression 
(i.e. no measurable tumor remaining) in each of the treatment groups is indicated between brackets. 
(B) Tumor volumes in the A431 model at day 36. Differences in average tumor size between treatment 
groups were analyzed by one-way ANOVA, ** P<0.01, *** P<0.001. Mice in the control groups (IgG1-
b12-MMAE, IgG1-b12-MMAF and IgG1-b12) were sacrificed before day 36 due to large tumor burden. 
(C) Mice in which initial treatment with TF-011-MMAE or TF-098-MMAE in the A431 xenograft model 
induced tumor regression, were kept in the study until tumors started growing again. Tumors were re-
treated with four doses of the same ADC (at the indicated time points) as they had received in the first 
treatment cycle. Curves represent individual mice. (D) Tumor growth in the different treatment groups 
in the HCT-116 xenograft model. Curves represent mean tumor size per treatment group (7 mice per 
group), error bars indicate SEM.
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SUPPLEMENTARY FIGURE S5 Anti-tumor activity of unconjugated TF HuMab in vivo. BxPC-3 (A,B,E,F) 
or HPAF-II (C,D,G,H) xenografts were established by s.c. injection in SCID mice. Treatment was initiated 
within 1 h after tumor inoculation (prophylactic treatment), or when tumors had reached a size of 100-
400 mm3 (therapeutic treatment). (A) Tumor growth in BxPC-3 xenografts after prophylactic treatment 
with 20 mg/kg TF HuMab. (B) Tumor size at day 42 after tumor inoculation in the BxPC-3 prophylactic 
treatment model. (C) Tumor growth in the HPAF-II xenograft model, after prophylactic treatment with 
20 mg/kg TF HuMab. (D) Tumor size at day 24 after tumor inoculation in the HPAF-II prophylactic 
treatment model. (E) Therapeutic treatment in the BxPC-3 xenograft model. Treatment was initiated on 
day 8 (15 mg/kg), when tumors had established, followed by weekly doses of 7.5 mg/kg. (F) Tumor size 
at day 43 after tumor inoculation in the BxPC-3 therapeutic treatment model. (G) Therapeutic treatment 
in the HPAF-II xenograft model. After tumors had established, mice were treated with 50 mg/kg TF 
HuMab on day 10, followed by 25 mg/kg on day 17. (H) Tumor size at day 24 after tumor inoculation in 
the HPAF-II therapeutic treatment model. Differences between treatment groups were analyzed using 
one-way ANOVA (B,D,F,H); * P<0.05, ** P<0.01, *** P<0.001. Error bars (A,C,E,G) indicate SEM.
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SUPPLEMENTARY FIGURE S6 Post-paclitaxel treatment with TF-011-MMAE in PDX models. PDX 
models were implanted s.c. in mice and when tumors had reached a size of 80-200 mm3, mice were 
randomized and treated with three or four doses of paclitaxel (20 mg/kg) at the indicated time points. 
Mice that showed tumor outgrowth after discontinuation of paclitaxel treatment were subsequently 
treated with two doses of 4 mg/kg TF-011-MMAE at the indicated time points. Curves and data points 
represent tumor sizes in individual mice.
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Legend blot 1,2: TF-011, TF-098, 
TF-114, TF-109
Legend blot 3,4: TF-111, TF-044, 
TF-013, TF-025
Blot 1/2 TF HuMab FVIIa Blot 3/4 TF HuMab FVIIa
slot 1 protein marker slot 1 protein marker
slot 2 - - slot 2 - -
slot 3 TF-011 - slot 3 TF-111 -
slot 4 TF-098 - slot 4 TF-044 -
slot 5 TF-114 - slot 5 TF-013 -
slot 6 TF-109 - slot 6 TF-025 -
slot 7 - 10 nM FVIIa slot 7 - 10 nM FVIIa
slot 8 TF-011 10 nM FVIIa slot 8 TF-111 10 nM FVIIa
slot 9 TF-098 10 nM FVIIa slot 9 TF-044 10 nM FVIIa
slot 10 TF-114 10 nM FVIIa slot 10 TF-013 10 nM FVIIa
slot 11 TF-109 10 nM FVIIa slot 11 TF-025 10 nM FVIIa
slot 12 - 50 nM FVIIa slot 12 pre-stained marker
slot 13 TF-011 50 nM FVIIa slot 13 TF-111 50 nM FVIIa
slot 14 TF-098 50 nM FVIIa slot 14 TF-044 50 nM FVIIa
slot 15 TF-114 50 nM FVIIa slot 15 TF-013 50 nM FVIIa
slot 16 TF-109 50 nM FVIIa slot 16 TF-025 50 nM FVIIa
slot 17 - - slot 17 pre-stained marker
slot 18 pre-stained marker slot 18 -
SUPPLEMENTARY FIGURE S7 Full-length blots for figure 1C. The cropped blots shown in the upper 
panel of Figure 1C (TF-011, TF-098, TF-114 and TF-109) were obtained from Blot 1 (p-ERK1/2) and Blot 
2 (total ERK1/2). The cropped blots in the lower panel of Figure 1C (TF-111, -044, -013 and -25) were 
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ABSTRACT
Antibody-drug conjugates (ADC) represent promising agents for targeted cancer ther-
apy. To allow rational selection of human antibodies with favorable characteristics 
for ADC development a screening tool was designed obviating the need of preparing 
individual covalently linked conjugates. Therefore, α-kappa-ETA’ was designed as a 
fusion protein consisting of a human kappa light chain binding antibody fragment 
and a truncated version of Pseudomonas exotoxin A. α-kappa-ETA’ specifically bound 
to human kappa light chains of human or human-mouse chimeric antibodies and Fab 
fragments. Antibody-redirected α-kappa-ETA’ specifically inhibited proliferation of 
antigen-expressing cell lines at low toxin and antibody concentrations. Selected an-
tibodies that efficiently delivered α-kappa-ETA’ in the novel assay system were used 
to generate scFv-based covalently linked immunotoxins. These molecules efficiently 
triggered apoptosis of target cells, indicating that antibodies identified in our assay 
system can be converted to functional immunoconjugates. Finally, a panel of human 
epidermal growth factor receptor (EGFR) antibodies was screened - demonstrating 
favorable characteristics with antibody 2F8. These data suggest that antibodies with 
potential for Pseudomonas exotoxin A-based ADC development can be identified 
using the novel α-kappa-ETA’ conjugate.
INTRODUCTION
Antibody-drug conjugates (ADC) represent promising agents in tumor therapy, po-
tentially overcoming some of the short-comings of “naked” antibodies or antibody 
derivatives that often are dependent on a functional host immune system [1-5]. ADC 
are bifunctional molecules that are composed of a targeting moiety represented by a 
monoclonal antibody or antibody fragment and a cytotoxic compound that is  either 
chemically cross-linked or genetically fused [6-8]. The antibody moiety is used to 
deliver cytotoxic compounds to distinct antigen-positive cells recognized by the re-
spective antibody. In the past, a variety of substances have been tested for ADC de-
sign. These include chemotherapeutic agents as well as toxins derived from plants or 
bacteria [9]. Often the toxic component only displays cytotoxicity when internalized. 
Therefore, for the development of ADC target antigens such as CD7, CD22, CD30 or 
CD33 on leukemias and lymphomas [6,10-12] and EGFR or HER2 on solid tumors 
were selected [13,14] due to a high internalization capacity after antibody binding 
or a high intrinsic turn over [6,7,9].
To date only a small number of ADC have been clinically approved with gemtu-
zumab-ozogamycin representing a prototypic conjugate composed of calicheamycin 
chemically linked to a CD33 IgG4 antibody [15,16]. Recently, novel ADC demonstrated 
impressive clinical results. Trastuzumab-DM1 (derivative of maytansine 1) showed 
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promising results in phase I and phase II clinical trials in patients with HER2-positive 
metastatic breast cancer [17-19]. Treatment with brentuximab vedotin, a chimeric 
CD30 antibody linked to the antimitotic agent monomethyl aurastatin E resulted in 
tumor regression for most patients with relapsed or refractory CD30-positive Hod-
gkin’s lymphomas in a phase I study [20]. BL22, a CD22-directed ADC, representing 
a group of single-chain immunotoxins with scFv fragments fused to a truncated ver-
sion of Pseudomonas aeruginosa exotoxin A, showed high response rates in phase 
II clinical trials in patients with hairy cell leukemia, achieving up to 47% complete 
remissions [21,22].
Irrespective of the ADC format, as chemical conjugate or single-chain fusion pro-
tein, selection of the targeting antibody is critical. Depending on epitope specific-
ity,  antibody binding to the targeted surface receptor may severely compromise 
surface redistribution, internalization and subsequently the intracellular routing of 
the  receptor and potentially routing of the ADC / receptor complex. For example, 
different CD20 antibodies have been demonstrated to either recruit CD20 into lipid 
rafts or not, resulting in altered indirect effector functions such as CDC [23,24]. In 
addition, EGFR-directed antibodies have been demonstrated to significantly differ 
in their capacity to trigger receptor down modulation and internalization [25-27]. 
Furthermore, most toxic compounds only display potent cytoxicity when delivered 
to the correct intracellular compartment (e.g. the endoplasmatic reticulum (ER) for 
Pseudomonas aeruginosa exotoxin A) [28]. Therefore, different antibodies may sig-
nificantly differ in their capacity to deliver selected cytotoxic compounds. As a con-
sequence, selecting the most promising antibody at early developmental stages may 
reduce costs and obviates the need for testing many candidate conjugates in parallel 
in complex test systems such as animal models. Simple screening tools that allow 
identification of promising antibody candidates in an easy but highly predictive 
way may speed up the developing process. Cytotoxic compounds fused to an anti-
body-binding domain allowing formation of a stable non-covalent ADC may repre-
sent universal tools for fast screening of a large number of antibodies. Recently, fu-
sion proteins of the IgG-binding motif from Streptococcal protein A or protein G and 
diphtheria toxin or Pseudomonas aeruginosa exotoxin A have been reported [29,30]. 
Although these molecules allowed formation of non-covalent ADC and screening of 
different murine and mouse/human chimeric antibodies for their potential to deliver 
a cytotoxic compound, this strategy displayed some limitations. As protein A and G 
display no species specificity and therefore also bind to bovine IgG present in high 
concentrations in most tissue culture media, establishing a high-throughput screen-
ing assay may be complicated, and may not allow screening by simple addition of 
antibody and antibody-binding toxin to the assay system [30]. Using antibody-bind-
ing domains with higher species specificity may overcome these shortcomings. Most 
therapeutic antibodies that enter clinical trials today are chimeric, humanized or 
fully human IgG antibodies containing human kappa light chains [31]. Therefore, in 
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the current report a novel Pseudomonas aeruginosa exotoxin A based fusion protein 
which specifically binds human kappa light chains was characterized as a screening 
tool to identify internalizing antibodies with potential in ADC development.
MATERIALS AND METHOD
Antibodies
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Raji, Ramos, Daudi, ARH-77, CEM, L363 and A431 cells were obtained from the Ger-
man Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). 
JK-6L cells [32] were established in our laboratory. Cell lines were cultured in RPMI 
1640-Glutamax-I medium (Invitrogen, Karlsruhe, Germany), containing 10% fetal calf 
serum, penicillin and streptomycin (R10+).
Construction of α-kappa-ETA’
AA truncated version of Pseudomonas exotoxin A (ETA’) was synthesized according to 
published sequences (Entelechon GmbH; Regensburg, Germany). During that process, 
the codon usage was adjusted to E.coli and a mutation reported to enhance cytotox-
icity (R490A) was introduced [33]. The KDEL endoplasmatic reticulum (ER)-retention 
motif was C-terminally introduced [34]. In addition, restriction sites allowing cloning 
into vector pet27b (Novagen) and the insertion of antibody binding domains such 
as scFv-fragments or domain antibodies as SfiI-cassettes were added [10,35]. The 
kappa light chain specific domain antibody was synthesized according to published 
sequences [36] and codon usage was adjusted to E.coli. The correct sequence of the 
final construct, pet27b-a- kappa-ETA’, was verified by Sanger sequencing.
Expression and purification of immunotoxins
The ETA’ fusion proteins were expressed under osmotic stress conditions as de-
scribed [37]. Induced cultures were harvested 16–20 h after induction. The bacterial 
pellet from one liter culture was resuspended in 200 ml of extraction buffer (0.5 M 
sucrose, 0.1 M Tris, 1 mM EDTA, pH 8.0). The suspension was stirred for 3 h at 4°C and 
cleared by centrifugation for 30 min at 20.000 g. The ETA’ fusion proteins were en-
riched by two step affinity chromatography using streptactin agarose matrix and Ni-
NTA agarose (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
Final elution fractions containing recombinant protein were extensively dialyzed 
against PBS and stored at 4°C until use. Purified proteins were quantitated using 
capillary electrophoresis on an Experion™ system (BioRad, Hercules, USA) according 
to the manufacturer’s protocol.
Flow cytometric analyses
For immunofluorescence staining, 3 x 105 target cells were washed in PBS supple-
mented with 1% bovine serum albumin (BSA; Sigma- Aldrich, Munich, Germany) and 
0.1% sodium-azide (PBA buffer). To analyze immunotoxin binding, cells were incu-
bated with either HM1.24-ETA’, 225-ETA’ or control proteins at indicated concen-
trations for 30 min on ice. After two times washing with 500 μl PBA buffer, cells 
were stained with Alexa-Fluor-488 coupled mouse anti-penta-his antibody (Qia-
gen, Hilden, Germany) or rabbit-anti-Exotoxin A polyclonal antibodies and FITC-la-
belled F(ab’)2-fragments of polyclonal goat anti-rabbit antibodies (Sigma-Aldrich). 
To  investigate α-kappa-ETA’ binding, cells were incubated with 20 μg/ml of the op-
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sonising antibody or irrelevant control molecules diluted in PBA-buffer for 30 min 
on ice. After washing 20 μg/ml α-kappa-ETA’ diluted in PBA-buffer was added and 
incubated for 30 min on ice. In the next step cells were washed as described. Poly-
clonal rabbit-anti-exotoxin A antibodies were added and cells were incubated for 
30 min on ice. Following a washing step cells were incubated with FITC-conjugated 
polyclonal goat-anti-rabbit F(ab’)2 fragments. After a final washing step cells were 
fixed in 1% paraformaldehyde / PBS solution. Cells were analyzed by flow cytometry 
(Epics XL or FC500, Coulter) using appropriate scatter settings.
SDS-PAGE / Western blot analysis / Coomassie staining
1-2 μg of the respective purified recombinant protein was loaded on 4-12% Tris-Gly-
cine gels (Invitrogen) under reducing conditions and were either directly stained 
with colloidal coomassie brilliant blue staining solution (Carl Roth GmbH) or blotted 
to PVDF membranes according to standard procedures. For the detection of purified 
exotoxin A-based fusion proteins membranes were blocked using 2% BSA / 2% non-
fat dry milk in tris-buffered saline (TBS) for 1h at RT. Polyclonal rabbit anti-Pseudo-
monas exotoxin A antibodies (Sigma Aldrich) were added to a final dilution of 1:5000 
and incubated for 1h at RT. Blots were washed with TBS-buffer containing 0.05% 
Tween 20 and 0.2% Triton X-100 three times for 5 min. HRP-conjugated polyclonal 
goat anti-rabbit antibodies were added in 2% BSA / 2% non-fat dry milk TBS solu-
tion for 1 h and washed as described above. Blots were finally developed using the 
ECL detection system (Pierce) and analyzed using a digital imaging system (Biorad). 
Detection of recombinant proteins by using anti-penta-his antibodies (Qiagen) was 
performed according to the manufacturer’s instructions.
ELISA
Maxisorp ELISA plates were coated with 25 μl of the respective proteins diluted 
in PBS (final concentration of 10 μg/ml) for 1h at 37°C. Plates were washed with 
125 μl of PBS and blocked with 100 μl of PBS / 3% BSA solution for 1 h at 37°C. 
α-kappa-ETA’ (25 μl) was added at a concentration of 20 μg/ml diluted in PBS / 3% 
BSA. After 1 h incubation at 37°C wells were washed 3 times with PBS and polyclon-
al rabbit-anti-Exotoxin antibodies (Sigma-Aldrich) diluted in PBS / 3% BSA (1:2000) 
was added and incubated for 1 h at 37°C. Wells were washed as described above 
and polyclonal goat-anti-rabbit-IgG (H+L) HRP antibodies (Dianova; 1:2000 diluted 
in PBS / 3% BSA) were added. After a final 1h incubation step at 37°C wells were 
washed as described and developed by adding 50 μl ABTS solution (Roche). After 
10 min incubation, absorbance was measured at 405 nm in a Tecan Rainbow plate 
reader. For control experiments demonstrating successful coating of proteins perox-
idase-conjugated polyclonal F(ab’)2 fragments goat-anti-mouse IgG (H+L) (Dianova) 




Measurement of cytotoxic effects of immunotoxins
For detection of cytotoxic effects of immunotoxin, cells were seeded at 2 x 104 cells 
per 100 μl in 96-well plates.
ETA’ fusion proteins in the presence or absence of antibodies were added at indi-
cated concentrations. After 3 d of treatment, vital cell mass was measured using the 
MTT assay (Cell Proliferation Kit I; Roche, Mannheim, Germany). For the detection of 
early stages of apoptosis and cell death triggered by immunotoxin treatment, cells 
were seeded at 2 x 105 cells per ml in 24-well plates with varying immunotoxin con-
centrations. Cells were stained with FITC-conjugated Annexin V and 7-AAD (Beckman 
Coulter, Fullerton, USA) according to the manufacturers´ protocol, and subsequently 
analyzed by flow cytometry.
Statistical analyses
Statistical analysis was performed using GraphPad Prism. Experimental data were 
analyzed using the student’s t-test, one- or two-way ANOVA repeated measures test 
with Bonferroni’s post test when appropriate. The null hypothesis was rejected when 
p < 0.05.
RESULTS
Construction and purification of the kappa light chain-directed immunotoxin 
α-kappa-ETA’
In order to redirect Pseudomonas exotoxin A to human kappa light chain-contain-
ing antibodies or antibody derivatives, α-kappa-ETA’, a kappa light chain-binding 
immunotoxin was designed. Therefore, a human kappa light chain-specific domain 
antibody was genetically fused to a truncated version of Pseudomonas exotoxin A 
(Fig.1A). The recombinant protein was secreted to the periplasm of E.coli and puri-
fied by two step affinity chromatography. Yields of the purified recombinant pro-
tein varied between 0.5-2 mg per liter of expression culture. Elution fractions from 
the second purification step were analyzed by SDS-PAGE and coomassie staining or 
western blot analysis. α-kappa-ETA’ migrated with an apparent molecular mass of 
55 kDa, closely resembling the calculated molecular mass (53.7 kDa; Fig. 1B). West-
ern blot analysis further confirmed the identity of the purified protein (Fig. 1B).
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FIGURE 1 Design and purification of α-kappa-ETA’. (A) Scheme of α-kappa-ETA’. For secreted bacterial 
expression a pelB leader sequence (L) was introduced at the 5´-end. For purification a combined 
6xhistidine- and strep-II-tag was added (S). ETA’ = truncated version of Pseudomonas exotoxin A; 
KDEL = endoplasmatic reticulum retention motif; dAb = domain antibody with human kappa light 
chain specificity. (B) α-kappa-ETA’ was expressed under osmotic stress conditions and purified from 
periplasmatic extracts using streptactin and Ni-NTA agarose beads. The purified protein was analyzed 
by SDS-PAGE and coomassie staining or western blot analysis using anti-penta-his or anti-exotoxin A 
specific antibodies. Lane 1 = molecular mass standard; lane 2 = purified α-kappa-ETA’; lane 3-5 = BSA as 
mass standard and specificity control for western blotting. Data are representative results from at least 
three experiments.
Kappa light chain-specific binding of α-kappa-ETA’
To demonstrate kappa light chain specific binding of α-kappa-ETA’, ELISA experi-
ments were performed. α-kappa-ETA’ specifically bound to human kappa light chain 
containing antibodies of different isotype and Fab fragments, while no binding 
to fusion proteins containing a human IgG1-Fc domain but lacking the antibodies’ 
constant kappa and CH1 regions (225-scFv-Fc and 4D5-scFv-Fc) or a murine IgG1 / 
kappa antibody was observed (Fig.2A). To further confirm human kappa light chain 
binding, cell lines expressing kappa or lambda light chain containing B cell receptors 
and cell lines lacking B cell receptor expression were analyzed for α-kappa-ETA’ 
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Daudi, ARH-77 and JK6-L while no binding was observed on lambda light chain 
expressing Ramos cells or B cell receptor-negative CEM, L363 and A431 cells. These 
results were in agreement with staining patterns observed with an anti-human kap-
pa light chain-specific monoclonal antibody (data not shown). Together these data 
indicate that α-kappa-ETA’ was successfully expressed and specifically bound anti-
bodies containing human kappa light chains.
Kappa light chain-specific binding of α-kappa-ETA’
To demonstrate kappa light chain specific binding of α-kappa-ETA’, ELISA experi-
ments were performed. α-kappa-ETA’ specifically bound to human kappa light chain 
containing antibodies of different isotype and Fab fragments, while no binding 
to fusion proteins containing a human IgG1-Fc domain but lacking the antibodies’ 
constant kappa and CH1 regions (225-scFv-Fc and 4D5-scFv-Fc) or a murine IgG1 / 
kappa antibody was observed (Fig.2A). To further confirm human kappa light chain 
binding, cell lines expressing kappa or lambda light chain containing B cell receptors 
and cell lines lacking B cell receptor expression were analyzed for α-kappa-ETA’ 
binding. As expected α-kappa-ETA’ bound to kappa light chain-positive cell lines 
Daudi, ARH-77 and JK6-L while no binding was observed on lambda light chain 
expressing Ramos cells or B cell receptor-negative CEM, L363 and A431 cells. These 
results were in agreement with staining patterns observed with an anti-human kap-
pa light chain-specific monoclonal antibody (data not shown). Together these data 
indicate that α-kappa-ETA’ was successfully expressed and specifically bound anti-
bodies containing human kappa light chains.
FIGURE 2 α-kappa-ETA’ specifically binds to human kappa light chain containing antibodies and cell 
lines expressing cell-surface immunoglobulin with kappa light chains. (A) Binding of α-kappa-ETA’ to 
human kappa light chain was analyzed by ELISA using various human kappa light chain containing 
antibodies or control proteins. Identity of coated human, mouse and rabbit antibodies was further 
checked using anti-mouse-, anti-rabbit- or anti-human-HRP conjugates. (B) α-kappa-ETA’ binding to cell 
lines expressing cell-surface-immunoglobulin with kappa light chains (Daudi; ARH-77; JK-6L), a cell line 
expressing cell-surface-immunoglobulin with l-light chains (Ramos) and cell lines that do not express 
cell-surface immunoglobulin (Raji; L363; CEM; A431) were analyzed by flow cytometry. α-kappa-ETA’ 
was detected with a Pseudomonas exotoxin A specific polyclonal antibody and FITC- or HRP-conjugated 
rabbit-specific secondary reagents. For ELISA experiments, mean values +/- SEM from triplicate wells 
are given. Data are representative results from three experiments.
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Antibody-dependent surface deposition of α-kappa-ETA’
To analyze antibody-dependent surface deposition of α-kappa-ETA’, antibodies and 
Fab fragments directed against two highly internalized surface antigens were inves-
tigated. HM1.24 is a surface receptor expressed on multiple myeloma cells, while 
EGFR is expressed on a variety of solid tumors. To demonstrate α-kappa-ETA’ bind-
ing to antibody-opsonized target cells, the kappa light chain-negative L363 myeloma 
cell line (HM1.24-positive) and the epidermoid carcinoma cell line A431 (EGFR-pos-
itive) were opsonized with target cell-specific mouse/human chimeric HM1.24-spe-
HM1.24-Fab + α-kappa-ETA’ CD16-Fab + α-kappa-ETA’
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FIGURE 3 α-kappa-ETA’ specifically binds to target cells opsonized with human/mouse chimeric Fab 
fragments or IgG1 antibodies containing kappa light chains. (A) To demonstrate specific redirected 
binding of α-kappa-ETA’ to L363 cells (HM1.24+, EGFR-, kappa light chain-), cells were incubated with 
a chimeric HM1.24-directed Fab fragment that binds HM1.24, a surface marker expressed on multiple 
myeloma cell lines or with a CD16-specific control Fab. (B) Analogous experiments were performed 
with A431 cells (HM1.24low, EGFR+, kappa light chain-). After opsonization, α-kappa-ETA’ was added 
and detected using anti-Pseudomonas exotoxin A antibodies and appropriate FITC-labeled secondary 
reagents. Data are representative results from three experiments that were performed.
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FIGURE 4 Kappa light chain-negative cell lines show differences in sensitivity to “non-targeted” 
α-kappa-ETA’. Kappa light chain-negative (A) A431 cells and (B) L363 cells were treated with increasing 
concentrations of α-kappa-ETA’ to determine the maximally tolerated dose that does not lead to 
induction of non-specific cell death. After 72 h vital cell mass was measured by MTT assay. Untreated 
cells served as controls. Data are mean values +/- SEM of three independent experiments.
cific Fab fragments or the EGFR-specifc mouse/human chimeric IgG1 antibody cetux-
imab, respectively. α-kappa-ETA’ specifically bound to opsonized target cells, while 
no binding was observed when irrelevant matched control molecules that lack cell 
binding activity were used (Fig.3).
Cytotoxic effect of non-targeted α-kappa-ETA’
α-kappa-ETA’ concentrations that do not show “unspecific” cytotoxic effects and 
consequently may be applicable for testing specific antibody-dependent delivery to 
kappa light chain-negative cell lines were determined. Therefore, kappa light chain 
negative cell lines L363 or A431 cells were incubated with increasing concentra-
tions of α-kappa-ETA’ and the direct growth inhibition effects were determined us-
ing the MTT assay. Interestingly, both cell lines differed significantly in sensitivity to 
non-targeted α-kappa-ETA’. L363 cells were quite resistant to α-kappa-ETA’ up to 10 
μg/ml, while A431 cells showed  cytotoxic effects already at concentrations greater 
than 0.1 μg/ml (Fig.4). Therefore, for  antibody-dependent delivery of α-kappa-ETA’, 
0.1 μg/ml was used for both cell lines.



































Antibody-dependent growth inhibition mediated by α-kappa-ETA’
To analyze whether antibody-dependent binding of α-kappa-ETA’ leads to intracel-
lular toxin delivery and growth inhibition of opsonized target cells, proliferation as-
says were performed. L363 cells or A431 cells were incubated with different target 
cell specific kappa light chain-containing antibody variants and isotypes, including 
Fab fragments, human/mouse chimeric IgG1, human IgG1, human IgG2 antibodies 
or corresponding isotype-matched control antibodies. In all cases analyzed strong 
inhibitory effects were observed when α-kappa-ETA’ was incubated together with a 
target cell binding antibody variant but not when a matched control antibody mole-
cule was used that does not bind to the respective target cell (Fig.5).
Antibody-dependent growth inhibition mediated by α-kappa-ETA’ is human kappa 
light chain dependent
Experiments displayed in Fig.5 demonstrated that a strong inhibitory effect on cell 
proliferation of A431 cells was observed when α-kappa-ETA’ was combined with the 
anti-EGFR antibody cetuximab or 2F8. Furthermore, significant inhibition of prolif-
eration was also observed when the EGFR directed antibodies were tested without 
adding α-kappa-ETA’. To test whether the inhibitory effect mediated by the combi-
nation of α-kappa-ETA’ and cetuximab was due to a kappa light chain-dependent 
delivery of α-kappa-ETA’ and not due to the independent action of α-kappa-ETA’ 
and the EGFR-directed antibody, experiments with the EGFR-directed murine IgG1 
antibody m225 were performed. m225 is the parental murine antibody used for the 
generation of the mouse/human chimeric antibody cetuximab, and therefore shares 
identical v-regions. In proliferation assays m225 and cetuximab similarly inhibited 
growth of A431 cells in a dose-dependent manner. Importantly, when α-kappa-ETA’ 
was added to m225 or cetuximab, a strong additional inhibitory effect was only 
observed in combination with cetuximab but not with the murine antibody m225 
(Fig.6). These data indicated that most likely a noncovalent toxin / antibody complex 
was formed with the human kappa light chain containing antibody cetuximab but 
not with murine kappa light chain containing antibody m225 (in ELISA experiments 
α-kappa-ETA’ did not bind to m225), resulting in the significant reduction in prolif-
eration.
502504-L-bw-deGoeij
Human kappa chain targeted ETA’ 121
















0 25 50 75 100 125
% of control
0 25 50 75 100 125
% of control


















FIGURE 5 α-kappa-ETA’ induced inhibition of proliferation of opsonized target cells. (A) L363 cells 
were incubated with recombinant HM1.24-specific mouse/human chimeric Fab fragments or an 
irrelevant similarly designed control molecule in the presence or absence of α-kappa-ETA’. (B-D) Similar 
experiments were performed with A431 cells and different EGFR-directed antibodies. (B) mouse/human 
chimeric IgG1/kappa antibody cetuximab; (C) fully human IgG1/kappa antibody 2F8; (D) fully human 
IgG2/kappa antibody panitumumab. Antibodies and Fab fragments were used at 1μg/ml, α-kappa-ETA’ 
was used at 0.1 μg/ml final concentration. Isotype matched irrrelevant antibodies served as negative 
controls. After 72 h vital cell mass was determined by MTT assay. Data are mean values +/- SEM of (A) 
three or (B-D) five independent experiments. (*) statistically significant difference compared to PBS-
treated control. (#) statistically significant difference compared to antibody-only treated cells. (p<0.05).
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FIGURE 6 Cytotoxic effect of kappa-directed ETA’ is human kappa chain specific. (A) A431 cells were 
incubated with increasing concentrations of (A) cetuximab or (B) with the parental murine IgG1/murine 
kappa antibody m225 (used for the generation of cetuximab) in the presence or absence of a constant 
concentration of α-kappa-ETA’. After 72 h vital cell mass was measured by MTT assay. Untreated cells 
served as controls. Data are mean values +/- SD of three independent experiments. (*) represents 
statistical difference between antibody vs antibody + α-kappa-ETA’ treatment. α-kappa-ETA’ was used at 
0.1 μg/ml.
Cytotoxicity mediated by genetically linked single chain immunotoxins
In a next set of experiments it was tested whether antibodies which were able to 
potently deliver α-kappa-ETA’ to antigen expressing cells can be converted to func-
tionally active covalently linked immunotoxins. Therefore, scFv fragments  derived 
from the v-regions of cetuximab or from a chimeric HM1.24-specific Fab fragment 
were genetically fused to the truncated version of Pseudomonas exotoxin A (Fig.7A). 
The two proteins HM1.24-ETA’ and 225-ETA’ were expressed in E.coli and purified 
(Fig.7A). 225-ETA’ and HM1.24-ETA’ specifically bound to antigen-expressing cells, 
while no binding was detected on antigen-negative cells (data not shown). HM1.24-
ETA’ induced apoptosis of HM1.24-expressing L363 cells at low concentrations 
(Fig.7B). This cytotoxic effect was completely inhibited by adding excess of the 
 parental HM1.24-specific antibody demonstrating strict antigen-dependent induc-
tion of apoptosis (data not shown). No induction of apoptosis was observed with 
antigen negative Raji cells (Fig.7B). 225-ETA’ mediated inhibition of proliferation of 
A431 cells, while an irrelevant control molecule did not show any inhibitory effect 
(Fig.7C). These data underline our hypothesis that antibodies which demonstrated 
strong  inhibitory effects in our α-kappa-ETA’ based screening assay can be success-
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Screening a panel of human EGFR antibodies
A panel of seven novel human kappa light chain-containing IgG antibodies recogniz-
ing different epitopes on EGFR’s extracellular domain (Fig.8A; Table II; [38]) was test-
ed in the screening system. All antibodies tested in combination with α-kappa-ETA’ 
showed significant inhibitory effects on growth of A431 cells, while only limited 
 inhibitory effects were observed without addition of α-kappa-ETA’ (Fig.8B). Clone 
2F8 demonstrated the strongest inhibitory effect with IC50 values ~5-fold lower 
than clone 008 which showed the weakest effect in the test panel (Fig.8B). There 
was no obvious correlation between affinity / avidity and extend of cytotoxic effect 
 (Table II). This observation was more closely in line with potency in internalization 
and EGFR down modulation previously observed for this antibody [39]. According 
to the presented data antibody 2F8 may be very well suited for the development 
of ADC.
Together these data suggest that α-kappa-ETA’ may represent an interesting novel 
screening tool for the identification of promising candidate antibodies for the de-
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FIGURE 7 Design and antigen-specific killing of scFv-based immunotoxins against tumor associated 
antigens. (A) Design and purification of the recombinant scFv-based immunotoxins. L=pelB secretion 
leader; S = STREP-II-6xHis-tag; ETA’ = truncated ETA fragment consisting of domain II and III of 
Pseudomonas exotoxin A; KDEL = endoplasmic reticulum retention motif; VL = V-region of the antibody 
light chain; VH = V-region of the antibody heavy chain. SDS-PAGE and coomassie staining was 
performed to analyze purity and integrity of 225-ETA’ and HM1.24-ETA’. HM1.24-ETA’ is shown as a 
representative result. (B) Dose-dependent induction of apoptosis and cell death of HM1.24-positive 
L363 multiple myeloma cells and antigen negative Raji cells was analyzed. 24h after treatment cells 
were analyzed by annexin V / 7-AAD staining and flow cytometry. (C) Antiproliferative activity of 225-
ETA’. Tartget cells A431. After 72 h, vital cell mass was measured by MTT assay. Data are mean values 
+/- SEM of three independent experiments. 
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Antibodies blocking ligand (EGF) binding:
2F8, panitumumab, cetuximab 
Antibodies not interfering with ligand (EGF) binding:





























10-6 10-5 10-4 10-3 10-2
antibody concentration (μg/mL)
10-6 10-5 10-4 10-3 10-2
antibody concentration (μg/mL)
panitumumab 003 008 018
005 0112F8
Antibody + α-kappa-ETA’ Antibody 
A
B
FIGURE 8 Fully human EGFR antibodies differ in their capacity to deliver α-kappa-ETA’. (A) Fully 
human antibodies directed against different subdomains I-IV of EGFR were analyzed in the novel 
screening assay. The 3D-model is based on protein structure pdb-file 1YY9 and was produced using 
the YASARA Structure software package. (B) A431 cells were incubated with increasing antibody 
concentrations in the presence (left graph) or absence (right graph) of a constant concentration of 
α-kappa-ETA’. After 72 h vital cell mass was measured by MTT assay. Untreated cells served as controls. 
Data are mean values +/- SEM of three independent experiments (each experiment set up in triplicates). 
α-kappa-ETA’ was used at 0.1 μg/ml. * = significant difference between 008 and 2F8 (p<0.05). # = 2F8 
significantly more effective compared to all other antibodies (p<0.05).
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DISCUSSION
A novel human kappa light chain binding immunotoxin, α-kappa-ETA’, was generated 
to allow screening for antibodies with potential in ADC development obviating the 
production of covalently linked individual conjugates. α-kappa-ETA’ was specifically 
delivered and significantly inhibited proliferation of target cells that were opsonized 
with antibodies directed against internalized antigens HM1.24 and EGFR. Derived 
single-chain immunotoxins HM1.24-ETA’ and 225-ETA’ were highly active, indicating 
that antibodies identified in the screening approach can be successfully converted 
to genetically linked immunotoxins. Finally, a set of 7 fully human anti-EGFR anti-
bodies was screened, with 2F8 identified as the most potent antibody in our novel 
screening assay.
Screening platforms allowing identification of antibody candidates for ADC in an 
easy but highly predictive way may speed up the developing process. To address 
this issue, recently fusion proteins of antibody binding proteins (IgG-binding motif 
from Streptococcal protein A or protein G) and diphtheria toxin or Pseudomonas exo-
toxin A were reported [29,30]. These molecules in contrast to α-kappa-ETA’ bound 
the Fc part of complete antibodies. Although this strategy allowed screening of dif-
ferent antibodies for their potential to deliver the cytotoxic fusion protein, some 
 caveats may limit its broad applicability. One of the proteins formed stable com-
plexes only after further treatment with a chemical cross-linker [30]. In addition, the 
fusion proteins due to their protein A/G based design bind to the Fc part of different 
antibody isotypes with different affinities potentially compromising data interpre-
tation when antibodies with different isotypes should be compared. Furthermore 
protein A/G based toxin fusions bind to bovine IgG in serum containing tissue culture 
medium if not covalently linked to the antibody [30]. Therefore, antibody screening 
with these molecules still requires pre-formation of the antibody-toxin-complex for 
reliable data interpretation or adaption of the target cell line to serum free condi-
tions [30]. These procedures either require purified antibodies or adaption of tissue 
culture conditions, further complicating potential high throughput screenings. Due to 
its high specificity for human kappa light chain, α-kappa-ETA’ may be ideally suited 
for screening different human antibodies, irrespective of the antibody isotype. A 
limitation of the presented concept is that potentially interesting murine antibodies 
from readily available hybridoma lines can not be tested, which is limited to human 
kappa light chain containing antibodies. Nevertheless, most therapeutic antibodies 
entering clinical trials today contain human kappa light chains, as reflected by the 
fact that to date all clinically approved chimeric, humanized and human antibod-
ies are based on kappa constant regions. Consequently, although limited to human 
antibodies the novel screening tool may be widely applicable for screening large 
numbers of human antibodies isolated from human hybridoma lines or transgenic 
mice harboring human antibody genes, such as the Humab- or Xeno-mouse strains 
502504-L-bw-deGoeij
128 Chapter 5
[31,40,41]. In addition α-kappa-ETA’ may represent an interesting tool for screening 
internalization characteristics of Fab or single-chain Fab fragments derived from 
phage display libraries [42,43]. In this setting α-kappa-ETA’ in contrast to protein A 
/ G based immunotoxins may obviate the need in converting isolated Fab fragments 
into complete antibodies. This assay system may easily be adapted for screening 
human lambda light chain containing or murine antibodies, by replacing the human 
kappa light chain-directed domain antibody by other antibody fragments with high 
immunoglobulin specificity. Whether antibodies with favorable characteristics iden-
tified by in vitro screening systems as described here will finally result in ADC with 
favorable in vivo characteristics ideally in a clinical setting has to be carefully eval-
uated in the future.
Antibody EC50 (FACS) [µg/mL]a IC50 (MTT) [µg/mL] Epitope location
2F8 (zalutumumab) 0.7 0.8 x 10-4 Domain III
panitumumab 0.6 1.9 x 10-4 Domain III
018 1.2 2.6 x 10-4 Domain III
011 2.7 1.4 x 10-4 Domain I/II
008 3.2 3.8 x 10-4 Domain I/II
005 3.0 1.1 x 10-4 Domain I/II
003 9.2 1.9 x 10-4 Domain I/II
TABLE 2 Characteristics of human IgG1/kappa EGFR antibodies. a Dose dependent binding to EGFR-
expressing cells was analyzed using indirect immunofluorescence staining and flow cytometry (data not 
show).
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ABSTRACT
The human epidermal growth factor receptor (HER)2 provides an excellent target 
for selective delivery of cytotoxic drugs to tumor cells by antibody-drug conjugates 
(ADC) as has been clinically validated by ado-trastuzumab emtansine (KadcylaTM). 
While selecting a suitable antibody for an ADC approach often takes specificity and 
efficient antibody-target complex internalization into account, the characteristics of 
the optimal antibody candidate remain poorly understood. We studied a large pan-
el of human HER2 antibodies to identify the characteristics that make them most 
suitable for an ADC approach. As a model toxin, amenable to in vitro high-through-
put screening, we employed Pseudomonas exotoxin A (ETA’) fused to an anti-kappa 
light chain domain antibody. Cytotoxicity induced by HER2 antibodies, which were 
thus non-covalently linked to ETA’, was assessed for high and low HER2 expressing 
tumor cell lines and correlated with internalization and downmodulation of HER2 
antibody-target complexes. Our results demonstrate that HER2 antibodies that do 
not inhibit heterodimerization of HER2 with related ErbB receptors internalize more 
efficiently and show greater ETA’-mediated cytotoxicity than antibodies that do in-
hibit such heterodimerization. Moreover, stimulation with ErbB ligand significantly 
enhanced ADC-mediated tumor kill by antibodies that do not inhibit HER2 heterod-
imerization. This suggests that the formation of HER2/ErbB-heterodimers enhances 
ADC internalization and subsequent killing of tumor cells. Our study indicates that 
selecting HER2 ADCs that allow piggybacking of HER2 onto other ErbB receptors 
provides an attractive strategy for increasing ADC delivery and tumor cell killing 
capacity to both high and low HER2 expressing tumor cells.
INTRODUCTION
The human epidermal growth factor receptor (HER)2 is a 185-kDa cell surface recep-
tor tyrosine kinase and member of the epidermal growth factor receptor (EGFR) fam-
ily that comprises four distinct receptors: EGFR/ErbB-1, HER2/ErbB-2, HER3/ErbB-3, 
and HER4/ErbB-4. Both homo- and heterodimers are formed by the four members 
of the EGFR family, with HER2 being the preferred and most potent dimerization 
partner for all other ErbBs [2,3]. HER2 has no known ligand, but can be activated 
via homodimerization when overexpressed, or by heterodimerization with other, 
ligand-occupied ErbB receptors [4]. Depending on the dimerization partner, HER2 
induces activation of the MAPK pathway, thereby stimulating proliferation, or the 
PI3K-Akt pathway, which promotes cell survival [5]. Over-expression of HER2 has 
been described in a wide variety of cancers, including breast, ovarian, gastric and 
non-small cell lung cancer [5].
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HER2 is a clinically well-validated target for antibody therapy and proven to be 
suitable for an antibody-drug conjugate (ADC) approach through ado-trastuzumab 
 emtansine (KadcylaTM) [6,7]. Ado-trastuzumab emtansine, which is approved for 
therapy of metastatic HER2-positive breast cancer [8], consists of trastuzumab con-
jugated via a non-reducible thioether linker to the fungal toxin and tubulin inhibitor 
maytansine. This ADC was designed to release the drug upon complete degradation 
in the lysosomes of targeted cells, and demonstrated great efficacy against HER2 
overexpressing tumors, without affecting healthy tissue with normal HER2 expres-
sion levels [6,7,9]. The drug was found to retain the mechanisms of action of unconju-
gated trastuzumab, including inhibition of PI3K/AKT signaling and HER2 ectodomain 
shedding, and induction of antibody-dependent cellular cytotoxicity (ADCC) [10].
While many antibody characteristics are taken into account when selecting a suit-
able antibody for HER2-targeted therapy, it is typically considered an advantage 
for an ADC approach if the HER2/antibody complex efficiently internalizes upon 
antibody binding. In healthy tissue, the intensity of ErbB receptor signaling in cells is 
controlled by accelerated receptor internalization and degradation upon ErbB ligand 
binding. However, for the orphan HER2 receptor, no such internalization mechanism 
exists and all expressed HER2 predominantly localizes to the plasma membrane [11-
13]. Notably, increased EGFR or HER3 expression results in increased endocytosis of 
HER2, especially in the presence of ligand [14,15].
In this study, we analyzed a diverse panel of human HER2 monoclonal antibodies 
(mAbs) for their suitability as an ADC. Internalization and cytotoxicity of HER2 an-
tibodies were studied in an in vitro test system by generating non-covalently linked 
immunotoxins using a human kappa light chain-directed truncated version of Pseu-
domonas exotoxin A. Receptor internalization and cytotoxicity was correlated with 
expression and activation levels of different ErbB receptors on tumor cells to iden-
tify HER2 antibodies that both internalize efficiently and, as an ADC, kill cells with a 
range of HER2 expression levels. In particular, HER2 antibodies that can utilize HER2 
heterodimer-driven internalization seem very attractive for future HER2-targeted 
ADC therapeutics, especially to target tumor indications with lower HER2 expression.
MATERIALS AND METHOD
Antibodies and cell lines
Human MCF7 and AU565 (breast cancer), NCI-H747 and Colo 205 (colon cancer) cells 
were from American Type Culture Collection (ATCC). Human A431 (epithelial squa-
mous carcinoma) cells were from the Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ). MCF7 cells were cultured in MEM (Lonza, BE12-169F) contain-
ing 10% heat inactivated calf serum (Hyclone, SH30087.04) and 0.01 mg/mL bovine 
502504-L-bw-deGoeij
HER2 antibody selection for antibody-drug conjugate development 137
insulin (Sigma, I0516). Colo 205 and A431 cells were cultured in RPMI 1640 (Lonza, 
BE12-115F) containing 10% heat inactivated calf serum. AU565 and NCI-H747 cells 
were cultured in RPMI 1640, containing 10% heat inactivated calf serum, 2% sodium 
bicarbonate (Lonza, BE17-613E), 1% sodium pyruvate (Lonza, BE13-115E), and 0.5% 
glucose (Sigma, G8769).
Human IgG1,ĸ HER2 mAb were generated by immunizing HuMAb® mice (Medarex, 
Milpitas, CA) [16] alternating with NS0 cells transiently expressing full length HER2 
(1255 aa, UniProt P04626) and a Keyhole Limpet Hemocyanin (KLH)-coupled C-ter-
minal His6-tagged HER2 protein fragment comprising the HER2 extracellular domain 
(HER2ECDHis). MAb were obtained by fusing mouse splenocytes and lymph node 
cells with the mouse myeloma cell line SP2.0 (ATCC) by electrofusion using a CEEF 50 
Electrofusion System (Cyto Pulse Sciences, Glen Burnie, MD, USA). Hybridomas were 
subcloned in semisolid medium using the ClonePix system (Genetix), and expanded 
and cultured based upon standard protocols [17]. Antibodies that bound HER2 ex-
pressing cell lines selectively were molecularly cloned and produced by transient 
transfection in HEK-293 cells, purified using protein A affinity chromatography 
(MabSelect SuRe, GE-Healthcare) and formulated in PBS containing Tween 80 and 
mannitol.
The HER2ECDHis constructs contained an optimal Kozak sequence and were cloned 
in the mammalian expression vector pEE13.4 (Lonza Biologics) [18,19] expressed 
in HEK-293F cells and purified using immobilized metal affinity chromatography. 
To allow a proper comparison, we also produced trastuzumab and pertuzumab in 
our transient HEK system. The variable region sequences of pertuzumab and tras-
tuzumab described in US patents 6949245 and 7632924, respectively, were cloned 
and transfected in HEK-293 cells. Both were expressed as a human IgG1 (allotype f) 
antibody with a kappa light chain. These two mAb preparations are referred to as 
TH-pertuzumab and TH-trastuzumab, respectively. Clinical grade trastuzumab (Her-
ceptin®) was purchased (Roche). Trastuzumab and TH-trastuzumab bound HER2 sim-
ilarly (data not shown) and, as an additional control, Supplementary Figure 4 illus-
trates that clinical grade trastuzumab and TH-trastuzumab induced similar efficacy 
in our in vitro kappa-directed ETA’ killing assay.
Cross-competition ELISA
ELISA plates were coated with HER2 antibodies at 4°C, 6–0.5 μg/mL. After blocking 
with PBSTC (PBS supplemented with 0.5% Tween 20 [Riedel-de-Haen, 63158] and 2% 
chicken serum [Invitrogen, 16110082]) for 1 hour at room temperature (RT), wells 
were incubated with 1 μg/mL soluble HER2ECDHis in the presence of an excess (10 
μg/mL) of competitor HER2 antibody. Bound HER2ECDHis was detected with 0.5 μg/
mL biotinylated rabbit-anti-6xhis antibody (Abcam, ab27025), followed by 0.1 μg/
mL streptavidin-poly-HRP (Sanquin, M2032). The reaction was visualized using ABTS 
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(Roche) and stopped with 0.2% oxalic acid. Fluorescence at 405 nm was measured 
on a microtiter plate reader (Biotek Instruments) and residual HER2ECDHis binding 
was expressed as percentage relative to maximal binding observed in absence of 
competitor antibody.
HER2 ECD domain shuffle
Sequences of domains I–IV of the human HER2 extracellular domain were ex-
changed one-by-one from human to chicken HER2 (Gallus gallus isoform B NCBI: 
NP_001038126.1), generating 5 different constructs: 1) fully human HER2 (UniProt 
P04626), hereafter named hu-HER2; 2) hu-HER2 with chicken domain I (replac-
ing amino acids (aa) 1-203 of human HER2 with the corresponding chicken HER2 
 region), named hu-HER2-ch(I); 3) hu-HER2 with chicken domain II (replacing amino 
acids (aa) 204-330 of human Her2 with the corresponding chicken Her2 region), 
named hu-HER2-ch(II); 4) hu-HER2 with chicken domain III (replacing aa 331-507 of 
human Her2 with the corresponding chicken Her2 region), named hu-HER2-ch(III); 
and 5) hu-HER2 with chicken domain IV (replacing aa 508-651 of human Her2 with 
the corresponding chicken Her2 region), named hu-HER2-ch(IV). The constructs were 
transiently transfected in FreestyleTM CHO-S (Invitrogen) cells using Freestyle MAX 
transfection reagent (Invitrogen, K9000-20). After culturing for 20 hours, HER2 
 antibody binding was analyzed by flow cytometry.
Flow cytometry
Binding of HER2 antibodies to membrane-bound HER2 on A431 cells was analyzed 
by flow cytometry as described [20]. Phycoerythrin (PE)-conjugated goat anti-hu-
man IgG (Jackson, 109-116-098) was used to detect binding of HER2 mAbs. EC50 
values were determined by means of non-linear regression using GraphPad Prism 
(GraphPad Software V4.03).
Proliferation assay
AU565 cells were seeded in serum-free culture medium, 9,000 cells/well, in 96-wells 
tissue culture plates (Greiner bio-one, 655180) in the presence of 10 μg/mL anti-
body. MCF7 cells were seeded in complete growth medium, 2,500 cells/well. After 
4 hours, medium was replaced with medium containing 1% serum, 10 μg/mL anti-
body and 1.5 ng/mL heregulin-β1 (PeproTech, 100-03). After 3 or 4 days incubation, 
10% Alamarblue (Invitrogen, DAL110) was added, and fluorescence was monitored 4 
hours later using the EnVision 2101 Multilabel reader (PerkinElmer). The Alamarblue 
signal in antibody-treated wells was plotted as a percentage relative to the signal in 
wells without antibody.
ERK-phosphorylation Alphascreen assay
AU565 cells were cultured overnight in 96-well plates (9,000 cells/well) in  serum-free 
medium. The medium was replaced with DMEM (Sigma-Aldrich, D6546) and the cells 
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were cultured 2 hours. 10 µg/mL antibody dilutions (in DMEM) were added, 30 min 
prior to stimulation with 1.67 ng/mL EGF (Bioresource, PHG0311). After 10 min, the 
cells were washed twice with PBS, lysed and analyzed for the presence of phos-
phorylated ERK with the phospho-ERK specific AlphaScreen® assay, according to the 
manufacturer’s protocol (PerkinElmer, TGRES500). Fluorescent units at 570 nm were 
measured with the EnVision 2101 Multilabel reader (PerkinElmer) using standard 
AlphaScreen® settings.
CypHer5E internalization assay
Cells were seeded in 384-well plates, 3,000 cells/well, in normal cell culture medium, 
containing 240 ng/mL goat anti-human-IgG Fab fragments (Jackson, 109-007-003) 
conjugated to CypHer5E (GE Healthcare, PA15401). CypHer5E is a pH-sensitive dye 
that is non-fluorescent at basic pH (extracellular: culture medium) and fluorescent at 
acidic pH (intracellular: endosomes, lysosomes). Serially-diluted antibodies (range 
2500-4.9 ng/mL) were added and plates were incubated at RT for 9 hours. Mean 
fluorescent intensities (MFI) of intracellular CypHer5E were measured per well using 
homogeneous Fluorometric Microvolume Assay Technology (FMAT, Applied Biosys-
tems). As read-out, fluorescence per cell was measured and multiplied with the num-
ber of positive cells per well (counts x fluorescence).
HER2 downmodulation ELISA
AU565 cells were seeded in 24-wells tissue culture plates (100,000 cells/well) in 
normal cell culture medium and cultured for 3 days at 37°C in the presence of 10 μg/
mL HER2 antibody. Cells were lysed by incubating 30 min at RT with 25 μL Surefire 
Lysis buffer (Perkin Elmer, TGRA2510K). Total protein levels were quantified using 
bicinchoninic acid (BCA) protein assay reagent (Pierce, 23227). HER2 protein levels 
were analyzed using a HER2-specific sandwich ELISA. A 1000-fold dilution of rabbit 
anti-human HER2 intracellular domain antibody (Cell Signaling, 2165) was used to 
capture HER2 and 0.15 μg/mL biotinylated goat anti-human HER2 polyclonal anti-
body (R&D, BAF1129), followed by 0.1 μg/mL streptavidin-poly-HRP, were used to 
detect bound HER2. The reaction was visualized using ABTS and stopped with oxalic 
acid. Fluorescence at 405 nm was measured and the amount of HER2 was expressed 
as a percentage relative to untreated cells.
Cytotoxicity assay using α-kappa-ETA’ toxin
Antibodies were pre-incubated with a predetermined concentration of α-kappa-ETA’ 
(see supplementary methods for preparation of α-kappa-ETA’) [21] that was not tox-
ic for cells. This procedure allows formation of non-covalently linked immunotoxins, 
obviating the production of chemically conjugated toxins that may vary in toxin 
content and position of linkage. Cells were seeded in normal cell culture medium in 
96-well tissue culture plates and serially diluted antibodies were added. As negative 
control, cells were incubated without antibody or with an isotype control antibody. 
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As a positive control for cytotoxicity, 10 μg/mL Staurosporin (Sigma, S6942) was 
added to cells without antibody. After 3 days, the amount of viable cells was quan-
tified using Alamarblue or ATPlite (PerkinElmer, 6016941), both measured using the 
EnVision 2101 Multilabel reader. Viability was calculated according to (signal anti-
body-treated cells – signal positive control) / (signal untreated cells – signal positive 
control) x 100%.
Statistical analysis
Data analyses were done using GraphPad Prism 5 software. Group data were report-
ed as mean ± SD. Dunett’s test was applied for statistical analysis.
RESULTS
Characterization of HER2 antibody cross-competition groups.
A panel of 134 human HER2-specific antibodies was generated in human antibody 
transgenic mice using hybridoma technology [17]. Based on apparent affinities and 
sequence diversity, 72 HER2 mAbs were selected for further characterization in a 
cross-competition ELISA with the HER2 extracellular domain (HER2ECDHis). Four 
distinct cross-competition groups of mAbs were defined (Supplementary Table 1). 
Group 1 comprised 12 mAbs, including mAb-169 and trastuzumab (Herceptin®), 
which has previously been mapped to an epitope in domain IV of HER2 [22,23]. 
Group 2 comprised 17 mAbs, including mAb-025 and HEK-293-produced pertuzum-
ab (TH-pertuzumab), which is known to recognize an epitope in domain II of HER2 
[1,24]. MAb-169 and -025 were chosen as representative mAbs for their Group 1 
and 2 respectively. Group 3 comprised 22 mAbs that did not compete for binding to 
HER2ECDHis with antibodies from other cross competition groups. Within Group 3 
some variation was observed as some antibodies did not compete with each other 
for binding to HER2ECDHis, but did compete with the other Group 3 antibodies. 
Therefore we divided these antibodies in two subgroups, 3a and 3b, for which two 
representative antibodies, 098 and 153, were selected for further characterization. 
Finally, Group 4 comprised 21 mAbs that competed with each other for binding to 
HER2ECDHis, but not with any of the other cross-competition groups. MAb 005 was 
selected from Group 4 for further characterization.
To map the regions recognized and characterize epitope diversity between the four 
different groups of mAbs, a HER2 ECD shuffle experiment was performed. Five con-
structs were generated by swapping the sequences of domain I, II, III or IV of the 
extracellular domain of human HER2 with the corresponding sequence of chicken 
HER2. The wild-type construct is referred to as hu-HER2 and the mutants as hu-
HER2-ch(I) to -(IV), respectively. The human and chicken HER2 orthologs show 67% 
homology in their ECD (62% homology in domain I, 72% in domain II, 63% in do-
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main III and 68% in domain IV). The generated constructs were expected to result 
in a protein with domains that are sufficiently homologous to allow correct folding, 
but different enough to remove epitopes recognized by human HER2 specific mAbs. 
Group 1 mAbs trastuzumab and 169 showed loss of binding to Hu-HER2-ch(IV), but 
not to the other shuffle proteins, confirming that the epitopes of Group 1 mAbs 
reside in HER2 domain IV (Table I, Supplementary Figure 1). Group 2 antibody 025 
only showed loss of binding for Hu-HER2-ch(II), confirming that its epitope resides 
in HER2 domain II. The distinction between Group 3a and 3b mAbs 098 and 153 was 
confirmed in the shuffle experiment in which mAb 098 showed loss of binding to 
Hu-HER2-ch(I) and a small decrease in binding to Hu-HER2-ch(II), whereas mAb 153 
only showed strong loss of binding to Hu-HER2-ch(II). The Group 4 mAb 005 showed 
loss of binding upon substitution of HER2 domain III, and partially decreased binding 
to Hu-HER2-ch(II).
Next, the epitopes of HER2 antibodies 005 and 153 were predicted using Chemically 
Linked Immunogenic Peptides on Scaffolds (CLIPS™) technology [25,26]. Antibody 
binding was tested on linear and looped CLIPS of 15 to 35 amino acids, which were 
designed to allow for mapping of conformational epitopes on the human HER2 ex-
tracellular domain. Group 3 mAb 153 demonstrated binding to peptides including 
sequence RCKGPLPTD, suggesting binding to domain II on top of HER2 (Supplemen-
tary Figure 2). For the Group 4 mAb 005, two distinct peptides were predicted to be 
part of the epitope (GISWLGLRSLREL and IHHNTHLCFVHTVPW), which both reside 
in domain III distant from the dimerization regions (Supplementary Figure 2). We 
were unable to map the representative mAbs from the other groups using the CLIPS 
approach.
Taken together, our data demonstrated that the HER2 mAbs could be divided in four 
major groups based on their binding sites on HER2, with Group 1 antibodies binding 
epitopes in HER2 domain IV, Group 2 binding epitopes in HER2 domain II, Group 3a 
and 3b antibodies binding epitopes in a region overspanning HER2 domain I/II, and 




clone Group wildtype I II III IV
Herceptin 1 +++ +++ +++ +++ -
169 1 +++ +++ +++ +++ ++
025 2 +++ +++ - +++ +++
098 3a +++ - ++ +++ +++
153 3b +++ +++ - +++ +++
005 4 +++ +++ ++ - +++
TABLE 1 Summary of antibody binding to different HER2 receptor constructs. Wild-type; hu-HER2, 
I; hu-HER2-ch(I), II; hu-HER2-ch(II), III; hu-HER2-ch(III), IV; hu-HER2-ch(IV) +++ Indicates wild-type 
binding or binding similar to wild-type binding, ++ indicates reduced EC50 but similar maximal binding 
compared to wild-type binding, - indicates no binding detected. See Supplementary Figure 1 for dose-
response binding curves.
HER2 mAb Cross-blocking group
1 2 3 4
Herc 169 025 098 153 005
Apparent affinity EC50 (nM) 5.7 6.1 3.9 2.3 4.2 5.3
Inhibition of ligand-independent growth + + - -* - -
Inhibition of ligand-induced growth -/+ - + - + -
Internalization -/+ -/+ + ++ ++ +
Downmodulation -/+ -/+ -/+ ++ ++ +
Kappa-ETA’ toxicity AU565 -/+ + ++ ++ ++ ++
Kappa-ETA’ toxicity A431 - - ++ ++ ++ ++
Effect EGF on killing - - - + - +
TABLE 2 Summary antibody characteristics. Summary of the different antibody characteristics and 
representation of the different HER2 epitopes recognized. Flow cytometry was applied to determine 
the apparent antibody affinities on A431 cells which were depicted as EC50 value. HER2 structure was 
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Proliferation inhibition by HER2 antibodies.
Representative antibodies from each cross-competition group were tested for their 
ability to inhibit HER2-driven proliferation. Because HER2 is an orphan receptor, it 
normally requires ligand-induced heterodimerization with other ErbB family mem-
bers for its signaling, such as EGF-induced EGFR/HER2 or heregulin-induced HER2/
HER3 heterodimerization [2]. However, when highly overexpressed, HER2 can signal 
as a homodimer in a ligand-independent fashion. HER2 homodimerization-induced 
signaling was distinguished from heterodimerization-induced signaling by analyzing 
ligand- independent and ligand-induced proliferation. The ability of HER2 mAbs to 
inhibit  ligand-independent proliferation was tested in AU565 cells, which express 
very high HER2 levels (Supplementary Table 2). Group 1 antibodies demonstrated 
significant inhibition of AU565 cell proliferation (Figure 1A), consistent with what 
has previously been described for trastuzumab [23]. MAb from Group 2 or 4 did not 
show any effect on ligand-independent AU565 proliferation. In contrast, both Group 
3 mAb  enhanced proliferation of HER2-overexpressing AU565 cells. These data in-
dicate that Group 1 mAb, which bind HER2 domain IV, can interfere with signaling 
induced by HER2 homodimerization when the receptor is highly overexpressed.
The potential of HER2 mAbs to inhibit HER2 heterodimerization-driven proliferation 
was tested in MCF7 cells, which express comparable levels of HER2 and HER3 (Sup-
plementary Table 2) and are responsive to the HER3 ligand heregulin-β1 [27]. Figure 
1B demonstrates that heregulin-β1-induced proliferation of MCF7 cells was inhibit-
ed by the HER2 domain II binding Group 2 mAbs and Group 3b mAb 153. The Group 
3a mAb 098, for which the epitope was mainly defined to residues in HER2 domain I 
and only displayed limited binding to domain II, did not affect heregulin-β1-induced 
MCF-7 proliferation. Group 1 and 4 antibodies also had no effect on heregulin-β1- 
induced proliferation, with the exception of trastuzumab, which demonstrated some 
inhibitory effect, although with lower significance.
HER2 can also signal through ligand-activated EGFR [2]. Therefore, our conclusions 
for HER2 heterodimerization-dependent signaling were confirmed by assessing 
EGF-induced EGFR/HER2 heterodimerization and downstream ERK phosphorylation 
in AU565 cells (Figure 1C). Here again, Group 2 mAb inhibited ligand-dependent 
signaling most prominently. These data suggest that binding to HER2 domain II is 
critical for the ability of HER2 antibodies to interfere with ligand-induced HER2 het-
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FIGURE 1 In vitro inhibition of proliferation and ERK phosphorylation by HER2 antibodies. A) Inhibition 
of proliferation of AU565 cells. Cell viability is presented as a percentage relative to untreated cells (± 
SD, n=3), (*P <0.05). B) Inhibition of proliferation of MCF7 Cell viability is presented as a percentage 
relative to cells stimulated with Heregulin-β1 only (± SD, n=3), (*P <0.05, **P <0.01). C) Inhibition of ERK 
phosphorylation in AU565. The amount of phosphorylated ERK was quantified using a phospho-ERK 
specific AlphaScreen® assay. Values depicted are the mean of at least two experiments ± SD.
502504-L-bw-deGoeij
HER2 antibody selection for antibody-drug conjugate development 145
HER2 antibody-induced internalization and HER2 downmodulation
A prerequisite for an ADC approach is efficient internalization of the antibody- target 
complex. A CypHer5E-based internalization assay was performed to investigate the 
internalization capacity of the mAbs. All 72 HER2 mAbs of the four cross- competition 
groups described above were tested. AU565 cells were incubated with HER2 mAbs 
that were indirectly labeled with the pH-sensitive dye CypHer5E conjugated to Fab 
fragments of a goat anti-human IgG antibody, which becomes fluorescent in the 
acid environment of the endosomal/lysosomal compartments upon internalization 
 (Figure 2A,B). Group 3 mAbs clearly showed enhanced receptor internalization com-
pared to the other cross-competition groups. Group 1 mAbs, in contrast, induced 
receptor internalization relatively poorly. This was further illustrated by the dose 
response curves generated for the representative mAbs of each cross- competition 
group (Figure 2B). These data show that antibody internalization was strongly 
 induced by Group 3 HER2 antibodies in particular, and to a lesser extent by anti-
bodies from the other cross-competition groups.
Upon internalization, antibody-target complexes enter the endosomal compartment, 
and are either transported to the lysosomes for degradation, or are recycled back 
to the plasma membrane. We investigated for representative mAbs of each cross- 
competition group whether HER2 mAb binding induced degradation of the HER2 
target. The total amount of HER2 protein in AU565 cells was quantified by ELISA 
after a 3-days antibody treatment. AU565 cells were seeded to confluence at the 
beginning of the experiment to minimize antibody-induced effects on proliferation. 
Both Group 3 antibodies induced HER2 downmodulation (~50% of untreated cells; 
Figure 3). In contrast, Group 1 and 2 antibodies hardly induced any downmodulation, 
whereas Group 4 antibody 005 induced intermediate HER2 downmodulation. Except 
for the Group 2 HER2 mAb 025, these data are in line with the internalization results, 
suggesting that internalization upon HER2 mAb binding results in degradation of 
the antibody-target complexes for Group 1, Group 3 and Group 4 antibodies. HER2 
antibody 025 behaved differently in that it showed internalization comparable to 
Group 4 mAb 005, but induced limited HER2 downmodulation. This might suggest 
that the antibody-target complex formed by mAb 025 is primarily directed towards 
the recycling pathway instead of the lysosomal degradation pathway. 
HER2-mAb activity in an in vitro kappa-directed ETA’ killing assay
To further investigate which antibodies were suitable for an ADC approach, an in 
vitro cell-based killing assay using the Pseudomonas exotoxin A (ETA’) fused to an 
anti-kappa light chain domain antibody (α-kappa-ETA’) amenable to high throughput 
screening was used [21]. This fusion protein allows formation of non- covalently-
linked immunotoxins with antibodies containing human kappa light chains. The 
α-kappa-ETA’ fusion protein needs to undergo furin-mediated proteolytic cleavage 
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FIGURE 2 Internalization and HER2-mAb α-kappa-ETA’ induced killing of AU565 cells. A/B) Cells 
were seeded and incubated for 9 hours at RT with CypHer5E-conjugated Fab fragments of goat anti-
human IgG and serially diluted HER2 antibodies. (A) Maximal ‘counts x fluorescence’ is plotted. Each 
dot represents a different antibody. In black are trastuzumab (Group 1) and TH-pertuzumab (Group 
2). The open symbols represent the representative mAbs from each Group. Within Group 3, mAb 098 
was depicted as triangle and mAb 153 as circle. Antibodies from Group 3 induced significantly more 
CypHer5E fluorescence compared to mAbs from Groups 1, 2 and 4 (P <0.001). B) Dose-response curves 
of mAbs representing each of the Groups (n=2). C/D) Viability of AU565 cells after 3 days incubation 
with HER2 antibodies pre-incubated with 0.1 µg/mL α-kappa-ETA’. Antibodies from Groups 3 and 4 
induced significantly more cytotoxicity compared to mAbs from Groups 1 and 2 (P <0.001). C) Each 
dot represents the maximal reduction in cell viability induced by a different antibody. In black are 
trastuzumab and TH-pertuzumab. The open symbols represent the representative mAbs from each 
Group. D) Dose-response curves of mAbs representing each of the Groups (± SD, n=2). An isotype 
control mAb (control) was used as negative control.
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domain. The released toxin is then transported to the endoplasmic reticulum and 
redirected to the cytosol where it inhibits protein synthesis and induces apoptosis 
[28]. We investigated whether there was a correlation between the efficiency of 
antibody-induced internalization, HER2-downmodulation and cytotoxicity mediat-
ed by immunotoxins derived from HER2 mAbs of the different cross-competition 
groups.
We screened our complete panel of 72 HER2 mAbs for inhibition of AU565 cell 
 viability when pre-incubated with α-kappa-ETA’. In general, α-kappa-ETA’ pre-in-
cubated Group 3 and Group 4 antibodies induced higher toxicity (lower cell viabili-
ty) in AU565 cells compared to α-kappa-ETA’ pre-incubated antibodies from Group 
1, including trastuzumab, and Group 2, including TH-pertuzumab, (Figure 2C). Re-
duced cell viability was evidently due to cellular toxicity rather than inhibition of 
proliferation, as effects of unconjugated antibodies on proliferation in the 3-days 
 assay were observed only at concentrations above 100 ng/mL (data not shown), at 
which α-kappa-ETA’ pre-incubated antibodies already demonstrated maximal effi-
cacy (Figure 2C). Moreover, microscopic inspection of the cells revealed morphologic 
characteristics typical for apoptotic cells, such as cell shrinkage, membrane bleb-
bing and loss of membrane asymmetry. The dose-response curves of different mAbs 
of each cross-competition group again show that Group 1 antibodies induced less 
 efficient cell killing than mAbs from the other cross-competition groups (Figure 2D). 























FIGURE 3 Antibody induced downmodulation of HER2. Relative percentage of HER2 expressed in 
AU565 cell lysate after 3 days incubation 10 µg/mL HER2 mAb. The amount of HER2 was quantified 
using a HER2-specific capture ELISA and plotted as a percentage relative to untreated cells indicated 
with - (± SD, N=3). An isotype control mAb (contr) was used as negative control.
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FIGURE 4 The effect of EGFR and its ligand EGF on HER2-mAb α-kappa-ETA’ induced toxicity. (A) A431 
cells were seeded in presence of HER2 antibodies pre-incubated with 0.1 µg/mL α-kappa-ETA’. After 3 
days, cell viability was quantified using Alamarblue and plotted as a percentage relative to untreated 
cells (n=2). (B/C) Colo 205 cells were seeded in presence or absence of HER2 antibodies pre-incubated 
with 0.25 µg/mL α-kappa-ETA’. After 30 minutes 1.5 ng/mL EGF (+) or medium (-) was added and after 
3 days, cell viability was quantified using ATPlite and plotted as a percentage relative to untreated 
cells (n=2). (C) The amount of viable cells after treatment with HER2 antibody pre-incubated with 0.25 
µg/mL α-kappa-ETA’ was plotted. Dark grey bars represent cell viability after treatment with 100 ng/
mL HER2 antibody. Increased cell survival after treatment with 10 ng/mL HER2 antibody was plotted 
as light grey bars. 10 μg/mL Staurosporin was used as positive control to determine 0% cell viability. * 
indicates that viability in presence of EGF was significantly lower compared to viability in absence of 
EGF (P<0.05).
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The selected mAb from Group 2 (025) was one of the more effective antibodies from 
this group and thus also induced efficient dose-dependent cytotoxicity. These results 
were consistent with internalization data in AU565 cells for each antibody.
The effects of EGFR and its ligand EGF on HER2-mAb α-kappa-ETA’ induced toxicity
The efficacy of α-kappa-ETA’ pre-incubated HER2 mAbs was further investigated 
using the low-HER2 expressing cell line A431 (Supplementary Table 2). After three 
days, cell viability was efficiently decreased by the Group 2, 3 and 4 antibodies, 
while Group 1 antibodies demonstrated minimal to no efficacy (Figure 4A). These 
results were comparable to what was observed for AU565 cells; however, differenc-
es between mAbs from Group 1 and other Groups were much more pronounced in 
A431. Because A431 cells have very high EGFR expression (Supplementary Table 2), 
resulting in EGFR/HER2 heterodimerization [29], we hypothesized that this might 
accelerate internalization of HER2, thereby increasing cell killing induced via α-kap-
pa-ETA’ pre-incubated HER2 antibodies. Since Group 1 antibodies inhibit ligand- 
independent dimerization and thus also the formation of EGFR/HER2 heterodimers 
on A431 cells, these antibodies may not be able to benefit from this internalization 
route and therefore are reduced in their ability to induce ADC-mediated toxicity. 
Together, these data might then suggest that high EGFR expression and thus EGFR/
HER2 heterodimerization in A431 cells is involved in increased α-kappa-ETA’-medi-
ated cytotoxic efficacy of the HER2 mAbs of Group 2, 3 and 4 compared to AU565 
cells with low EGFR expression.
Ligand binding to EGFR typically causes accelerated internalization of the receptor 
[12,30-34]. Therefore, we tested our hypothesis by assessing the cytotoxic capacity 
of α-kappa-ETA’ pre-incubated HER2 mAbs on Colo205 cells in the absence or pres-
ence of EGF. Colo205 cells show low levels of both EGFR and HER2 on the cell surface 
(Supplementary Table 2), although the density of both receptors may be somewhat 
higher than expected due to the small size of these cells. More importantly, Colo205 
cells are responsive to EGFR activation by EGF. Results with kappa-ETA’ pre-incubat-
ed HER2 mAbs on Colo205 cells in the absence of EGF were comparable to AU565 
and A431 cells, i.e., Group 1 mAbs showed less cell killing than the representative 
mAbs from the other Groups (Figure 4C). Upon EGF stimulation, only Group 3a HER2 
mAb 098 and Group 4 mAb 005 showed enhanced α-kappa-ETA’-mediated cytotox-
icity (Figure 4B/C), whereas EGF did not affect α-kappa-ETA’-mediated cytotoxicity 
induced by Group 1 or 2 or the Group 3b mAb (153).
These results support our hypothesis that the formation of HER2/ErbB-heterodimers 
is beneficial for HER2 antibody-mediated drug delivery into target cells. Therefore, 
antibodies that inhibit the formation of ligand-induced or ligand-independent HER2/
ErbB-heterodimers seem less suitable for an ADC approach compared to antibodies 




In the present study, we characterized a broad panel of human HER2 antibodies 
generated in human antibody transgenic mice and studied their effects on receptor 
signaling, internalization and downmodulation of antibody-receptor complexes. To 
investigate which HER2 antibodies were most suitable for an ADC approach, we used 
an assay sytem based on a high affinity kappa light chain-specific domain antibody 
fused to a truncated form of Pseudomonas exotoxin A (α-kappa ETA’) [21]. Toxic-
ity induced by non-covalently linked toxin/HER2 antibody conjugates was tested 
on tumor cells with different expression levels of the ErbB receptors. Our results 
 indicated that the formation of HER2/ErbB-heterodimers is beneficial to achieve 
sufficient HER2 antibody-mediated drug delivery into target cells.
Especially on tumor cells that do not over-express HER2 to extremely high levels, 
the formation of HER2/ErbB heterodimers may represent an attractive approach for 
HER2 antibodies to deliver an ADC.
Most ADCs, including ado-trastuzumab emtansine, make use of non-cleavable linkers, 
or linkers that require proteolytic cleavage in lysosomes for drug release, such as 
thioether, disulfide and peptide-based valine-citrulline (SGN-35) linkers [9,35]. This 
differs from Pseudomonas exotoxin A-based conjugates, which are cleaved by furin 
in the endosomes, resulting in separation of the catalytic domain from the anti-
body-binding domain. Although the kinetics are not entirely understood, it should 
be noted that rapid lysosomal transport of Pseudomonas exotoxin A-based conju-
gates may hamper furin mediated cleavage and consequently reduce cytotoxicity 
[36]. Antibodies that deliver kappa-ETA’ more effectively into the lysosome, might 
therefore induce a lesser degree of killing, because of toxin degradation. The kap-
pa-ETA’ assay could therefore underestimate the potential value of such antibodies 
for an ADC approach. Nevertheless, in our panel of antibodies, we did not identify 
antibodies that were ineffective in the kappa-toxin assay while inducing rapid in-
ternalization as shown by strong CypHer5E fluorescence (Supplementary Figure 3). 
Furthermore, Pseudomonas exotoxin A has been used by a variety of investigators 
in preclinical and clinical testing to enhance the efficacy of antibody-based drugs 
[37-41], e.g., scFv[FRP5]-ETA (single chain Fv directed against HER2) [41], VB4-845 
(scFv targeting EpCAM) [37], SS1P (dsFv directed against mesothelin) [40] and CAT-
8015 (stabilized Fv fragment targeting CD22) [28]. Therefore the exotoxin A-based 
screening system should reliably identify antibodies with favorable characteristics 
for ADC development.
Based on cross-competition ELISA, HER2 extracellular domain shuffle and  CLIPSTM 
technology, a panel of 72 HER2 antibodies was divided into four different cross-com-
petition groups. It was observed that antibodies from Groups 2, 3 and 4, which did 
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not inhibit ligand-independent HER2 dimerization, induced enhanced internaliza-
tion and α-kappa-ETA’-mediated cytotoxicity compared to antibodies from Group 
1, which inhibited ligand-independent HER2 dimerization. This contrast was most 
prominent for cells with low HER2 expression but increased EGFR expression (AU565 
cells -HER2 high, EGFR low- versus A431 cells -HER2 low, EGFR high-), demonstrat-
ing that toxicity induced by α-kappa-ETA’ pre-incubated Group 1 antibodies, such as 
trastuzumab, cannot be enhanced via co-expression with EGFR. Due to over-expres-
sion of EGFR on A431 cells, internalization of HER2 was mostly driven by the forma-
tion of ligand-independent HER2/EGFR heterodimers. Various studies have demon-
strated that internalization of HER2 is dependent on expression levels of other ErbB 
family members, especially EGFR [11,14,42], and that degradation of HER2 could be 
enhanced through co-expression of EGFR or HER3 [15]. However, no correlation has 
been observed thus far between cytotoxicity of anti-HER2 immunotoxins and the 
relative antibody affinities, epitopes recognized or amount of immunotoxin inter-
nalized [43]. Also here, no correlation was observed between antibody affinities and 
toxicity induced in a α-kappa-ETA’ model system. However, a clear correlation was 
observed between the different HER2 cross-competition groups and the amount of 
toxicity induced in the α-kappa-ETA’ model system.
Trastuzumab’s ability to inhibit the formation of ligand-independent HER2/HER3 
 dimers has been described [23]. It may very well be that trastuzumab also inhibits 
formation of ligand-independent EGFR/HER2 dimers. This could explain why anti-
bodies from Groups 2, 3 and 4, which did not disrupt ligand-independent EGFR/HER2 
dimerization on A431 cells, still induced efficient killing of these cells. It should be 
noted, however, that besides differences in ErbB expression levels, other differen-
ces caused by the distinct origins of A431 (epithelial carcinoma) and AU565 (breast 
cancer) may influence the outcome of the results as well. Moreover, Pseudomonas 
exotoxin A exerts its cytotoxic activity by inhibiting protein synthesis [44]. Because 
Group 3 antibodies enhanced proliferation of high HER2 expressing tumor cells, 
this may also enhance the cytotoxic effects induced by ETA’. In addition, antibody- 
induced receptor activation has been demonstrated to enhance endocytic degrada-
tion of HER2 [45,46]. Antibody 005, however, had no effect on HER2-mediated pro-
liferation, but demonstrated enhanced internalization and α-kappa-ETA’-mediated 
cell killing. This result indicates that receptor crosslinking may be favorable, but not 
crucial for enhancing receptor internalization.
The relevance of HER2 heterodimerization on internalization of antibody- receptor 
complexes was further supported by the observation that stimulation with EGF 
 enhanced toxicity of α-kappa-ETA’ pre-incubated HER2 antibodies 005 and 098, 
which did not inhibit heterodimerization of HER2. Toxicity induced via antibodies 
025 and 153, which do inhibit ligand induced HER2 heterodimerization, was un-
affected. The observation that EGF-induced activation of HER2 can potentiate the 
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 action of a HER2-directed immunotoxin was also observed by Wels et al [47]. No-
tably, toxicity induced by α-kappa-ETA’ pre-incubated antibodies 169 and trastu-
zumab was also unaffected upon EGF stimulation, supporting the findings that HER2 
domain IV may be involved in stabilization of ligand-induced HER2/EGFR heterod-
imers [48]. The possibility that differences observed between clinical grade trastu-
zumab and other HER2 antibodies were due to differences in the constant antibody 
domains, was excluded by comparing clinical grade trastuzumab with HEK-293-pro-
duced trastuzumab (TH-trastuzumab). No differences in toxicity were observed be-
tween the two batches when tested in the α-kappa-ETA’ toxin assay with AU565 
cells (Supplementary Figure 4).
It is generally believed that trastuzumab drives internalized HER2 away from the 
recycling pathway toward the lysosomal degradation pathway, although the contri-
bution of this mechanism to the anti-tumor effect of trastuzumab is not fully under-
stood [11-13]. We have demonstrated that antibodies that inhibit HER2/EGFR sig-
naling, also showed reduced internalization, as observed with trastuzumab. By using 
antibodies that do not inhibit HER2 heterodimerization, it was possible to kill lower 
HER2-expressing tumor cells. This illustrates that the most effective unconjugated 
antibodies are not necessarily the most effective ADCs. Since HER2 expression and 
expression of other ErbBs is required to enhance the efficacy of these HER2-ADCs, 
they may be more tumor-specific while targeting a broader range of tumor indica-
tions. In this case, however, we were not able to demonstrate superiority of partic-
ular antibody groups in vivo because the non-covalent interaction of α-kappa-ETA’ 
with IgG does not hold in vivo and covalent conjugation of α-kappa-ETA’ to IgG failed.
In conclusion, these results demonstrate that maximum HER2-ADC delivery and 
 tumor kill requires the formation of HER2/ErbB heterodimers. Therefore, inhibition 
of receptor signaling seems less favorable for an ADC approach. Especially on low-
HER2 expressing tumors, piggybacking with other ErbBs may represent an attrac-
tive approach to increase intracellular delivery of an ADC.
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SUPPLEMENTARY METHODS
Preparation of α-kappa-ETA’
The human kappa light chain-directed toxin contains a truncated version of exotoxin 
A (ETA’) from Pseudomonas aeroginosa comprising domains Ib, II, and III [44] Domain 
Ia was replaced by a high affinity domain antibody with human kappa light chain 
specificity. The C-terminal located endogenous endoplasmatic reticulum retention 
motif REDLK was replaced by the KDEL motif to improve intracellular retrograde 
transport [49] A combined 6xhistidine- and strep-II tag was added at the N-terminus 
for purification purposes. A pelB leader sequence was introduced at the 5´-end of 
the construct for directing protein expression to the periplasmatic space. The immu-
notoxin was expressed under osmotic stress conditions and purified from periplas-
matic extracts by two step affinity chromatography using streptactin and Ni-NTA 
agarose beads as described [21] The purified protein was analyzed by SDS-PAGE and 
coomassie staining, capillary electrophoresis or western blot analysis.
Supplementary Method 2: Epitope mapping
Epitope mapping was performed at Pepscan using their proprietary CLIPS™ tech-
nology, as described by Teeling et al [25] Over 5,000 different Chemically Linked 
Immunogenic Peptides on Scaffolds (CLIPSTM) were generated; linear or looped with 
sizes ranging from 15 to 35 amino acids, which functionally mimic overlapping epi-
topes of the extracellular domain of HER2. The peptides were synthesized using 
standard Fmoc-chemistry and deprotected using trifluoric acid with scavengers. Sub-
sequently, the deprotected peptides were reacted on microarrays for 30-60 min, the 
microarrays were washed extensively with excess of millipore H2O and sonicated 
in disrupt-buffer containing 1% sodium dodecylsulfate / 0.1% betamercaptoetha-
nol in phosphate buffered saline (PBS) at 70°C for 30 min, followed by sonication 
in millipore H2O for another 45 min. Subsequently, 1 μg/mL antibody in PBS/1% 
Tween was added to detect binding to CLIPS using an ELISA-type read-out. 1/1000 
diluted HRP-conjugated rabbit anti-human Ab and 2,2’-azino-bis(3-ethylbenzthiazo-
line-6-sulphonic acid substrate (ABTS) were used to detect and visualize antibody 
binding.
Supplementary Method 3: Quantitative determination of cell surface antigens
Qifikit (DAKO) was used to detect and quantify cell surface expression of EGFR, HER2 
and HER3, according to manufacturer’s protocol [50]. In brief; cells were stained with 
10 μg/mL mouse anti-human EGFR (BD), mouse anti-human HER2 (R&D systems), 
mouse anti-human HER3 (Oncogene), following incubation with polyclonal goat 
anti-mouse IgG FITC (DAKO). In parallel a series of bead populations, containing a 
well-defined number of antibody molecules per bead, was stained with the polyclon-
al goat anti-mouse IgG FITC antibody. Mean fluorescence intensities (MFI) were mea-
sured using flow cytometry, and a calibration curve with the MFI of the  individual 
502504-L-bw-deGoeij
158 Chapter 6
bead populations was plotted against the number of mAb molecules on the beads. 
This curve was used to interpolate the number of EGFR, HER2 or HER3 molecules 
per cell.
SUPPLEMENTARY TABLES
Immobilized mAb competing mAb 
Herc 169 pert 025 098 153 005
Herc 6 15 100 107 101 101 137
169 19 45 101 98 105 102 97
pert 104 100 9 20 103 100 151
025 98 98 8 18 102 99 99
098 107 102 104 108 17 110 126
153 134 111 121 97 115 28 174
005 126 103 115 109 117 121 18
Cross-competition group 1 1 2 2 3a 3b 4
 75 - >100% competition   25 - 74% competition   0 - 24% competition
SUPPLEMENTARY TABLE 1 Cross-competition ELISA. Cross-competition ELISA reveals at least 
4 distinct cross-competition groups. HER2 antibodies were coated at their predetermined coat-
concentrations, and incubated with HER2ECDHis in absence or presence of an excess of a second 
(competitor) HER2 antibody. Bound Her2ECDHis was detected using a biotinylated rabbit-anti-6xhis 
antibody in combination with streptavidin-poly-HRP. Depicted values are mean binding percentages 
relative to the binding observed in the absence of competitor antibody, of three individual experiments. 
Shaded boxes indicate competition (e.g. HER2ECDHis in the presence of soluble Herceptin only shows 
6% of total binding to immobilized Herceptin; which therefore provides a 94% inhibition as indicated by 
the dark shading). Cross-competition group designations are indicated at the bottom (Herc = Herceptin; 
Pert = TH-pertuzumab).
EGFR HER2 HER3
AU565 35,000 1,000,000 27,000
Colo 205 10,000 30,000 6,000
A431 1,000,000 15,000 15,000
MCF7 n.d. 19,000 22,000
SUPPLEMENTARY TABLE 2 Quantitative flow cytometry. Number of EGFR, HER2 and HER3 molecules 
per cell quantified with quantitative flow cytometry analysis (n.d.: not detected).
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SUPPLEMENTARY FIGURE 1 HER2 shuffle analysis. Loss of HER2 antibody binding to CHO-S cells 
transfected with hu-HER2 (  ), hu-HER2-ch(I) (  ), hu-HER2-ch(II) (  ), hu-HER2-ch(III) (  ) or hu-HER2-
ch(IV) (  ) constructs analyzed by means of flow cytometry. Constructs were generated by swapping 
the sequences of domains I, II, III, IV of the extracellular domain of human HER2 with the corresponding 






SUPPLEMENTARY FIGURE 2 Analysis of binding of antibodies 005 and 153 to HER2-ECD CLIPS. 
Model depicting the binding epitopes of antibodies 005 and 153 as mapped by use of CLIPS technology. 
Two epitopes were visualized in two different representations of the crystal structure of HER2ECD by 
use of VMD molecular modeling software. The epitope for antibody 005 was located at the rear end 
of HER2 domain III, whereas the epitope for antibody 153 was located on top of the receptor at HER2 
domain II.
SUPPLEMENTARY FIGURE 3 Correlation analysis. Correlation between the percentage of AU565 cells 
killed in the kappa-ETA’ assay and the MFI of CypHer5E. Spearman’s coefficient r = 0.5373.
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SUPPLEMENTARY FIGURE 4 CHO vs. HEK produced trastuzumab in the α-kappa-ETA’ model system. 
Cell kill induced by clinical grade Herceptin compared with HEK-293 produced Herceptin in α-kappa-
ETA’ assay with AU565 cells. A final concentration of 0.5 μg/mL α-kappa-ETA’ was used. Viability was 
plotted as a percentage relative to untreated cells. 10 μg/mL Staurosporin was used as positive control.
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ABSTRACT
Antibody drug conjugates (ADC) are designed to be stable in circulation and to release 
potent cytotoxic drugs intracellularly following antigen-specific binding, uptake and 
degradation in tumor cells. Efficient internalization and routing to lysosomes where 
proteolysis can take place is therefore essential. For many cell surface proteins and 
carbohydrate structures on tumor cells, however, the magnitude of these processes 
is insufficient to allow for an effective ADC approach. We hypothesized that we 
could overcome this limitation by enhancing lysosomal ADC delivery via a bispecific 
antibody (bsAb) approach, in which one binding domain would provide tumor spec-
ificity, whereas the other binding domain would facilitate targeting to the lysosomal 
compartment. We therefore designed a bsAb in which one binding arm specifical-
ly targeted the lysosome-associated membrane glycoprotein 3 (LAMP3 or CD63), a 
protein that is described to shuttle between the plasma membrane and intracellular 
compartments. We optimized the targeting characteristics of the CD63 antibody and 
combined it in a bsAb with a HER2 binding arm, which was selected as model antigen 
for tumor specific binding. The resulting bsHER2xCD63his demonstrated strong bind-
ing, internalization and lysosomal accumulation in HER2-positive tumor cells, and 
minimal internalization into HER2-negative cells. By conjugating bsHER2xCD63his to 
the microtubule-disrupting agent duostatin-3, we were able to demonstrate potent 
cytotoxicity of bsHER2xCD63his-ADC against HER2-positive tumors, which was not 
observed with monovalent HER2- and CD63-specific ADCs. Our data demonstrate, 
for the first time, that intracellular trafficking of ADCs can be improved using a bsAb 
approach that targets the lysosomal membrane protein CD63 and provide a ratio-
nale for the development of novel bsADCs that combine tumor-specific targeting 
with targeting of rapidly internalizing antigens.
Introduction
Antibody Drug Conjugates (ADCs) are emerging as powerful anti-cancer  treatments. 
Over 50 different ADCs are currently in clinical evaluation, while brentuximab  vedotin 
(Adcetris) and trastuzumab emtansine (Kadcyla) have already been approved for 
the treatment of Hodgkin lymphoma and metastatic breast cancer,  respectively [1]. 
These ADCs, as well as virtually all other ADCs in clinical development, are designed 
to be stable in circulation and to release their cytotoxic payload after internaliza-
tion and lysosomal processing of the antigen/ADC complex [2]. The requirement for 
antigen- and antibody-mediated internalization limits the number of suitable ADC 
targets. In many cases, intracellular processing of ADCs is inefficient. Following inter-
nalization, receptors such as transferrin [3], HER2 [4,5], cell adhesion molecule L1 [6] 
and integrins [7], are continuously recycled back from the endosomal compartment 
to the plasma membrane. High antigen expression and highly toxic payloads are 
required to ensure activity of ADCs. Therefore approaches that increase internal-
ization, lysosomal targeting and intratumoral processing of ADCs are highly desired.
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We previously demonstrated that ADCs that are more efficiently internalized and 
transported to the lysosomes induce more effective cytotoxicity [8]. Therefore, we 
set out to improve ADC-mediated drug release by improving their intracellular de-
livery. We generated an ADC based on a bispecific antibody [9], in which one binding 
arm was responsible for tumor cell binding and the other binding arm was designed 
to facilitate internalization and lysosomal delivery of the toxic payload. Ideally, such 
a bispecific ADC would allow utilization of tumor antigens that do not or poorly 
internalize for an ADC approach, thereby greatly enhancing the pool of potential 
ADC targets. An antibody specific for the lysosome-associated membrane glycopro-
tein 3 (LAMP3 or CD63) was selected to provide a Fab arm that facilitates internal-
ization and lysosomal transport. CD63 is a member of the tetraspanin superfamily 
and is ubiquitously expressed. The major pool of CD63 resides in intracellular com-
partments such as endosomes and lysosomes, but some expression can be found 
on the cell surface. Although the biology of CD63 is not completely understood, 
CD63 has been described to regulate transport of other proteins typically through 
endocytosis [10]. For example, complex formation between CD63 and the gastric 
 H,K-ATPase β-subunit, results in the redistribution of H,K-ATPase from the cell sur-
face to CD63-positive intracellular compartments [11]. Furthermore, CD63 has been 
described to regulate surface expression of membrane-type 1 matrix metallopro-
teinase by targeting the enzyme for lysosomal degradation [12], and silencing of 
CD63 in endothelial cells prevents internalization of vascular endothelial growth 
factor receptor 2 (VEGFR2) in response to its ligand VEGF [13]. Also across differ-
ent tumor types, CD63 has been demonstrated to continuously shuttle between the 
plasma membrane and lysosomes, which was dependent on the presence of AP2 and 
clathrin [14]. Thus CD63 seems an attractive antigen to facilitate internalization and 
lysosomal delivery.
To study our hypothesis that a CD63-specific Ab-arm could promote internalization 
and lysosomal targeting of a bsAb also including a tumor-specific, poorly internal-
izing binding arm, we generated a bsAb recognizing CD63 and the human epider-
mal growth factor receptor 2 (HER2). HER2 is a clinically well validated ADC target 
through the clinical experience and approval of trastuzumab emtansine [15]. How-
ever, for internalization to be most effective HER2 requires cross-linking of HER2 
molecules. Especially on tumor cells that highly overexpress HER2, Ab-induced 
cross-linking has been described to improve internalization of HER2 [5,16,17]. The 
notion that monomeric HER2 does not internalize well suggested to us that a bsAb 
with monovalent HER2 binding characteristics may represent a suitable model sys-
tem for testing whether internalization of cell surface molecules can be increased 
through binding to CD63.
We found that a bsAb targeting HER2 and CD63 was efficiently transported to lyso-
somes of HER2-positive tumor cells. This effect was not observed with monovalent 
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control antibodies only targeting HER2 or CD63. By conjugating bsHER2xCD63 with 
the microtubule disrupting agent duostatin-3, we were able to demonstrate that a 
bsHER2xCD63-ADC induced potent in vitro and in vivo cytotoxicity of HER2-positive 
tumor cells. Monovalent ADCs targeting HER2 or CD63 alone had no effect on tumor 
growth which demonstrates that CD63 targeting can be used to improve payload 
delivery of poorly internalizing ADCs.
MATERIALS AND METHOD
Cell lines
Human SK-OV-3 (ovarian cancer), HCC1954 (breast ductal carcinoma) and Colo 205 
(colorectal adenocarcinoma) cells were obtained from American Type Culture Collec-
tion (ATCC). SK-OV-3 cells were cultured in Minimal Essential Medium Eagles (ATCC) 
containing 10% heat inactivated calf serum (Hyclone). HCC1954 and Colo 205 cells 
were cultured in RPMI 1640 (Lonza) containing 10% heat inactivated calf serum. To 
guarantee cell line authenticity, cell lines were aliquoted and banked, and cultures 
were grown and used for a limited number of passages before starting a new culture 
from stock. Cell lines were routinely tested for mycoplasma contamination. HER2 cell 
surface expression was quantified by QIFIKIT analysis (DAKO) according to the man-
ufacturer’s guidelines, using a mouse anti-human HER2 antibody (R&D) as described 
previously [8].
Antibody generation, site-directed mutagenesis and conjugation
Cloning and production of HER2 antibody IgG1-153 has been described elsewhere 
[16]. The variable domain heavy and light chain regions of CD63 antibody 2192 
were obtained from hybridoma 2.19 [18], by 5’-RACE of the variable regions from 
hybridoma derived RNA and sequencing. Variable regions were cloned in the mam-
malian expression vector pcDNA3.3 (Invitrogen) containing the relevant constant do-
mains (codon optimized, Invitrogen) with the relevant heavy chain constant  domain 
mutations (K409R or F405L). CD63 antibody mutations were introduced either by 
site  directed mutagenesis or direct gene synthesis. Antibodies were produced by 
cotransfection of heavy chain and light chain vectors and transient expression in 
HEK-293 freestyle cells (Invitrogen) as described by Vink et al [19]. Bispecific an-
tibodies (Duobody) were made by controlled Fab-arm exchange as described by 
Labrijn et al [20]. The IgG1-b12 antibody was included as isotype control [21].
Duostatin-3 conjugated antibodies were generated by covalent conjugation of 
 valine-citrulline-duostatin-3 (Duo3) on antibody lysine groups of IgG1-HER2-F405L 
and IgG1-b12-F405L as described previously [8]. After conjugation, IgG1-HER2-
F405L-Duo3 and IgG1-b12-F405L-Duo3 were Fab-arm exchanged with IgG1-HER2-
K409R, IgG1-CD63-K409R and IgG1-b12-K409R, to generate bsHER2xCD63-Duo3, 
502504-L-bw-deGoeij
168 Chapter 7
bsHER2xb12-Duo3, bsCD63xb12-Duo3, and IgG1 b12-Duo3 and IgG1 Her2-Duo3 
controls all having an equal DAR of one duostatin-3 molecule per Ab, as determined 
by hydrophobic interaction chromatography (HIC).
CD63 binding ELISA
The binding of Histidine-mutated IgG1-2192 to CD63 was tested by ELISA. In short, 
ELISA plates (Greiner) were coated overnight at 4⁰C with 0.8 µg/mL goat anti-human 
IgG (Jackson). The plates were blocked with 2% chicken serum and incubated with 1 
µg/mL histidine-mutated IgG1-2192. Serially diluted (1-0.0005 µg/mL) recombinant 
human CD63 (Creative Biomart) was added followed by 1 µg/mL mouse anti- poly-
histidine-biotin (R&D). The reaction was visualized using ABTS and stopped with ox-
alic acid. Fluorescence at 405 nm was measured and depicted using GraphPad Prism 
5 software.
CD63 affinity measurements
Kinetics of human His-tagged CD63 (1 µg/ml, 77 nM) (Creative BioMart) were 
 assessed using label-free Bio-Layer Interferometry on an Octet RED384 (ForteBio). 
Anti-CD63 wild type or mutants containing histidine substitutions were immobilized 
on Anti-Human IgG Fc Capture Biosensors (ForteBio) at 1 µg/mL. Association and 
dissociation kinetics were determined in citric acid/Na2HPO4 buffer pH7.4 sup-
plemented with 0.1 % BSA Fraction V (Roche) and 0.02% Tween-20 (Sigma-Aldrich), 
 using a shaker speed of 1000 rpm at 30°C. The dissociation constant KD (M) was 
determined with ForteBio Data Analysis v7.0, using the 1:1 model in combination 
with a local full fit. The six clones with lowest KD values were measured twice, other 
clones were measured once.
mAb-FITC accumulation assay with whole blood
Whole blood samples from healthy donors were collected in Heparin tubes. Whole 
blood was diluted 1:2 in RPMI-1640 supplemented with 10% heat inactivated cosmic 
calf serum. CD63 antibodies were conjugated with FITC (Thermo Scientific) according 
to manufacturer’s instruction and added at final concentration of 10 µg/mL, to whole 
blood cells. Following 1 hour incubation at 4⁰C or 3 and 16 hours incubation at 37⁰C, 
erythrocytes were lysed by incubating 15 minutes at 4⁰C with erythrocyte  lysis buf-
fer (155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA at pH 7.4). Fluorescence inten-
sities of FITC were measured on a flow cytometer (BD). Granulocytes were gated us-
ing mouse anti-human CD66b-PerCP-Cy5.5 (BD) and thrombocytes were gated using 
mouse anti-human CD62-APC (BD).
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Confocal microscopy
SK-OV-3 cells were grown on glass coverslips (Thermo Fisher Scientific) at 37°C for 
16 hours. One hour prior to antibody treatment, cells were pre-incubated with 50 
μg/mL leupeptin (Sigma) to block lysosomal activity. Antibody (1 μg/mL) was added 
and cells were incubated for 1, 3 or 16 hours at 37°C. Cells were fixed, permeabilized 
and incubated 45 min with goat anti-human IgG1-FITC (Jackson) to stain for human 
IgG and mouse anti-human CD107a-APC (BD) to stain for lysosomes. Coverslips were 
mounted (Calbiochem) on microscope slides and imaged with a Leica SPE-II confocal 
microscope (Leica Microsystems) equipped with LAS-AF software. 12-bit grayscale 
TIFF images were analyzed for colocalisation using MetaMorph® software (Molecular 
Devices). Colocalisation was depicted as arbitrary units [AU] representing the total 
pixel intensity of antibody overlapping with the lysosomal marker LAMP1. This val-
ue was divided by the total pixel intensity of LAMP1, to correct for differences in cell 
densities between different pictures.
HER2 downmodulation assay
HCC1954, SK-OV-3 and Colo 205 cells were seeded (1 million cells/flask) in T25 
flasks (Greiner) and incubated overnight at 37⁰C to obtain a confluent monolayer. 
 Antibodies were added (10 µg/mL) and cells were cultured for another 3 days at 
37⁰C, washed and lysed. Total protein levels were quantified using bicinchoninic acid 
(BCA) protein assay reagent (Pierce), according to manufacturer’s instruction. Next, 
ELISA plates (Greiner) were coated with 1 µg/mL rabbit anti-human HER2 (Cell Sig-
nalling Technology), blocked with 2% chicken serum (Hyclone) and incubated with 
50 µL cell lysate. Goat anti-human HER2-biotin (R&D, 50 ng/mL) was added to detect 
HER2, followed by streptavidin-poly-HRP (Sanquin, 100 ng/mL). The reaction was 
visualized using ABTS and stopped with oxalic acid. Fluorescence at 405 nm was 
measured and the amount of HER2 was expressed as a percentage relative to un-
treated cells.
Cytotoxicity assay
Cells were seeded in 96-well tissue culture plates (5,000 cells/well) and incubated for 
6 hours at 37⁰C. Serially diluted ADCs (10-0.0005 µg/mL) were added and the cells 
were incubated for 3 days at 37⁰C. Cell viability was assessed using  CellTiter-GLO 
(Promega), according to the manufacturer’s guidelines. The percentage of viable cells 
was depicted as a percentage relative to untreated cells.
Tumor xenograft model
6-11 week old female SCID mice (C.B-17/IcrPrkdc-scid/CRL) were purchased from 
Charles River. Subcutaneous tumors were induced by inoculation of 5 x 106 SK-OV-3 
cells in the right flank of the mice. Tumor volumes were calculated from digital caliper 
measurements as 0.52 x length x width2 (mm3). When tumors reached 200–400 mm3, 
mice were grouped into groups of 7 mice with equal tumor size distribution and mAbs 
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were injected intraperitoneally (8 mg/kg). During the study, blood samples were col-
lected into heparin-containing tubes to confirm the presence of human IgG in plasma. 
IgG levels were quantified using a nephelometer (Siemens Healthcare). Mice that did 
not show human IgG in plasma were excluded from the analysis.
Statistical analysis
Data analysis was done using GraphPad Prism 5 software. Group data were reported 
as mean ± SD. Statistical analysis of xenograft studies was done with one-way ANO-
VA at the last day that all groups were complete. Mantel-Cox analysis of Kaplan-Mei-
er curves was performed to analyze statistical differences in progression-free sur-
vival time.
RESULTS
Generation of a low affinity CD63 antibody
To improve intracellular trafficking of ADCs, we set out to generate a bispecific ADC 
that specifically binds to tumor cells with one Fab-arm, while its second Fab-arm is 
 being used to facilitate internalization and lysosomal delivery of the cytotoxic pay-
load. The resulting bsADC should only induce cytotoxicity in tumor cells expressing 
both antigens. A bsAb targeting HER2 and CD63 was selected as a model for such 
an ADC. CD63 is ubiquitously expressed and expression is found predominantly in 
the endosomal and lysosomal compartment, although some expression was also de-
scribed on the plasma membrane [10,18]. To ensure tumor specificity of the bsAb, 
the CD63 arm of the bsHER2xCD63 should not bind and internalize in absence of 
the tumor-specific arm. We hypothesized that a CD63 antibody with low affinity tar-
get binding would fulfill these criteria. Therefore we first set out to generate a panel 
of mutated CD63 antibodies with variable CD63 affinity. It has been demonstrated 
that single amino acid histidine substitutions can be used to alter Ab affinity [22,23]. 
Hence site-directed mutagenesis was applied to introduce histidine substitutions in 
the variable heavy and light chain domains of CD63-specific monoclonal Ab 2192. The 
resulting clones were screened for binding to soluble CD63 with ELISA (Figure 1A) and 
 label-free Octet (Figure 1B). Antibodies that showed diminished but detectable binding 
to CD63 were further analyzed with confocal microscopy to visualize internalization 
and lysosomal targeting. SK-OV-3 cells were grown on glass coverslips and incubated 
with histidine-mutated CD63 antibody (CD63his). As a control we also tested monova-
lent bsCD63xb12 that recognizes CD63 with one Fab-arm, while the second Fab-arm 
recognizes an irrelevant antigen in this context (HIV-1 gp120). After 1 and 16 hours 
incubation, cells were fixed and permeabilized and human IgG1 was stained with an 
anti-human IgG-FITC antibody while lysosomes were stained with an anti-LAMP1-APC 
antibody. Figure 2 demonstrates the lysosomal accumulation of the wild type CD63 
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Ab and the asparagine into histidine (N74H)-mutated CD63 Ab (IgG1-CD63his) that was 
selected for the development of a low affinity CD63 arm.
After 1 hour incubation, no IgG1-CD63 was detected at the plasma membrane or 
intracellularly (Figure 2A). However after 16 hours of antibody exposure, IgG1-
CD63 and the low affinity IgG1-CD63his were abundantly present in the lysosomes 
of  SK-OV-3 cells, as indicated by the colocalisation with LAMP1 (Figure 2B and 2D). 
This highlights the transient expression of CD63 at the plasma membrane and its 
constitutive endocytosis and trafficking to the lysosomes. Monovalent bsCD63xb12 
also showed substantial transport to lysosomes after 16 hours incubation (Figure 
2C). In contrast, hardly any lysosomal transport was observed for the low affini-
ty monovalent bsCD63hisxb12, as shown in Figure 2E. This indicates the successful 
generation of a CD63 Fab-arm that should not induce internalization in tissues only 
expressing CD63.
Binding and internalization of CD63 antibodies in healthy tissue was assessed by 
measuring intracellular accumulation of FITC-conjugated CD63 antibodies in granu-
locytes and thrombocytes [10,18]. Whole blood from healthy donors was incubated 
with FITC conjugated antibodies for 1 hour at 4⁰C or for 3 and 16 hours at 37⁰C. 
Erythrocytes were lysed and remaining lymphocytes and thrombocytes were ana-




























FIGURE 1 Binding of CD63 antibody affinity variants to CD63. (A) ELISA plates coated with goat anti-
human IgG1 were incubated with a fixed concentration of Histidine-mutated antibody variants of CD63 
mAb 2192. Serially diluted recombinant human CD63 was added to determine Ab binding and depicted 
as OD405 values in correlation to CD63 concentration. The dose response of the selected N74H mutant 
is indicated. (B) Anti-CD63 antibodies containing histidine substitutions were immobilized on anti-
human IgG Fc Capture Biosensors and the affinity for human His-tagged CD63 was determined using 
Bio-Layer Interferometry. The dissociation constant KD (M) was calculated and plotted for each mutant. 
For a number of antibody variants the KD could not be measured accurately because insignificant CD63 


















FIGURE 2 Intracellular accumulation of CD63 antibody variants in tumor cells. SK-OV-3 cells were 
incubated 1 hour (A) or 16 hours (B-E) with IgG1-CD63 (A, B) bsCD63xb12 (C), IgG1-CD63his (D) or 
bsCD63hisxb12 (E). Lysosomes were stained with mouse anti-human LAMP1-APC (red), CD63 antibodies 
were stained with goat anti-human IgG1-FITC (green). Colocalisation of anti-human IgG1-FITC with anti-
human LAMP1-APC is depicted in orange (bottom panel).
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lyzed on a flow cytometer to measure intracellular accumulation of FITC conjugated 
antibodies. Figure 3 shows no detectable binding of CD63 antibodies to granulocytes 
or thrombocytes after 1 hour. However, FITC fluorescence of IgG1-CD63 on granu-
locytes was clearly increased after 16 hours of incubation, indicating accumulation 
of IgG1-CD63 into granulocytes. In contrast, FITC fluorescence of bsCD63hisxb12 was 
hardly increased after 16 hours. Thus, by using a low affinity CD63-specific Fab-arm, 
we were able to minimize binding and intracellular accumulation of a monovalent 






















































































































































FIGURE 3 Binding and intracellular accumulation of IgG1-CD63his in whole blood cells. Whole blood 
samples from two healthy donors were incubated 1 hour at 4°C, 3 hours at 37°C or 16 hours at 37°C 
with 10 µg/mL of FITC-conjugated CD63 antibody. After incubation, erythrocytes were lysed and 
fluorescence intensities of FITC were measured for the granulocyte (A, C) and thrombocyte (B, D) 
populations using a flow cytometer. Data shown are mean ± standard deviation of 2 measurements, 
obtained in two separate donors.
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A CD63-specific Fab-arm facilitates lysosomal targeting of poorly internalizing 
antibodies
Next, we investigated whether the CD63his-specific Fab-arm could be used to 
 facilitate internalization and lysosomal targeting of a HER2-specific Fab-arm. HER2 
antibody 153 (IgG1-HER2), which is known to internalize as bivalent IgG [16], was 
used to generate a bispecific IgG1 (bsHER2xCD63his) that can bind to both, HER2 
and CD63. To validate the use of a monovalent HER2-specific IgG (bsHER2xb12) 
as a model for an IgG with poor internalization characteristics, we first investigat-
ed Ab-induced downmodulation of the monovalent bsHER2xb12. For this, the total 
amount of HER2 protein in tumor cell lines with different expression levels of HER2; 
HCC1954 (500,000 HER2/cell), SK-OV-3 (200,000 HER2/cell) and Colo205 (50,000 
HER2/cell) was quantified after three days of incubation with HER2 antibody and 
compared with untreated cells. IgG1-HER2 induced ~40% downmodulation of total 
HER2 in HCC1954 cells that express high levels of HER2 (Figure 4A), which was in 
line with previously published results [16]. Despite the fact that the monovalent 
bsHER2xb12 showed dose-dependent binding to HER2-positive SK-OV-3 cells (Sup-
plementary Figure S1), no downmodulation of HER2 was observed (Figure 4A). This 
highlights that antibody-dependent receptor cross-linking was critical for increasing 
the degradation of HER2. The bsHER2xCD63his was able to restore the downmodula-
tion of HER2 on HCC1954 cells. Moreover, on cell lines with lower HER2 expression, 
such as SK-OV-3 (Figure 4B) and Colo205 (Figure 4C), bsHER2xCD63his also induced 


























































































































FIGURE 4 Antibody-dependent downmodulation of HER2 in tumor cell lines. Relative percentage of 
HER2 expressed in AU565 (A), SK-OV-3 (B) and Colo205 (C) cell lysates after three days incubation 
with 10 μg/mL antibody. The amount of HER2 was quantified using a HER2-specific capture ELISA and 










































































































































































































FIGURE 5 BsHER2xCD63his colocalizes with 
lysosomes in SK-OV-3 cells. SK-OV-3 cells 
were incubated 1 hour (A), 3 hours (B) or 16 
hours (C, D) with bsHER2xCD63his (A-C), and 
bsHER2xb12 (D). Lysosomes were stained 
with mouse anti-human LAMP1-APC (red), 
CD63 antibodies were stained with goat 
anti-human IgG1-FITC (green). Colocalisation 
of anti-human IgG1-FITC with anti-human 
LAMP1-APC is depicted in orange. (E) 
Arbitrary units [AU] represent the total pixel 
intensity of antibody overlapping with the 
lysosomal marker LAMP1, divided by the 
total pixel intensity of LAMP1. Data shown 
are mean ± standard deviation of 3 images.
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We next investigated lysosomal transport of bsHER2xCD63his using confocal mi-
croscopy. SK-OV-3 cells were incubated with bsAb and left for 1, 3 and 16 hours 
at 37⁰C. Following fixation and permeabilization, human IgG1 was stained with an 
anti-human IgG-FITC antibody and lysosomes were stained with an anti-LAMP1-APC 
antibody. Figure 5A and 5B demonstrate that after 1 and 3 hours of incubation, 
bsHER2x CD63his predominantly localized to the plasma membrane. Whereas after 
16 hours (Figure 5C), plasma membrane staining of bsHER2xCD63his was reduced 
while colocalization with the lysosomal marker LAMP1 was increased. The lysosom-
al colocalisation of bsHER2xCD63his was more abundant as compared to control Abs 
only targeting HER2 or CD63 (Figure 5D and 5E). These data indicate that binding of 
bsHER2xCD63his predominantly occurs through interaction with HER2 while interac-
tion with CD63 induces sub-sequential transport to lysosomes.
BsHER2xCD63his-duostatin-3 effectively kills HER2-positive tumor cell lines
To investigate whether the strong lysosomal targeting observed with  bsHER2xCD63his 
results in increased cytotoxicity of a bsHER2xCD63his-ADC, we conjugated bsHER2x-
CD63his with the antimitotic agent duostatin-3 [8], using a valine-citrulline linker 
that is cleaved by lysosomal proteases [24]. The resulting duostatin-3 conjugated 
antibodies were incubated with tumor cell lines after which cell viability was as-
sessed using CellTiter-GLO. The decrease in viable tumor cells was expressed as per-
centage compared to untreated cells. The high HER2-expressing HCC1954 cell line 
was efficiently killed by bsHER2xHER2-ADC and bsHER2xCD63his-ADC (Figure 6A). 
The monovalent bsHER2xb12-ADC also induced cytotoxicity of HCC1954 cells, but 
the IC50 value was considerably higher. A marked difference between the ADCs was 
found on SK-OV-3 cells (Figure 6B). BsHER2xHER2-ADC and bsHER2xb12-ADC in-
duced modest cytotoxicity of SK-OV-3 cells, while cytotoxicity induced by bsHER2x-
CD63his-ADC was considerably higher. Viability of the low HER2-expressing cell line 
Colo 205 was not affected by any of the ADCs (Figure 6C). The cytotoxicity assay 
with bsHER2xCD63his-ADC was also performed in presence of an excess of unconju-
gated IgG1-CD63 and unconjugated IgG1-HER2, to block CD63 and HER2 binding at 
the cell surface, respectively (Figure 6D). Both conditions increased the IC50 value of 
bsHER2xCD63his-ADC induced cytotoxicity, indicating that binding to both HER2 and 
CD63 at the plasma membrane is required to induce maximal cytotoxicity.
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FIGURE 6 Cytotoxicity of bsHER2xCD63his-Duo3, bsHER2xb12-Duo3, bsCD63hisxb12-Duo3, IgG1 HER2-
Duo3 and IgG1 b12-Duo3 in vitro. HCC1954 (A), SK-OV-3 (B) and Colo205 (C) cells were seeded in 96-
well tissue culture plates together with serially diluted ADCs. SK-OV-3 (D) cells were also incubated with 
serially diluted ADCs plus 10 μg/mL unconjugated IgG1-HER2 or IgG1-CD63. After three days incubation 
at 37°C viability was assessed using CellTiter-GLO and depicted as a percentage relative to untreated 
cells. (A-C) Data shown are mean ± standard deviation of at least 2 different experiments.
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The in vivo anti-tumor activity of a monomeric HER2-ADC is rescued by dual 
targeting of HER2 and CD63
The strong cytotoxicity of bsHER2xCD63his-ADC in SK-OV-3 cells in vitro, led us to 
investigate the anti-tumor effect of bsHER2xCD63his-ADC on SK-OV-3 tumor xeno-
grafts. SCID mice were inoculated subcutaneously with 5 million SK-OV-3 cells. When 
tumors reached an average size of 200 mm3, mice were treated with a single dose 
of 8 mg/kg ADC. Figure 7 demonstrates that bsHER2xCD63his-ADC induced signif-
icant inhibition of tumor growth, while the monovalent bsHER2xb12-ADC or bsC-
D63hisxb12-duo3, had no effect on tumor growth. This provides a strong proof-of-
concept and demonstrates that a low affinity CD63-specific Fab-arm can be used to 
induce lysosomal delivery and toxin release of a poorly internalizing ADC in tumors 
in vivo.






















































FIGURE 7 Efficacy of bsHER2xCD63his-Duo3, bsHER2xb12-Duo3, bsCD63hisxb12-Duo3, IgG1 b12-Duo3 
and IgG1-b12 in a SK-OV-3 xenograft model. Mice were inoculated subcutaneously with 5 x 106 SK-OV-3 
cells. When average tumor volume reached >200 mm3, mice were divided in groups of 7 mice with 
equal tumor size distribution and injected intraperitoneally at indicated time points with 8 mg/kg ADC. 
Tumors were measured twice a week by using calipers and the mean tumor volume ± SEM (mm3) was 
plotted against time (A), as well as time to progression indicated by the percentage of mice with tumors 
<500mm3 (B).
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DISCUSSION
In the present study, we tested the possibility of enhancing lysosomal delivery of 
ADCs by targeting a tumor-specific antigen in combination with an antigen that facil-
itates trafficking to the lysosomes. To this end, a bispecific ADC was generated that 
combines tumor-specific targeting through HER2, with enhanced lysosomal delivery 
through CD63. The binding affinity of the CD63 arm was modified in order to limit 
monovalent target binding and to direct the targeting characteristics of the bsAb to 
tumor cells that co-express HER2 and CD63. The resulting bsHER2xCD63his demon-
strated binding and lysosomal accumulation into HER2-positive tumor cells, but not 
CD63-positive granulocytes or thrombocytes.
By conjugating bsHER2xCD63his with Duostatin-3, we were able to generate an ADC 
that induced in vitro and in vivo cytotoxicity of HER2-positive tumor cells. While 
treatment with monovalent CD63 and HER2 ADCs had no effect on growth of SK-
OV-3 tumors in vivo, bsHER2xCD63his-ADC showed clear inhibition of tumor growth. 
This demonstrates that a bispecific Fab-arm recognizing an antigen involved in 
 intracellular trafficking can be used in combination with a tumor-specific Fab-arm, 
to facilitate intracellular delivery of ADCs.
The use of bispecific antibodies to improve efficacy of ADCs has been investigat-
ed by others previously. However by recognizing two separate tumor-specific tar-
gets, these bispecific ADCs were designed to target tumors with heterogeneous 
target expression. Thus, the ADCs would be able to recognize and kill tumors that 
 express either one of the tumor targets, or both, broadening anti-tumor activity and 
 reducing escape from therapy. A bispecific fusion protein targeting epithelial cell 
adhesion molecule (EpCAM) and CD133 was investigated in preclinical studies to 
deliver a bacterial toxin to EpCAM-positive tumor cells as well as cancer stem cells 
expressing CD133 [25]. Similarly, a fusion protein targeting the EGF receptor and the 
urokinase receptor (uPAR) was used to target tumor cells through EGFR and tumor 
stroma through uPAR [26]. While DT2219, a bispecific recombinant immunotoxin 
targeting CD19 and CD22 positive B-cell tumors, demonstrated broader reactivity 
against B-cell malignancies as compared to individual immunotoxins targeting CD19 
or CD22 alone [27,28].
Our bsHER2xCD63his-ADC has a different mechanism of action and can only induce 
efficient cytotoxicity when both antigens are expressed on the same cell. However 
this approach can be applied to tumor antigens with poor or suboptimal internaliza-
tion, thereby strongly expanding the number of tumor antigens that could be target-
ed by an ADC. For HER2, an antigen that only shows Ab induced downmodulation 
at high expression levels, bsHER2xCD63his was able to induce downmodulation of 
HER2 even on low HER2-expressing cell lines. This suggests that this approach may 
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also be applicable to cell lines expressing low copy numbers of the targeted tumor 
antigen. However, exposure of Colo205 cells to bsHER2xCD63-ADC did not result in 
substantial cytotoxicity despite down modulation of HER2 on these cells. This may 
in part be due to the low drug-to-antibody ratio (DAR) of our ADCs. Tubulin inhibitor 
conjugated antibodies usually contain on average 3-4 drug molecules per antibody 
[29], while our ADCs had a DAR of one. Increasing the DAR of bsHER2xCD63-ADC 
may therefore result in further improving the cytotoxicity so that also low HER2- 
expressing tumor cells can be killed. However, as more potent ADCs might also affect 
normal cells expression low levels of HER2, the decreased therapeutic window of 
such constructs should be carefully considered.
Another explanation for the lack of efficacy against low HER2-expressing tumors 
may be related to the mechanism of action of bsHER2xCD63his-ADC. The affinity of 
the CD63-specific Fab-arm was reduced to prevent uptake of bsHER2xCD63his-ADC 
by healthy tissues that express CD63 [10,18]. On tumor cell lines that also expressed 
high numbers of HER2 molecules, CD63 binding was restored. We hypothesize that 
on these cells, bsHER2xCD63his-ADC first bound to HER2, resulting in high density of 
bsHER2xCD63his-ADC on the plasma membrane (Figure 8). This enabled bsHER2x-
CD63his-ADC to bind to CD63 once it shuttles to the plasma membrane. On cell 
lines with low HER2 expression, the likelihood that HER2 and CD63 binding occurs 
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FIGURE 8 Proposed model of the mechanism of action of bsHER2xCD63his-ADC on healthy and 
diseased cells.
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is decreased. As a consequence bsHER2xCD63his-ADC can no longer bind to both 
HER2 and CD63. There are no reports describing complex formation between HER2 
and CD63. While CD63 expression at the plasma membrane has been described to 
concentrate to tetraspanin-enriched microdomains [30], HER2 has been described to 
localize to lipid rafts [31]. A proteomics approach used to identify proteins in lipid 
rafts did not reveal any tetraspanins amongst the 241 identified proteins [32]. Thus 
at low copy number both receptors may very well be expressed in different micro-
domains at the cell surface. Selection of tumor-specific antigens that are known to 
interact with CD63 may improve bivalent binding of bsADC at low copy numbers. For 
example, CD63 has been described to interact with other tetraspanins (CD81, CD82, 
CD9 and CD151), integrins, MHCII, CXCR4, TM4SF5, syntenin-1, TIMP-1, H, K-ATPase 
and MT1-MMP [10]. Furthermore, antigens that are highly overexpressed, but lack 
lysosomal transport, may also represent attractive candidates. Glycosylphosphati-
dylinositol (GPI) anchored proteins [3,33], adhesion molecules [6] and integrins [7] 
often recycle back to the plasma membrane after endocytosis, with only a minor 
fraction being targeted for lysosomal degradation. Using HER2 as a model antigen 
we have demonstrated that such antigens can be redirected for lysosomal degrada-
tion by a bsAb that also targets an antigen that is involved in intracellular trafficking 
CD63. Hence these antigens may represent attractive targets for the development of 
a bsADC that combines tumor-specific targeting with enhanced lysosomal delivery 
through CD63.
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SUPPLEMENTAL FIGURES
SUPPLEMENTARY FIGURE S1 Binding of bsHER2xCD63his to SK-OV-3 cells as assessed by flow 
cytometry. SK-OV-3 cells were incubated with serially diluted antibodies followed by incubation with 
goat anti-human IgG1-FITC to detect binding. Mean fluorescence intensities of FITC are depicted in 
relation to the antibody concentration. Data shown are mean ± standard deviation of 2 experiments.


























Owing to improved conjugation technologies and appropriate targeting, the clinical 
landscape of ADCs is rapidly expanding. Over 50 ADCs are in the clinic and many 
more are in preclinical development. To ensure the clinical success of ADCs it is 
 important to find the right combination of tumor antigen, targeting antibody, conju-
gation linker and cytotoxic drug. The aim of this thesis was to improve our under-
standing of antibody - antigen requirements that are needed for the development 
of safe and effective ADC treatments. For the first generation of ADCs that were 
generated, the antibody selection criteria focused on differential antibody binding 
to tumor cells relative to normal tissue [1,2]. However it was soon appreciated that 
certain antibody-drug conjugates require internalization and lysosomal processing 
to be effective [3]. The first clinically approved ADC gemtuzumab ozogamycin (My-
lotarg), made use of a CD33-specific hinge-stabilized IgG4 antibody (hP67.6) that, by 
itself, did not induce cytotoxicity, ADCC or CDC [4]. The antigen was selected based 
on its expression on acute myeloid leukemia (AML) cells and lack of expression out-
side the myeloid cell lineages and pluripotent stem cells, while the antibody showed 
to be rapidly internalized upon target binding [5]. Thus antigen and antibody selec-
tion were driven by criteria needed for the development of an ADC. However this 
was not always the case. Brentuximab vedotin (Adcetris) was generated by conju-
gating the CD30 antibody cAC10 with MMAE. This antibody was selected because it 
was able to inhibit proliferation and induce apoptosis of Hodgkin lymphoma cells [6]. 
Unfortunately the unconjugated antibody showed minimal clinical activity, which 
spurred efforts to enhance antitumor activity through the development of an ADC 
[7]. Likewise, trastuzumab was conjugated with maytansin to overcome resistance 
to treatment with the unconjugated antibody [8] and the PSMA antibody huJ591 (a 
humanized version of MLN591) was selected for development of MLN2704-ADC, 
because huJ591 was clinically validated [9,10]. Previously existing monoclonal an-
tibodies were therefore used for the development of these ADCs. This approach had 
the following advantages (A) lower cost of development (Ab production and screen-
ing were no longer needed and production cell lines potentially were already avail-
able); (B) shorter development time lines; (C) reduced clinical safety risk (Ab pharma-
cokinetics, biodistribution and potential antibody-dependent adverse effects were 
known); (D) it potentially allowed for combining cytotoxic effects of payload deliv-
ery with optimal inhibition of receptor signaling or engagement of immune  effector 
mechanisms. Nevertheless, such repurposing of unconjugated antibodies for an ADC 
approach has the disadvantage that internalization was not always included as a 
criterion in the selection of the mAb. Using the α-kappa-ETA’ assay, we found that 
HER2 antibodies that bind different HER2 domains differ in their capacity to deliver 
α-kappa-ETA’ to tumor cells. HER2 Abs that did not interfere with receptor heterodi-
merization and did not inhibit tumor growth, induced the highest amount of cytotox-
icity in the α-kappa-ETA’ assay [11] (chapter 5). Others have also demonstrated that 
screening for internalizing HER2 antibodies results in selection of clones that rec-
ognize distinctive non-overlapping epitopes in comparison to trastuzumab [12,13]. 
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Thus combining antagonistic antibodies with cytotoxic payloads may not  always re-
sult in the most optimal payload delivery. Furthermore, to completely block receptor 
signaling in vivo, target binding should be saturated, which may require relatively 
high dosing of unconjugated antibodies in vivo [14]. ADCs usually have a lower max-
imum tolerated dose (MTD) compared to unconjugated antibodies, which could result 
in lower dosing of ADCs and limit their ability to saturate target binding and induce 
antagonism. This would make selection of tumor inhibitory  antibodies even less crit-
ical. That noted, however, dosing regimens of trastuzumab (4 mg/kg followed by a 
weekly maintenance dose of 2 mg/kg [15]) and trastuzumab emtansine (Kadcyla) 
(3.6 mg/kg every three weeks [16]) are not that different.
ANTIBODY SELECTION
The importance of proper antibody selection for ADC development was also demon-
strated for other antigens than HER2. Studies with the CD22 expressing Burkit 
lymphoma cell line BJAB have demonstrated that large differences in anti-tumor 
efficacy between different CD22 antibodies conjugated with MCC-DM1 may occur 
[17]. In addition, inotuzumab ozogamicin, a calicheamicin-conjugated CD22 ADC, was 
generated through conjugation of mAb G5/44 that was selected because of its high 
endocytosis capacity [18]. Likewise antibodies targeting different epitopes on neural 
cell adhesion molecule (NCAM) [19], mucin-1 [20] and TF [21,22] showed differential 
capacity to induce endocytosis.
For TF-specific antibodies, bivalent antibody binding seemed more critical for 
 antibody internalization than Ab affinity. This was demonstrated by clones TF-011 
and TF-098, which differed ~100-fold in TF binding affinity but showed comparable 
 internalization, while internalization of Fab fragments of TF-011 was clearly less 
efficient [21,22] (Chapter 3). Similar results were found for HER2 clone 153, which 
could downmodulate HER2 as bivalent IgG1, but not as monovalent IgG1 (Chapter 7). 
Another study, comparing bivalent and monovalent HER2-ADCs demonstrated a 100-
fold greater cytotoxicity of IgG1-HER2-mcMMAF compared to Fab-HER2-mcMMAF 
[23]. Studies with Fab fragments of the EGFR antibody cetuximab also demonstrated 
that antibody-induced crosslinking was required to induce significant endocytosis of 
EGFR [24,25]. This demonstrates that the choice of ADC format can have significant 
impact on the rate of endocytosis.
Similar to ADCs, immunotoxins are designed to facilitate delivery of toxic payloads 
to tumor cells. Immunotoxins are typically composed of single-chain variable frag-
ments (scFv) fused to bacterial toxins. They have entered clinical testing more than 
two decades ago, but toxicity at low dosing and strong immunogenicity have ham-
pered the approval of immunotoxins as anti-cancer agents. Moreover unlike ADCs, 
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immunotoxins lack the capacity to crosslink their targeted antigen, which may limit 
their efficacy. Nevertheless, monovalent immunotoxins targeting EGFR and HER2 
have demonstrated effective delivery of their cytotoxic payload to tumor cells 
[26,27]. This may seem contradictory with our observation that Fab fragments of 
TF-011 and HER2-153 were not internalized [22]. However, although Fab fragments 
of TF-011 and HER2-153 cannot increase endocytosis of TF and HER2 respectively, 
endocytosis of Fab fragments can still take place through piggybacking with the reg-
ular turnover of the targeted antigen.
Indeed, some receptors do not require Ab induced crosslinking for maximal pay-
load delivery. Studies comparing internalization of IgG1 and Fab fragments directed 
against CD73, demonstrated that mAb IgG1-AD2 caused CD73 to cluster and inter-
nalize. This effect was also observed with Fab fragments of AD2, but not with anoth-
er IgG1-CD73 mAb recognizing a distinct epitope [28]. Likewise, studies comparing 
efficacy of Ricin A-conjugated anti-CD22 IgG1 and Fab fragments demonstrated that 
cytotoxicity was mostly dependent on the antibody epitopes recognized and not so 
much on the antibody format used. IgG1 and Fab fragments induced similar cytotox-
icity with only a difference in IC50 value that correlated with loss of avidity for the 
Fab fragments [29,30]. One could hypothesize that for such antigens a monovalent 
ADC may be more effective compared to a bivalent ADC (assuming that drug-to- 
antibody ratios are equal), because a bivalent ADC may occupy two binding sites and 
thus two antigens, whereas a monovalent ADC can only bind one antigen. Thus for 
antigens that are not dependent on bivalent antibody binding for Ab-induced inter-
nalization, the same amount of antigen may internalize two times more monovalent 
ADCs as compared to bivalent ADCs.
In summary, selection of antibodies that recognize distinctive epitopes or have the 
ability to crosslink their antigen may affect the redistribution of Ab/antigen com-
plexes from the plasma membrane into intracellular compartments. Depending on 
the internalization characteristics of the targeted antigen, different antibody for-
mats may be preferred.
ANTIGEN SELECTION
Ideally a successful ADC should target an antigen that is exclusively and homoge-
nously expressed on tumor cells, present at high copy numbers on the plasma mem-
brane and well internalized and targeted to the lysosomes following antibody bind-
ing. Unfortunately these requirements are rarely met in a single antigen. Most tumor 
antigens are also expressed to some extent on healthy tissues, tumor expression is 
often heterogeneous between and within tumors, and internalization and lysosomal 
targeting are relatively inefficient. Luckily the rapid ADC developments help us to 
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redefine these parameters. Tumor specificity for example, although preferred, is not 
an absolute requirement for ADC development. Firstly, potential toxicity to normal 
cells is affected by the nature of the payload selected. Tubulin targeting agents are 
only effective against proliferating cells, thus some expression of the targeted anti-
gen on healthy tissue that is non-dividing can be tolerated when using these agents. 
Secondly, antigens may not always be accessible for antibodies. Either because the 
organ or tissue in which it is expressed is less accessible for antibodies (e.g.; brain 
[31]), or because the antigen is only present in intracellular compartments (e.g.; TF 
expression in resting monocytes [32]). Thirdly, many tumor antigens are differen-
tially expressed, with cell surface copy numbers in tumor tissue exceeding those in 
normal tissue. Thus, by selecting the right mAb-toxin combination some expression 
in healthy tissues can be tolerated. This was also demonstrated by the approval of 
trastuzumab emtansine. Expression of HER2 has been described for various healthy 
organs such as: heart, skin and epithelial cells of the gastrointestinal tracts [33]. 
However, for trastuzumab emtansine no related toxicity has been reported in these 
tissues [16]. Also various other ADCs that have progressed to phase II clinical testing, 
show expression of the targeted antigen in healthy tissue: EGFR (basal layer skin) 
[34], GPNMB (brain [rats], basal layer skin, bone osteoclasts) [35], CEACAM5 (co-
lon, stomach) [36], TROP2 (skin, pancreas, liver, kidney) [37,38], NaPi2b (liver, lung, 
breast) [39] and PSMA (endothelium, prostate) [40].
The prerequisite that an ADC target should be well internalized holds true, however, 
also this parameter is not fixed. The CD30 antibody cAC10 has been demonstrated to 
internalize into CD30-positive Hodgkin lymphoma cells, but a large part of the anti-
body is still present on the plasma membrane after 20 hours incubation [41]. Similar 
results were obtained when HER2 positive breast cancer cells were incubated with 
radiolabeled 125I-trastuzumab. Antibody internalization was clearly demonstrated, 
but the majority of 125I-trastuzumab was still present on the cell membrane after 24 
hours incubation [42]. Despite the fact that only a portion of these antibodies was 
internalized, both antibodies demonstrated impressive preclinical and clinical activ-
ity when conjugated with cytotoxic payloads [7,16]. This can be explained by the 
high surface expression of both receptors on tumor cells that compensates for the 
partial internalization [22,43]. Furthermore the inefficient endocytosis of HER2 may 
contribute to the tumor specificity of trastuzumab emtansine by sparing healthy 
tissues that moderately express HER2 [22,44,45]. More recently ADCs targeting the 
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) have entered 
phase II clinical development. This antigen was long considered to be non-internal-
izing. Later studies have demonstrated that some internalization does occur, pre-
sumably through the normal turnover of the cell membrane. Together with the high 
number of CEACAM5 molecules at the surface of tumor cells this enables sufficient 
payload delivery to kill the targeted tumor cell [46-48]. Likewise, the B-lymphocyte 
antigen CD20 that is highly expressed in chronic lymphocytic leukemia can be uti-
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lized for an ADC approach, even though it shows moderate internalization [49,50]. 
Also here the high expression of the targeted antigen made it possible to induce 
cytotoxicity through vcMMAE-conjugated CD20 antibodies [51].
Thus poorly internalizing tumor antigens can be utilized for an ADC approach pro-
vided that they are highly overexpressed (> 105 molecules/cell). Our studies compar-
ing EGFR, HER2 and TF as targets for an ADC approach support these findings. We 
demonstrated that a duostatin-3 conjugated HER2-ADC was only effective against 
tumor cell lines expressing at least 2 x 105 HER2/cell [22] (chapter 3). In contrast, 
TF-011 conjugated with duostatin-3 was already effective against cell lines with 
≥2 x 104 TF/cell. Confocal experiments revealed that in contrast to HER2-antibodies, 
virtually all extracellular bound TF-antibodies were transported to lysosomes within 
16 hours incubation [22]. Furthermore, high expression of TF was found on a large 
number of cancer indications, with limited expression on healthy tissues [21]. Hence 
TF represents an attractive ADC target that combines high expression on tumor cells 
with strong internalization and lysosomal targeting.
Also for TF some expression has been reported on healthy tissues such as cells in 
the sub-endothelial vessel wall (e.g. pericytes, smooth muscle cells and fibroblasts) 
that interact with FVIIa when vascular integrity is disrupted [52]. The subendothe-
lial localization is thought to limit TF exposure to clotting factors present in the 
blood. Subendothelial TF expression is found in a variety of vital organs, including 
the brain, heart, intestine, kidney, lung, placenta, uterus and testes However imag-
ing studies in cynomolgus monkeys, that were shown to have TF tissue expression 
comparable to humans (Genmab, data on file), only revealed minor accumulation of 
radiolabeled  TF-011 in testis of male cynomolgus monkeys. Furthermore,  tisotumab 
vedotin showed an acceptable toxicity profile in cynomolgus monkeys, with a rela-
tively narrow range of findings. When treated with a dose of 3 mg/kg, moderate and 
reversible neutropenia was observed, in addition to mild and reversible skin and 
testicular toxicity. No toxicity was observed at a dose of 1 mg/kg  tisotumab vedotin. 
Xenograft studies in mice demonstrated efficacy at doses as low as 0.5 mg/kg of 
tisotumab vedotin, with tumor regression being observed at doses of 2 and 4 mg/
kg [21]. The safety of tisotumab vedotin is currently being tested in a Phase I clinical 
trial. The dose escalation phase of the study is still ongoing but at the highest dose 
reported thus far (1.8 mg/kg) the MTD in humans was not yet reached [53]. Usually 
the MTD of vcMMAE conjugated antibodies does not exceed 2.5 mg/kg (chapter 2), 
indicating that the therapeutic index of tisotumab vedotin is expected to be narrow. 
Unfortunately this seems to hold true for all ADCs that are currently being tested 





Tumor-specific antigens that are highly over-expressed represent attractive targets 
for an ADC approach, yet they also pose a challenge. The high expression may create 
a barrier for antibodies to penetrate deeper into the tumor [54-56]. This so called 
“binding site barrier” was first described in 1990 [57]. It was hypothesized that 
mAbs with high affinity for their tumor antigen, stably bind to the first encountered 
antigen, making transport across the vasculature a considerable barrier. High antigen 
density and rapid antibody internalization and degradation may further increase the 
barrier effect. To overcome the impaired tumor penetration of antibodies, one could 
simply increase the dosage. However, this may also result in accumulation in nor-
mal tissues [58]. Especially for ADCs the elevated blood concentration, may result 
in off-target toxicity before therapeutic efficacy is reached. Consequently, various 
researchers have demonstrated that reducing the antibody affinity improves tumor 
penetration [54-56]. However, this may also negatively affect antibody retention in 
the tumor as well as antibody internalization and degradation [56].
Using immunohistochemistry, we also demonstrated that HER2 is highly and homo-
geneously expressed in various tumor xenografts (Figure 1A). Similarly, in human 
 tumor biopsies, over 75% of the cells that stained positive for cytokeratin, a marker 
for human epithelial cells, also stained positive for HER2, which was determined 
with the Herceptest [59]. This homogeneous staining pattern was also observed 
for tumor xenografts with lower HER2 expression, such as NCI-H441. To examine 
whether the high and homogeneous expression of HER2 poses a binding site barrier, 
mice bearing SKOV3 tumor xenografts were treated with 3 and 30 mg/kg trastuzum-
ab. After two days, tumors were harvested and stained with rabbit anti-human IgG 
to detect trastuzumab. Figure 1B shows a homogeneous staining pattern for tumors 
treated with 30 mg/kg trastuzumab. However when tumors were treated with 3 
mg/kg trastuzumab, antibody staining was restricted to tumor cells surrounding the 
blood vessels. This clearly demonstrates that tumor penetration of HER2 antibodies 
can be hampered by a binding site barrier. This may limit the potency of HER2-spe-
cific ADCs, such as T-DM1 which is dosed at 3.6 mg/kg [16], a dose that may not be 
sufficient to overcome this barrier. Therefore approaches to improve tumor pene-
tration of ADCs or their cytotoxic payloads may improve anti-tumor efficacy. One 
such method is the selection of linker-drugs that have bystander activity, which was 
successfully demonstrated for TF-011-MMAE [21], or by selecting more potent linker 






30 mg/kg trastuzumab 3 mg/kg trastuzumab
Int: 3+, cells: ≥ 75%
NCI-N87
Int: 3+, cells: ≥ 75%
NCI-H441
Int: 1+, cells: ≥ 75%
FIGURE 1 HER2 binding site barrier. (A) BT-474, NCI-N87 and NCI-H441 tumor xenograft biopsies 
were stained for HER2 using the Herceptest (DAKO). Staining intensities and percentage positive 
cells is depicted for representative images. (B) SKOV3 tumor xenografts treated with 3 and 30 mg/kg 




The development of novel payloads may help to improve the therapeutic index 
of ADCs. Currently there are two main classes of ADC payloads; the tubulin tar-
geting agents (maytansin, auristatin and tubulysin) and the DNA-damaging agents 
 (calicheamicin, duocarmycin, pyrrolobenzodiazepine (PBD), doxorubicin and SN-38) 
 (Table 1). The tubulin targeting agents are most abundantly used and are available 
as the auristatin-derivatives MMAE and MMAF and the maytansine-derivatives DM1 
and DM4. Their mitotic spindle inhibition primarily affects proliferating cells, which 
makes tubulin-targeting agents generally less toxic than DNA damaging agents, that 
also act on non-proliferating cells. From a tumor killing perspective this has the 
drawback that tubulin targeting agents do not target non-proliferating tumor cells. 
Furthermore tubulin-targeting agents are usually substrates for multidrug resis-
tance (MDR) pumps [60,61]. The latter can be avoided by using different conjugation 
linkers that, after intracellular processing, give rise to slightly different metabolites 
which are less susceptible to MDR pumps [61]. In general tubulin targeting agents 
are used for development of ADCs that target tumor-enriched antigens with some 
expression on healthy tissues.
DNA-targeting agents have a broader spectrum of efficacy, ranging from highly 
potent DNA minor groove binders calicheamicin, duocarmycin and PBD dimers, to 
the less potent topoisomerase inhibitors SN-38 (active form of irinotecan [62]) and 
doxorubicin. Up to now, the DNA minor groove binders have been employed for 
ADCs directed against hematological tumors that are easily accessible and show lim-
ited expression on healthy tissue. In addition, a calicheamicin-conjugated EphrinA 
ADC (PF-06647263) has recently entered clinical development [63]. This antigen was 
selected because of its selective overexpression on cancer stem cells (CSC). The rel-
ative low proliferation rate and the high expression of drug efflux mechanisms on 
CSC set hurdles for tubulin targeting agents. This can be overcome by using DNA 
damaging agents such as duocarmycin and PBD dimers that have demonstrated ef-
ficacy against multidrug resistant cell lines [62,64]. Calicheamicins are generally less 
active in cells expressing the multidrug resistance phenotype [65], but this can be 
overcome by selecting different linkers [66], though it is not clear whether such 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The choice of linker can also impact the bystander kill activity of ADCs. Bystander 
cytotoxicity occurs when the cytotoxic payload is released from the ADC by an-
tigen positive tumor cells, after which it can diffuse into neighboring, potentially 
target-negative, tumor cells and induce cytotoxicity. This can be convenient when 
targeting solid tumors with heterogeneous antigen expression but it also has the 
potential to harm normal cells. Cytotoxic payloads like MMAE, DM1, DM4, duocar-
mycin and PBDs are highly membrane permeable and have the intrinsic capacity to 
diffuse into other nearby tumor cells to induce bystander kill [22,67-69]. However, 
the bystander capacity of ADCs can be manipulated by carefully selecting the com-
bination of the cytotoxic payload and the linker (linker-drug combination). Studies 
comparing efficacy of DM1-conjugated CanAg-ADCs demonstrated that the use of a 
non-cleavable linker (SMCC) prevents bystander kill induced by anti-CanAg-SMCC-
DM1, presumably because the DM1 metabolite that is released after intracellular 
processing of the ADC is less permeable [68]. Alternatively, the membrane permea-
bility of the payload itself can be modified. This was demonstrated for the auristatin 
analog MMAF, which is negatively charged preventing uptake of the unconjugated 
toxin by healthy cells [21]. Similar to this, the tubulin targeting agent duostatin3, 
that was used in our preclinical studies, lacks the ability to induce bystander killing, 
but was highly active against antigen positive tumor cells [22].
For the development of TF-011-MMAE, a tubulin targeting agent was preferred over 
a DNA damaging agent because TF expression was not limited to tumor cells. For 
example, expression of TF was found on sub-endothelial cells surrounding the blood 
vessels and on mature keratinocytes in the skin. These cells are generally slow or 
non-proliferating which makes them less sensitive to treatment with the tubulin 
targeting agents. We also compared efficacy between vcMMAE and mcMMAF conju-
gates of TF-011. The linker-drug combinations were equally effective in vitro, how-
ever TF-011-vcMMAE outperformed TF-011-mcMMAF in vivo. We believe this can 
be attributed to the heterogeneous expression of TF in vivo, which was counteracted 
by the bystander activity of TF-011-MMAE. Similar to our observations in xenograft 
models, TF expression appears to be heterogeneous in human cancer, thus, a linker-
drug combination with bystander activity was selected for our TF-specific ADC.
TOXICITY
The selection of a linker-drug combination with bystander activity has the potential 
downside of inducing bystander damage to healthy tissues. Clinical studies with bi-
vatuzumab mertansine, a CD44v6 antibody conjugated through a cleavable disulfide 
linker with DM1, demonstrated skin toxicity. These skin reactions were generally 
reversible but because of a fatal skin toxicity (epidermal necrolysis), clinical de-
velopment of bivatuzumab mertansine was halted [70]. It was demonstrated that 
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keratinocytes, which reside in the basal layer of the skin, had high expression of 
CD44v6. These cells are not dividing, however they are in close proximity to highly 
proliferating epidermal stem cells that reside in the lower part of the epidermis. 
Unlike trastuzumab-emtansine which was conjugated through a non-cleavable SMCC 
linker, bivatuzumab mertansine has the potential to induce bystander kill. There-
fore DM1 released by CD44v6 positive keratinocytes may have leaked into nearby 
epidermal stem cells causing damage to these highly proliferating cells. In nonclin-
ical toxicity studies with tisotumab vedotin, reversible skin toxicity was observed. 
Although TF was not expressed by proliferating cells in the basal layer of the skin, 
these cells may be exposed to MMAE through release of free MMAE by TF-positive 
mature keratinocytes.
For most ADCs currently in clinical development, dose-limiting toxicities such as 
neutropenia are described as unrelated to the targeted antigen (chapter 2). However 
it can not be excluded that these toxicities partly arise from a bystander effect in-
duced by targeting antigen-positive tumor cells. Various ADCs targeting hematolog-
ical malignancies such as brentuximab vedotin, inotuzumab ozogamicin, gemtuzum-
ab ozogamicin, polatuzumab vedotin and coltuximab ravtansin have been reported 
to induce neutropenia and thrombocytopenia. These ADCs also have the ability to 
induce bystander killing. Thus bystander activity in the bone marrow where both tu-
mor cells and myeloid progenitor cells are present may contribute to these observed 
toxicities. However similar dosing of ADCs that did not target tumor cells located in 
the bone marrow also induced neutropenia and thrombocytopenia (i.e. trastuzumab 
emtansine, glembatumumab vedotin, indusatumab vedotin and DMUC5754A). This 
may come from toxicity of the free payload released by ADCs processed elsewhere 
in the body. Although these toxins are usually hydrophobic and are easily absorbed 
by the nearest cell, which would limit localization to the bone marrow, free MMAE 
can be measured in plasma from patients treated with ADC, peaking 2-3 days after 
dosing [71]. On the other hand, trastuzumab emtansine does not have bystander 
activity and needs to be absorbed by the cell to induce toxicity. FcγRIIa binding 
has been described to facilitate “unspecific” uptake of trastuzumab emtansine by 
megakaryocytes, ultimately leading to intracellular concentrations of ADC that are 
above the threshold for cytotoxicity [72]. The affinity of FcγRIIa for monovalent IgG 
is very low (>10−7 M), and requires extremely high IgG concentrations for FcR-medi-
ated binding to take place. However the leaky vasculature of the bone marrow (and 
also spleen) may result in high local concentrations of ADC that might enable antigen 
independent uptake mechanisms via Fc-receptors or pinocytosis.
Alternatively, toxicity may be the result of circulating ADC-containing immune com-
plexes, that can be rapidly cleared through FcR binding [73]. The conjugation of an-
tibodies with small molecule payloads creates a hapten-like structure. When admin-
istered by itself, the small molecule payload does not induce immunogenicity, but 
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conjugated to a carrier (antibody) these structures may show increased immunoge-
nicity, resulting in the production of anti-payload antibodies. These antibodies may 
bind to circulating ADCs, resulting in the formation of immune complexes, especially 
for ADCs conjugated with high DAR’s. These immune complexes can be cleared by 
macrophages in the liver, spleen, but also the bone marrow, which may expose my-
eloid progenitor cells to the toxic payload. A study comparing biodistribution and 
pharmacokinetics of an anti-Lewis Y antibody and ADC in cancer patients, showed 
increased uptake of the ADC in the liver. Furthermore the ADC was rapidly cleared 
from the bloodstream and showed less uptake in the tumor as compared to the na-
ked antibody [74]. However, anti-drug antibodies or immune complexes were not 
detected.




FIGURE 2 Overview of potential mechanism of toxicity induced by ADCs and strategies to minimize 
these toxic effects.
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Although the mechanism behind the toxicity of ADCs remains poorly understood, 
strategies to improve tumor specificity, control bystander activity or prevent uptake 
by FcR expressing cells may help to improve the therapeutic window of ADCs (Fig-
ure 2). Alternatively improvements in linker stability, DAR and the site of conjuga-
tion have been proposed to reduce systemic toxicity of ADCs.
NOVEL FORMATS
The use of novel antibody platforms may help to improve the efficacy of ADCs. We 
have used bsAb technology to improve internalization and lysosomal targeting of 
poorly internalizing tumor antigens. The bsAb made use of a binding arm direct-
ed against the lysosomal membrane protein CD63, to facilitate internalization and 
lysosomal transport of a second binding arm directed against the model antigen 
HER2. The resulting bsHER2xCD63 demonstrated efficient internalization, lysosomal 
targeting and toxin mediated killing of HER2-positive tumor cells, which was not ob-
served with control ADCs only targeting either HER2 or CD63 (chapter 7). Although 
not yet demonstrated, this approach has the potential to improve payload delivery 
of various poorly internalizing tumor antigens, thereby broadening the number of 
suitable ADC targets. Tumor antigens that are considered non- or poorly internaliz-
ing can only be utilized for an ADC approach when they are highly over-expressed. 
Using the bsAb approach, these tumor antigens may already be internalized at lower 
copy number which may increase the number of patients eligible to ADC treatment.
Internalization of mAb/receptor complexes can also be increased by using a bsAb 
that targets two different epitopes on the same antigen [75]. This was demonstrated 
through generation of a bsAb that binds two non-overlapping epitopes on HER2, 
represented by mAbs 153 and 169 (bsAb-HER2153xHER169) [11]. The bsAb-HER2153x-
HER169 induced strong degradation of HER2 as well as inhibition of tumor growth 
in vivo. This effect was thought to result from enhanced clustering of HER2 at the 
cell surface, induced by bsAb-HER2153xHER169. This was supported by other studies 
showing that the combinations of HER2 antibodies that recognize distinct non-over-
lapping epitopes induced strong receptor endocytosis and degradation [76-79]. In 
addition, clustering of surface receptors can also be induced using IgM antibodies. 
Binding of IgM antibodies to the FcμR results in clustering of cell surface receptors 
leading to rapid lysosomal degradation [80]. Unfortunately the poor pharmacoki-
netics of IgM antibodies are unfavourable for an ADC approach. HexaBody, a novel 
antibody formats that combines the PK of IgG1 antibodies with the formation of 
hexamers after antigen binding on cells, may overcome this limitation [81]. This plat-
form is based on an IgG1 antibody containing a single point mutation that enhances 
the formation of hexamers through enhanced Fc:Fc clustering. Unlike IgM molecules 
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this interaction does not occur in solution but requires antigen binding before hex-
amerization can take place.
Alternatively novel ADC formats can be used to combine targeting of different tumor 
antigens to enhance the efficacy in tumors with heterogeneous target expression. 
This has been demonstrated with a bispecific fusion protein targeting the tumor bulk 
through epithelial cell adhesion molecule (EpCAM) and cancer stem cells through 
CD133 [82], and a bispecific fusion protein targeting the tumor bulk through EGFR 
and tumor stroma through the urokinase receptor (uPAR) [83]. This approach howev-
er requires that both tumor antigens are well internalized upon monovalent binding. 
DT2219, a bispecific recombinant immunotoxin targeting CD19 and CD22 positive 
B-cell tumors may fulfill these criteria as both antigens are considered to be rapid-
ly internalizing independent of antibody induced cross-linking [29,30]. The bsADC 
DT2219 demonstrated broader reactivity against B-cell malignancies as compared 
to individual immunotoxins targeting CD19 or CD22 alone [84,85]. Furthermore, the 
use of a bsADC instead of the combination of the individual ADCs has the advantage 
that tumor cell kill induced by the bsADC may be increased without increasing tox-
icity to healthy tissues. Whereas the combination of two individual immunotoxins 
likely combines improved tumor cell kill with an increase in toxicity because both 
ADCs have to be distributed to the tumor, increasing the concentration of untargeted 
ADC in circulation.
Another novel antibody format that may help to improve ADC treatment is based on 
a masking peptide that blocks antigen binding in circulation. Various well internal-
izing tumor antigens can not be targeted with ADCs because of their expression on 
healthy tissues, which may result in unwanted toxicity [70] or introduce a ‘sink-ef-
fect’ that limits the exposure of the tumor to the ADC. By blocking antibody-binding 
sites in the circulation and enhancing local binding at the tumor-site, toxicity of ADCs 
may be reduced while improving their PK. This was demonstrated through introduc-
tion of a masking peptide linked to the binding site of an antibody through a matrix 
metalloproteinase (MMP)-sensitive – linker peptide. The masking peptide blocks an-
tibody binding in circulation, however when localized to the tumor, the masking pep-
tide is cleaved by MMPs, that are highly expressed in the tumor microenvironment, 
thus exposing the antibody binding site and allowing target binding by the ADC. This 
approach was successfully demonstrated by conjugating a masking peptide to the 
N-terminus of the light chain of the EGFR antibody cetuximab [86]. When conjugated 
with the masking peptide, cetuximab demonstrated improved safety and increased 
half-life in nonhuman primates as well as tumor specific accumulation in xenograft-
ed mice. These results suggest that the use of ADCs with masked binding sites may 
broaden the number of suitable ADC targets.











The goal of this thesis was to better understand the antibody and antigen require-
ments needed for effective ADC treatment. Ideal ADC targets are rare, however an-
tibodies, linkers and payloads can be used to optimize efficacy of ADCs targeting 
existing and novel tumor antigens. Considerations for ADC development are sum-
marized in Figure 3. By carefully selecting the most suitable combination of antigen, 
antibody, linker and payload, novel tumor antigens can be utilized for ADC devel-
opment. Novel antibody platforms such as, bispecific antibodies, antibodies with 
capped binding sites and antibodies with modulated FcR binding may help to further 
improve the exciting and developing field of ADCs.
FIGURE 3 Considerations for ADC development.
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Antibody-Drug Conjugates (ADCs) represent a new class of anti-cancer therapeutics 
that combine the tumor specificity, pharmacokinetics and biodistribution of anti-
bodies with the cytotoxic capacity of chemotherapeutic payloads. Currently over 50 
ADCs are in clinical development with variable success. Clinical efficacy is driven by 
the right combination of tumor antigen, targeting antibody, conjugation linker and 
cytotoxic payload. The expression level of ADC targets on tumor cells and healthy 
tissue as well as the intracellular trafficking of the antibody component are crucial 
parameters for selection of the linker-drug combination. This thesis addresses the 
selection criteria of tumor specific antibodies and antigens for the development of 
ADCs. 
Chapter 1 provides an introduction on the general biology of antibodies and ADCs, 
as well as the main objective of this thesis. Chapter 2 is a review that deliberates the 
target requirements for ADC development and the therapeutic window of currently 
existing ADCs. Dosing regimens of ADCs are often hampered by toxicities unrelated 
to the targeted antigen. Strategies to overcome these toxicities, such as the use of 
novel DNA damaging payloads with picomolar efficacy as well as adapting the inter-
action of ADCs with the immune system may help to increase the therapeutic win-
dow of ADCs. However, studies addressing the safety and establishing the maximum 
tolerated dose (MTD) of such ADC approaches are mandatory.
In Chapter 3 we explored Tissue Factor (TF) as a novel ADC target. Intracellular 
routing of TF was compared with the targets of two clinically applied ADCs, hu-
man epidermal growth factor receptor 2 (HER2) and epidermal growth factor recep-
tor (EGFR). We found rapid and constitutive transport of TF to lysosomes of tumor 
cells which translated into effective cytotoxicity induced by Duostatin-3 conjugated 
TF-antibodies. Furthermore, unlike HER2-vcDuo3, TF-vcDuo3 required relatively low 
surface expression of the target antigen to be effective. This was further emphasized 
in Chapter 4, where TF-011 was selected as the preferred TF-specific antibody for 
the development of tisotumab vedotin (TF-011-MMAE). TF-011 was able to induce 
antibody dependent cellular cytotoxicity (ADCC) and to inhibit TF:FVIIa-mediated in-
tracellular signaling without interfering with the role of TF in coagulation. Although 
the unconjugated antibody had minimal anti-tumor efficacy in vivo, the same anti-
body conjugated with vcMMAE demonstrated almost complete tumor regression in a 
wide variety of patient-derived xenograft (PDX) models, despite the heterogeneous 
target expression in some of these models. This may in part be due to a so-called by-
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stander effect, where antigen-negative tumor cells are killed through toxins released 
by antigen-positive tumor cells.   
In Chapter 5 we describe the development of a high throughput in vitro assay that 
can be used for the identification and selection of internalizing antibodies capa-
ble of delivering a cytotoxic payload to tumor cells. For this, a modified version of 
the Pseudomonas exotoxin-A was used. The alpha-2-macroglobulin receptor binding 
domain of Pseudomonas exotoxin-A was replaced with a human kappa light chain 
binding domain. By combining the resulting fusion protein (α-kappa-ETA’) with an-
tibodies targeting EGFR or HM1.24, we were able to demonstrate α-kappa-ETA’ me-
diated cytotoxicity of tumor cells expressing EGFR or HM1.24. These results support 
the identification and selection of antibodies with favorable internalization char-
acteristics for ADC development. In Chapter 6 the α-kappa-ETA’ assay was used to 
screen a large panel of HER2 Abs for their ability to deliver α-kappa-ETA’ into tumor 
cells. Substantial differences in cytotoxicity were found between HER2 Abs from 
different cross-competition groups, when non-covalently linked to α-kappa-ETA’. By 
correlating α-kappa-ETA’ mediated cytotoxicity with inhibition of ErbB signaling and 
inhibition of HER2 driven proliferation we found that Abs that did not interfere with 
heterodimerization of HER2 induced greater α-kappa-ETA’ mediated cytotoxicity. 
These results demonstrated that the characteristics of antibodies that are favorable 
for an ADC approach, i.e. internalization and capacity to induce toxin-mediated cell 
kill, may differ from those that are favorable for therapy with naked antibodies, 
such as inhibition of receptor signaling. Therefore antibodies that are effective with-
out drug-conjugation may not always represent the best antibody candidates for an 
ADC approach.
Because some tumor targets are less optimal for an ADC approach due to poor in-
ternalization characteristic, we developed an alternative strategy to improve in-
ternalization of poorly internalizing antibodies or antigens, which is described in 
Chapter 7. As a model, we generated a bispecific ADC (bsHER2xCD63-Duo3) that 
combines tumor-specific targeting through HER2, with targeting of CD63 to facilitate 
trafficking to the lysosome. The monovalent HER2-specific Fab-arm, by itself, was 
unable to induce internalization, and consequently, the monovalent HER2-specific 
ADC showed poor anti-tumor activity. The affinity of the CD63 Fab-arm was chosen 
such that monovalent CD63 binding was inefficient, in order to limit CD63 targeting 
to tumor cells that co-express HER2 and CD63. While monovalent ADCs targeting 
HER2 or CD63 had no effect on tumor growth, bsHER2xCD63-Duo3 showed strong 
anti-tumor efficacy against HER2-positive xenografts, which provides a rationale for 
the development of novel bsADCs that combine tumor specific targeting with target-
ing of rapidly internalizing antigens.   
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In conclusion, the work in this thesis describes the Ab and antigen requirements 
for optimal payload delivery and supports the development of novel and improved 
ADCs. Important considerations for ADC development, such as antigen expression 
and internalization, Ab format and epitopes as well as the type of linker-payload 
used, are summarized in Chapter 8. There is no such thing as the perfect ADC. How-
ever by increasing our knowledge on the requirements for successful ADC devel-
opment we may enable the development of next generation ADCs with a superior 
therapeutic window.  
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De gemene deler
Kanker is een verzamelnaam voor ziektes die ontstaan door lichaamseigen cellen 
waarvan de celdeling is ontspoord. In ons lichaam bevinden zich allerlei verschil-
lende typen cellen die qua uiterlijk en functie erg van elkaar kunnen verschillen. In 
theorie kan vanuit elk van deze gezonde cellen een kankercel ontstaan. De kans hier-
op is erg klein, maar wanneer er veranderingen (mutaties) optreden in het DNA van 
een gezonde cel, kan deze cel transformeren tot een kankercel. Deze mutaties vinden 
continu plaats en worden meestal door de cel zelf opgespoord en hersteld. Bekende 
risicofactoren voor kanker zoals roken, ongezond eten en ouderdom vergroten het 
aantal mutaties in het DNA waardoor de kans ook groter wordt dat er een kankercel 
ontstaat. Veel van deze mutaties hebben geen gevolgen voor de celdeling waardoor 
ze geen kwaadaardige gevolgen hebben. Mocht er toch een cel ontstaan met een 
kwaadaardige mutatie dan gaat deze cel normaal gesproken in apoptose. Dit is een 
soort zelfmoordproces waarbij de cel zijn eigen DNA kapotmaakt, dood gaat en ver-
volgens wordt opgeruimd door gespecialiseerde cellen van ons afweersysteem (het 
immuunsysteem). In het geval van een kankercel werkt dit mechanisme niet goed. 
Hierdoor krijgt de kankercel vrij spel en kan deze naar hartenlust gaan delen, waar-
door een tumor kan ontstaan.
Antilichamen als anti-kanker therapie
Ons immuunsysteem is gespecialiseerd in het herkennen en bestrijden van lichaams-
vreemde indringers zoals virussen en bacteriën, maar omdat een kankercel ontstaat 
vanuit een lichaamseigen cel heeft ons immuunsysteem moeite om deze cellen op te 
sporen. De twee belangrijkste wapens van het immuunsysteem zijn witte bloedcellen 
en antilichamen, die er samen voor zorgen dat lichaamsvreemde indringers worden 
bestreden. Om de behandeling van kanker te bevorderen, ontwikkelen veel bedrijven 
antilichamen (ook wel immunoglobulinen) die specifiek in staat zijn om kankercel-
len te herkennen. Zulke tumor-specifieke antilichamen kunnen het immuunsysteem 
vertellen waar zich in ons lichaam kankercellen bevinden, en vervolgens bijdragen 
aan het opruimen van die kankercellen. In Hoofdstuk 1, Figuur 1 is een schemati-
sche weergave te zien van een antilichaam. Elk antilichaam bestaat uit twee delen: 
het Fab-domein en het Fc-domein. Het Fab-domein, of antigeen bindend domein, is 
het gedeelte waarmee het antilichaam eiwitstructuren kan herkennen die op een 
kankercel voorkomen. Het Fc-domein is het gedeelte waarmee een antilichaam het 
immuunsysteem kan activeren. Cellen van ons immuunsysteem hebben receptoren 
op hun oppervlak die specifiek in staat zijn om te binden aan het Fc-domein van een 
antilichaam. Deze interactie kan ervoor zorgen dat gespecialiseerde cellen van ons 
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immuunsysteem (NK-cellen, granulocyten en macrofagen), de tumor cel doden en 
opruimen. Het Fc-domein van een antilichaam kan ook worden herkend door com-
plement factoren. Dit zijn eiwitten die zich in onze bloedbaan bevinden. Zodra deze 
eiwitten aan antilichamen binden ontstaat er een gat in de tumor cel waardoor de 
cel dood gaat. Daarnaast zijn sommige tumor-specifieke antilichamen in staat om de 
groei van tumor cellen te remmen zonder hulp van de andere componenten van het 
immuunsysteem. Dit gebeurt bijvoorbeeld als het antilichaam bindt aan een eiwit 
dat is betrokken bij de groei van tumor cellen. De behandeling van kankerpatiënten 
met antilichamen kan erg goed werken. Op dit moment worden vooral patiënten met 
specifieke vormen van leukemie succesvol behandeld met antilichamen. Helaas zijn 
er ook vormen van kanker waarbij behandeling met antilichamen tot nu toe minder 
succesvol is. Bijvoorbeeld in situaties waarin de kankercellen ongevoelig (resistent) 
zijn of worden voor deze behandeling.  
Antilichaam-drug conjugaten
Een methode om de anti-tumor activiteit van antilichamen te vergroten is door er 
giftige stoffen (toxines), zoals chemotherapeutica, aan te koppelen. Chemotherapie 
is naast het bestralen en het chirurgisch verwijderen van tumoren de meest voor-
komende behandeling tegen kanker. Er zijn allerlei verschillende soorten chemo-
therapeutica die de groei van tumoren kunnen remmen. Helaas beschadigen deze 
medicijnen ook gezonde cellen in ons lichaam. Door deze toxines te koppelen aan 
tumor-specifieke antilichamen proberen we ervoor te zorgen dat de chemotherapie 
zijn dodelijke werking alleen nog maar uitoefent op tumor cellen. Deze vorm van 
medicijnen noemen we antilichaam-drug conjugaten (ADC’s). Het antilichaam wordt 
hierbij gebruikt als een soort transportmiddel om de chemotherapie in de tumorcel 
te krijgen, en daarbij zo min mogelijk schade aan te richten aan gezonde cellen. Dit 
idee is niet nieuw en werd ruim 100 jaar gelden al beschreven door Nobelprijs win-
naar Paul Ehrlich. Sindsdien hebben diverse onderzoekers geprobeerd om ADC’s te 
maken, maar pas in 2000 kwam het eerste ADC (Mylotarg®) op de markt. Helaas werd 
dit ADC door tegenvallende resultaten in kankerpatiënten ook weer terug getrokken 
van de markt. Tegenwoordig zijn de conjugatiemethodes sterk verbeterd waardoor 
ADC’s veiliger en effectiever zijn en daadwerkelijk kunnen worden gebruikt voor de 
behandeling van kankerpatiënten. Er zijn inmiddels twee nieuwe ADC’s op de markt. 
Adcetris® voor de behandeling van patiënten met lymfeklierkanker en Kadcyla® voor 
de behandeling van patiënten met borstkanker. Daarnaast is in Hoofdstuk 2, Tabel 
1 een overzicht te zien van de verschillende ADC’s die op dit moment in kanker-
patiënten worden getest. In de laatste kolom staat de maximaal tolereerbare dosis 
(MTD) voor kankerpatiënten weergegeven. Dit is de maximale hoeveelheid van het 
medicijn die kan worden gegeven aan patiënten, zonder dat er ernstige bijwerkingen 
optreden. Hoofdstuk 2 van dit proefschrift beschrijft een literatuurstudie waaruit 
blijkt dat de minimale dosis waarbij ADC’s tumorgroei remmen in een diermodel, 
nagenoeg gelijk is aan de MTD van de ADC’s in patiënten. Dit betekent dat we voor 
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optimale behandeling van kanker patiënten het liefst een hogere dosis van de ADC 
zouden willen geven, maar dit is voor de huidige ADC’s niet mogelijk omdat de ADC 
dan ook gezonde cellen aantast. Als gevolg wordt er een lagere dosis van het medi-
cijn gegeven,  en dat belemmert de effectiviteit van de behandeling. 
Promotieonderzoek
Gedurende mijn promotie onderzoek heb ik onderzocht hoe we de effectiviteit van 
ADC’s kunnen verbeteren. Voor een effectieve ADC behandeling is het van belang dat 
ADC’s worden opgenomen door de tumor cel en worden afgebroken in een specifiek 
compartiment binnenin de cel; het lysosoom. Als de ADC wordt afgebroken komt het 
toxine vrij en kan het toxine zijn werk doen en de tumorcel doden (zie ook Hoofd-
stuk 1, Figuur 2). Echter, veel eiwitten worden niet goed door de tumor cel opgeno-
men en komen daardoor niet in het lysosoom terecht. Een ADC dat zo’n eiwit herkent 
op de tumorcel, zal dus ook niet in het lysosoom terecht komen waardoor het toxine 
niet vrijkomt, en het ADC geen effectiviteit laat zien. In Hoofdstuk 3 hebben we on-
derzocht welke eiwitten het beste door de tumor cel worden opgenomen, om zo te 
kijken welke eiwitten het meest geschikt zijn voor het ontwikkelen van een ADC. In 
deze studie hebben we gevonden dat tissue factor, een eiwit wat op veel tumoren 
voorkomt, heel efficiënt wordt opgenomen door tumor cellen. We denken daarom 
dat antilichamen die tissue factor herkennen, heel geschikt zijn voor het maken van 
ADC’s. In Hoofdstuk 4 wordt beschreven hoe we verschillende antilichamen gericht 
tegen tissue factor hebben gemaakt en hoe we het beste antilichaam (TF-011) heb-
ben geselecteerd voor het maken van een ADC. Door een toxine te koppelen aan dit 
antilichaam, laten we onder andere zien dat een ADC die tissue factor herkent erg 
sterke remming van tumor groei geeft. Het ADC wordt op dit moment getest in kan-
kerpatiënten, waarbij we vooral onderzoeken of het medicijn veilig is. 
In Hoofdstuk 5 wordt een methode beschreven die kan worden gebruikt om grote 
hoeveelheden antilichamen te vergelijken als ADC, om zo het meest geschikte an-
tilichaam te selecteren voor de ontwikkeling van een ADC. Het is erg veel werk om 
een ADC te maken. Daarom hebben we een truc bedacht waarmee we eenvoudig 
kunnen testen of antilichamen in staat zijn om een toxine in een tumor cel te krijgen. 
Hiervoor gebruiken we een toxine dat wordt uitgescheiden door een bacterie. Dit 
toxine kan niet aan tumor cellen binden en is daardoor niet schadelijk. Echter het 
toxine kan wel specifiek aan onze antilichamen binden. Als zo’n antilichaam wordt 
opgenomen door een tumor cel, dan kan het toxine met het antilichaam meeliften 
en de tumor cel alsnog doden. Door het toxine te mengen met verschillende antili-
chaam is het mogelijk om te testen welke combinatie van antilichaam en toxine in 
staat is om tumorcellen te doden. In Hoofdstuk 5 laten we zien dat deze truc goed 
werkt. Vervolgens wordt deze truc in Hoofdstuk 6 gebruikt om een grote hoeveel-
heid antilichamen gericht tegen een specifiek tumor eiwit te testen. Hoewel deze 
antilichamen allemaal hetzelfde tumoreiwit herkennen, vonden we grote verschillen 
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in de mate waarin deze antilichamen in staat waren cellen te doden in combinatie 
met het bacteriële toxine. Hiermee hebben we aangetoond dat niet elk antilichaam 
geschikt is om een ADC te maken. Het is daarom belangrijk om verschillende antili-
chamen te testen om zo de het beste antilichaam te selecteren voor de ontwikkeling 
van een ADC. 
Voor sommige tumor eiwitten lukt het niet om een antilichaam te vinden wat goed 
wordt opgenomen door de tumorcel en uiteindelijk terecht komt in het lysosoom. Dit 
maakt het niet gemakkelijk om een ADC te ontwikkelen. Toch zouden we ook deze 
eiwitten graag willen gebruiken om tumorcellen te kunnen doden met behulp van 
een ADC. Hoofdstuk 7 beschrijft een methode waarmee de opname van antilichamen 
door tumor cellen, en het transport naar lysosomen, kan worden verbeterd. Hierbij 
maken we gebruik van een techniek om bispecifieke antilichamen te maken. Dit zijn 
antilichamen die twee verschillende eiwitten kunnen herkennen. Door een antili-
chaam te maken wat naast een tumoreiwit, ook een eiwit kan herkennen dat zorgt 
voor transport naar het lysosoom, proberen we de opname van antilichamen door 
tumor cellen te verbeteren. De studie in Hoofstuk 7 toont aan dat dit bispecifieke 
antilichaam veel beter wordt opgenomen door tumor cellen in vergelijking tot een 
antilichaam dat alleen het tumor eiwit herkent. Daarnaast zien we dat dit bispeci-
fieke antilichaam beter in staat is om tumor cellen te doden, zodra we het koppelen 
aan een toxine. 
Samengevat laten de resultaten beschreven in dit proefschrift zien dat we door de 
juiste tumor eiwitten en antilichamen te selecteren, de effectiviteit van ADC’s in 
tumormodellen kunnen verbeteren. Daarnaast hebben we meer inzicht gekregen in 
welke eigenschappen van tumoreiwitten en antilichamen, belangrijk zijn voor de 
ontwikkeling van ADC’s. Deze kennis kan ons helpen om de ontwikkeling van toe-




En dan nu het meest gelezen deel van menig proefschrift. Dit proefschrift bestaat 
uit maar liefst zes wetenschappelijke artikelen waarvan vier reeds gepubliceerd. Dit 
alles had ik natuurlijk niet kunnen doen zonder hulp van al mijn Genmab collega’s! Ik 
hoop dan ook dat iedereen bij Genmab zich aangesproken voelt als ik zeg bedankt! 
Een aantal van jullie wil ik graag even persoonlijk benoemen. 
Laat ik beginnen bij het begin, mijn stage bij Jeroen en Wim. Ik wil jullie bedanken 
voor het vertrouwen dat jullie in mij hebben geschonken en het feit dat jullie een 
goed woordje voor me hebben gedaan bij Jan en Paul. Zonder jullie was ik waar-
schijnlijk nooit als promovendus bij Genmab aan het werk gegaan. 
Tijdens mijn promotietraject heb ik het genoegen gehad om met veel verschillen-
de collega’s te mogen samenwerken. In mijn eerste jaar ben ik ondergebracht bij 
Edward en later Joost en Luus, waarbij we hartstochtelijk opzoek zijn gegaan naar 
antagonistische cMet antilichamen. Vervolgens ben ik overgestapt naar het HER2 
project en daar heb ik samen met Simone en Wim gewerkt aan het karakteriseren 
van een panel HER2 antistoffen. Tijdens deze periode kwam ik ook in contact met 
het anti-kappa toxine van Matthias en Christian, en hiermee werd voorzichtig een 
link gelegd naar de ADCs. Vanaf dat moment begonnen de artikelen binnen te stro-
men en werd de definitieve overstap naar de ADCs gemaakt. Hier heb ik me onder 
toeziend oog van Wim, Patrick, David, Michel en Esther mogen ontpoppen tot ADC 
expert. Gedurende deze periode heb ik ontzettend veel van jullie geleerd, vooral ook 
omdat een ieder van jullie het onderzoek op geheel eigen wijze inricht. Met Wim kon 
ik uren lang discussiëren over een bindingscurve, terwijl David vanuit vogelperspec-
tief het onderzoek de juiste richting in stuurde. Ik wil jullie allemaal bedanken voor 
de leerzame en leuke periode. Terwijl de directe begeleiding steeds veranderde was 
er één constante factor gedurende mijn promotie onderzoek, en dat is mijn promotor 
Paul. Wat het onderwerp ook was, jij kwam altijd met goede adviezen aanzetten en 
wist lijn aan te brengen in mijn steeds veranderende onderzoek, waarvoor zeer veel 
dank! 
Gedurende mijn promotie onderzoek is er een enorme berg werk verricht, en dat 
had ik niet kunnen doen zonder de hulp van een aantal zeer getalenteerde studenten 
Pascal, Maarten en Claudia. Maarten bedankt voor het opzetten van de confocale 
microscopie experimenten, deze lopen als een rode draad door mijn boekje en suc-
ces met Labficience. Claudia (CLF) bedankt voor je hulp op het TF project, het heeft 
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een mooie publicatie opgeleverd en het had niet veel gescheeld of we hadden het 
gebruik van biseksuele antistoffen gepatenteerd. 
Dan is er nog iemand die inmiddels wel heel veel werk heeft verzet… Hendrik! Naast 
de enorme berg experimenten die je hebt uitgevoerd, ben je ook een zeer goede 
sparringpartner en een zeer prettige collega om mee samen te werken. Je hebt het 
als rustige Urker jongen niet gemakkelijk gehad toen je op één kamer kwam te zitten 
met Patrick en mij, maar inmiddels heb je alle schroom van je afgezet en je ontwik-
keld tot steunpilaar binnen ons cluster. Daarmee is ook meteen de link gelegd naar 
die andere persoon die het werken bij Genmab tot een feestje maakt… Patrick! Vanaf 
de eerste dag bij Genmab was er meteen een goede klik, waardoor we zowel binnen 
als buiten Genmab een hoop mooie dingen hebben meegemaakt. Daarnaast is je 
parate kennis over B-cell tumoren een grote waarde voor Genmab waar we hopelijk 
nog lang gebruik van mogen maken. 
“I'm pretty sure there's a lot more to life than being really, really, ridiculously smart. 
And I plan on finding out what that is”, Antonio, Georg en Jelte-Jan, bedankt! Daar-
naast wil ik ook graag Marije bedanken voor het goede voorbeeld wat ze heeft ge-
geven, Mina voor de ontelbare batches die ze voor me heeft vrij gegeven, Tom voor 
zijn CD63 connectie, Aran, Joyce en Janine voor hun hulp bij de Fab-arm exchange 
proeven. Richard, Esther en Rob voor het beschikbaar stellen van de confocale mi-
croscoop en hun hulp bij het opzetten van de proeven, John voor zijn hulp bij het 
schrijven van de review, Esther B. voor het vele review werk en Joost (scicomvisu-
als) voor zijn hulp bij het vervaardigen van dit mooie boekje.
Als afsluiting wil ik mijn lieve vriendin Brenda bedanken voor haar steun. Je hebt 
me geleerd dat het leven niet alleen draait om werk en bier, er zijn ook andere zaken 
die nog belangrijker zijn…
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